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Resumen 
 
La terapia fotodinámica (Photodynamic Therapy, PDT) es un tratamiento contra el 
cáncer y otras enfermedades clínicamente aprobado que emplea luz para activar a un 
fotosensitizador y generar oxígeno singlete y otras especies de oxígeno reactivas 
(reactive oxygen species, ROS) capaces de inducir la muerte celular. Desde un punto de 
vista químico, la eficacia de esta fototerapia se ve limitada por la falta de oxígeno 
disponible en tumores, los cuales son generalmente hipóxicos. Por tanto, los 
profármacos anticancerígenos con metales que son fotoactivables han surgido como 
una fotoquimioterapia alternativa que no depende de la presencia de oxígeno, debido 
a sus propiedades fotoquímicas únicas. 
Entre los diferentes tipos de compuestos fotoactivables, los complejos antitumorales 
de PtIV se han estudiado extensamente como posibles profármacos y tienen un papel 
relevante en las prácticas preclínicas. Normalmente,  los compuestos de PtIV 
experimentan su fotoreducción para generar especies citotóxicas de PtII (e.g. cisplatin) 
cuando han sido irradiados con luz UV, una característica que potencialmente podría 
reducir los efectos secundarios que se producen con quimioterapias sistémicas.  
Sin embargo, ciertas limitaciones fotoquímicas están íntimamente relacionadas a esta 
clase de compuestos y es necesario corregirlas para avanzar en su aplicación. Por 
ejemplo, la profundidad de la penetración de luz en el tejido necesita mejorarse 
desplazando hacia el rojo del espectro la longitud de onda de excitación utilizada para 
activar los complejos de PtIV. Esta cuestión es una tarea complicada ya que 
normalmente causa una reducción en la eficiencia fotoquímica.  
La riboflavina, la vitamina B2, es una biomolécula exógena esencial para nuestro 
metabolismo. La riboflavina se convierte rápidamente en  flavín mononucleótido 
(FMN) y flavín adenín dinucleótido (FAD) intracelularmente. FMN y más 
frecuentemente FAD se une a cientas de existentes apo-flavoenzimas. Las flavinas y 
flavoenzimas han promovido un enorme interés en investigación debido a su rol clave 
en funciones catalíticas biológicas y su localización. 
 iv 
 
En mi tesis, he combinado conceptos sobre catálisis junto con las destacadas 
propiedades fotofísicas y fotoquímicas de las flavinas para abordar las limitaciones de 
la fotoquimioterapia con metales. Estas limitaciones están asociadas con las pobres 
propiedades de absorción de los complejos metálicos, especialmentelos compuestos 
de PtIV. Los complejos metálicos son típicamente considerados como catalizadores, los 
cuales convierten sustratos en compuestos más valiosos, mientras que aquí, empleo 
de manera  poco convencional  las flavinas como fotocatalizadores para activar 
profármacos con metales que actúan como sustratos. Esta aplicación sin precendentes 
consigue la activación fotocatalítica de los complejos de PtIV y RuII-areno con gran 
eficiencia y selectividad, incluso en ambiente biológico. 
La presente tesis está dividida en dos partes principales, los dos primeros capítulos 
definen el contexto de la investigación desarrollada en mi trabajo, mientras que del 
capítulo tres al cinco se describe el trabajo experimental que he llevado a cabo durante 
los cuatro años de mi beca de doctorado. 
 
Capítulo 1 destaca los principales components empleados en la aplicación 
fototerapeútica con metales estudiada en esta tesis. En este capítulo, en primer lugar 
describo las ventajas y limitaciones de los profármacos de platino en la terapia contra 
el cáncer, en concreto centrándome en agentes fotoactivables. A continuación, 
presento las propiedades fotoquímicas y fotofísicas de las flavinas y flavoproteínas 
elegidas, destacando algunas de sus aplicaciones clave. 
 
Capítulo 2 contextualiza la aplicabilidad de metalofármacos catalíticos en entornos 
biológicamente relevantes y para terapia contra el cáncer. Diferentes estrategias 
dirigidas a dianas terapéuticas han sido descritas en este campo emergente. Por una 
parte se incluyen en esta área los metalofármacos que interaccionan con biomoléculas 
intracelulares, al mismo tiempo que también se describen los metalofármacos que son 
 v 
capaces de producir in situ agentes anticancerígenos a partir de sustratos 
extracelulares. 
 
Capítulo 3 describe el descubrimiento de una nueva reacción bioortogonal, que 
consiste en la activación fotocatalítica de profármacos anticancerígenos de PtIV 
mediante el fotosensitizador biológico riboflavina (vitamina B2). La riboflavina bajo 
irradiación de luz a  460 nm consigue la eficiente conversión fotocatalítica de PtIV en 
especies de PtII en entornos biológicos induciendo resultados citotóxicos comparables 
a los del cisplatino. Las bajas dosis de luz junto con los altos número de recambio 
fotocatalíticos hacen de este sistema una estrategia atractiva para ampliar la acción 
antineoplástica de los agentes quimioterapeúticos con metales con control espacio-
temporal.  
^Riboflavin As Bioorthogonal Photocatalyst For The Activation Of A 
PtIV Prodrug _ 
Alonso-de Castro, S.; Ruggiero, E.; Ruiz-de-Angulo, A.; Rezabal, E.; 
Mareque-Rivas, J.C.; Lopez, X.; López-Gallego, F. and Salassa, L. 
Chem. Sci., 2017, 8, 4616t 4625. 
 
Capítulo 4 investiga el mecanismo biológico a través del cual la riboflavina activa 
fotocatalíticamente dos profármacos de PtIV que inducen la muerte celular  en diversas 
líneas de células cancerígenas. La combinación de administrar riboflavina y los 
profármacos de PtIV  al ser irradiados muestra un efecto sinérgico entre la terapia 
fotodinámica y fotoquimioterapia en el tratamiento de las células Capan-1 (cáncer 
pancreático) dentro de las diferentes líneas celulares  evaluadas. Además, obteniendo 
una ruta diferente de muerte celular comparada con la obtenida en los controles con 
cisplatino. Parte de este trabajo ha sido llevado a cabo durante 4 meses de estancia en 
el grupo de Dr. Walter Berger en la Medical University of Vienna. 
^ ]}o}P] o  activity of PtIV prodrugs triggered by riboflavin-mediated 
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Alonso-de Castro, S.; Terenzi, A.; Hager, S.; Englinger, B.; Faraone, A.; 
Galanski, M.; Keppler, B. K.; Berger, W. and Salassa, L. Sci. Rep. 2018, 
Submitted. 
 
Capítulo 5 explora la capacidad de FAD (flavín adenín dinucleótido), FMN (flavín 
mononucleótido), y cuatro flavoproteínas para actuar como fotocatalizadores poco 
convencionales para la conversión de complejos anticancerígenos de PtIV y RuII en sus 
especies potencialmente tóxicas. Las flavoproteínas evaluadas son capaces de 
convertir los sustratos metálicos con diferentes velocidades  dependiendo de la 
accesibilidad y la carga de la superfície del centro activo de la flavina. Una de las 
flavoproteinas probadas (NOX: NADH oxidasa de Thermus thermophilus), en presencia 
de NADH (forma reducida de la coenzima nicotinamida adenín dinucleótido), cataliza la 
activación de PtIV en la oscuridad también, indicando por primera vez que las 
flavoproteínas pueden contribuir al inicio de la actividad de los agentes 
quimiterapeúticos de PtIV.  
^ ]}}Z}P}vo      o ˙]     ]À  ]}v  }(   Wo ]vµ u   v   Zµ Zv]µu 
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    ˙ &     v  &oÀ}}]v_   
Alonso-de Castro, S.; L. Cortajarena, A.; López-Gallego, F. and Salassa, 
L. Angew. Chem. Int. Ed. 2018, 57, 3143 t 3147 (VIP, Very Important 
Paper) 
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Además del trabajo mencionado anteriormente, durante mi doctorado también he 
contribuido en el desarrollo de otros proyectos de investigación y en la preparación de 
artículos de revisión.  Estas actividades no están incluídas en esta tesis, aunque han 
sido instrumentals para obtener más conocimiento en las áreas de compuestos de 
coordinación fotoactivables, nanomateriales de conversión ascendente y agentes de 
 vii 
MRI (resonancia magnética de imagen). Como resultado de mi Implicación en estos 
proyectos, he contribuido a la preparación de 4 artículos publicados en revistas 
internacionales revisadas por pares y 1 artículo de divulgación. 
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Summary 
 
Photodynamic Therapy (PDT) is a clinically approved treatment for cancer and other 
diseases that employs light to activate a photosensitizer and generate singlet oxygen 
and other reactive oxygen species (ROS) able to induce cell death. From a chemical 
point of view, the efficacy of this phototherapy approach is limited by the lack of 
oxygen available in tumours, which are generally hypoxic. Hence, light-activatable 
metal-based anticancer prodrugs have emerged as an alternative oxygen-independent 
photochemotherapy, owing to their unique photochemical properties. 
Among the various classes of photoactivatable compounds, PtIV antitumour agents are 
intensively studied as prodrug candidates and have a relevant role in preclinical 
practice. They typically undergo photoreduction into cytotoxic PtII species (e.g. 
cisplatin) when irradiated with UV light, a feature that may potentially help reducing 
side-effects of systemic chemotherapies.  
Nevertheless, an intimately related photochemical feature for this class of compounds 
need to be improved for advancing their use towards application. Tissue penetration 
needs to be enhanced by red-shifting excitation wavelengths employed to activate PtIV 
complexes, a challenging task that often causes dramatic reductions in terms of 
photochemical efficiency.  
Riboflavin, vitamin B2, is an essential exogenous biomolecule for our metabolism.  
Riboflavin is rapidly converted into flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD) intracellularly. FMN and more frequently FAD bind hundreds of the 
existing apo-flavoenzymes. These flavins and flavin dependent-enzymes have 
motivated an enormous interest in research due to their key role in biological catalytic 
functions and localization.  
In my thesis, I have combined catalysis concepts and the outstanding photophysical 
and photochemical features of flavins to address the limitations of metal-based 
photochemotherapy associated with the poor absorption properties of metal 
complexes, particularly of PtIV compounds. Metal complexes are typically regarded as 
 x 
catalysts which convert organic substrates in more valuable compounds, whereas 
here, I unconventionally employ flavins as photocatalysts to activate metal-based 
prodrugs which act as substrates. This unprecedented approach achieves 
photocatalytic activation of PtIV and RuII-arene complexes with high efficiency and 
remarkable selectivity, even in the biological environment. 
This thesis manuscript is divided in two main parts, the first two chapters define the 
framework of the research developed in my work, while chapter three to five report 
on the experimental work that I have carried out in the four years of my Ph.D. 
fellowship. 
 
Chapter 1 outlines the main components employed in the metal-based 
phototherapeutic approach studied in this thesis. In this chapter, I first describe the 
advantages and limitations of platinum prodrugs in cancer therapy, in particular 
focusing on photoactivatable agents. Then, I present the photochemical and 
photophysical properties of flavins and selected flavoproteins, highlighting some of 
their key application. 
Chapter 2 contextualizes the applicability of catalytic metallodrugs in biological 
relevant environments and for cancer therapy. Different targeting strategies have been 
reported in this emerging field, including metallodrugs that react with biomolecules 
and organometallic catalysts that are able to produce in situ anticancer agents from 
extracellular substrates. 
Chapter 3 describes the discovery of a new bioorthogonal reaction, that is the 
photocatalytic activation of PtIV anticancer prodrugs by the biological photosensitizer 
riboflavin (vitamin B2). Riboflavin under 460-nm light irradiation achieves efficient 
photocatalytic conversion of PtIV into PtII species in biological environment inducing 
comparable cytotoxic results to cisplatin. Low light doses used and high photocatalytic 
turnovers make this system an attractive strategy to amplify the antineoplastic action 
of metal-based chemotherapeutics with spatio-temporal control.  
 xi 
^Riboflavin As Bioorthogonal Photocatalyst For The Activation Of A 
PtIV Prodrug _  
Alonso-de Castro, S.; Ruggiero, E.; Ruiz-de-Angulo, A.; Rezabal, E.; 
Mareque-Rivas, J.C.; Lopez, X.; López-Gallego, F. and Salassa, L. 
Chem. Sci., 2017, 8, 4616 t 4625. 
 
Chapter 4 investigates the biological mechanism through which riboflavin-
photocatalytic activation of two PtIV prodrugs induces cell death in a number of cancer 
cell lines. Among the different cell lines tested, the combination of riboflavin and PtIV  
prodrugs shows a synergistic effect between photodynamic therapy and 
photochemotherapy in the treatment of Capan-1 cells (pancreatic cancer), obtaining a 
different cell death pathway compared to cisplatin. Part of this work has been carried 
out during a 4-months stay in the group of Dr. Walter Berger at the Medical University 
of Vienna. 
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Alonso-de Castro, S.; Terenzi, A.; Hager, S.; Englinger, B.; Faraone, A.; 
Galanski, M.; Keppler, B. K.; Berger, W. and Salassa, L. Sci. Rep. 2018, 
Submitted. 
 
Chapter 5 explores the capability of FAD (flavin adenine dinucleotide), FMN (flavin 
mononucleotide), and four flavoproteins to act as unconventional photocatalysts for 
the conversion of PtIV and RuII anticancer complexes into their potentially toxic species. 
The flavoproteins tested are capable to convert the metal substrates with different 
rates depending on the pocket accessibility and surface charge of the flavin binding 
pocket. One of the flavoproteins tested (NOX: NADH oxidase from Thermus 
thermophilus), in the presence of NADH (reduced form of the coenzyme nicotinamide 
adenine dinucleotide), catalyses PtIV activation in the dark as well, indicating for the 
 xii 
first time that flavoenzymes may contribute to initiating the activity of PtIV 
chemotherapeutic agents.  
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In addition to the aforementioned work, during my Ph.D. I have also contributed to the 
development of other research projects and to the preparation of review articles. 
These activities are not included in this thesis, yet they were instrumental in obtaining 
more insights in the areas of photoactivatable coordination compounds, upconversion 
nanomaterials and MRI (magnetic resonance imaging) agents. As a result of my 
involvement, I contributed to the preparation of 4 articles published in international 
peer-reviewed journals and 1 outreach journal article. 
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1.1 Platinum complexes 
Platinum complexes are essential in the panel of chemotherapy treatments. With the 
discovery in 1965 by Barnett Rosenberg that cisplatin (cis-
diamminedichloridoplatinum) caused cell division arrest in Escherichia coli (E. coli) via 
an electrolysis experiment,1 medicinal inorganic chemistry became an emerging field. 
Later in 1978, cisplatin was the first PtII complex approved for cancer treatment by the 
Food and Drug Administration (FDA). Since then, other seven PtII compounds obtained 
the approval in clinics worldwide (carboplatin and oxaliplatin) or in selected countries 
(nedaplatin, lobaplatin, heptaplatin, miriplatin and dicycloplatin) (Figure 1).2,3  
 
 
Figure 1. Schematic structures of clinically approved PtII drugs. 
 
As a consequence of the impact produced by cisplatin discovery, other metal 
complexes have also been studied for anticancer purposes; for example ruthenium, 
cobalt, rhodium, iridium and gold. Among non-platinum compounds, it is important to 
highlight that the Ru(III)  complexes NAMI-A and KP1019 (where NAMI-A = 
(ImH)[trans-RuCl4(dmso-S)(Im)], Im = imidazole; and KP1019 = (IndH)[trans-
RuCl4(Ind)2], Ind = indazole) reached clinical trials. In the case of NAMI-A, owing to the 
long Ru body retention time observed in Phase I, NAMI-A was combined with 
 ’u] ]v  ]v   WZ   /l / /   µ ]  v  o   ^]vµ ((]]vo  ˙ (( ]À  (}  (µZ  µ _X  
On the other hand, the relatively low solubility of KP1019 did not allow further dose 
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escalation in Phase I. Therefore, another Phase I study was performed with the more 
soluble sodium derivative Na[trans-RuCl4(Ind)2] (KP1339). Very recently, the Phase I 
results in the US showed KP1339 to be suitable for combination therapies due to 
disease control avoiding proliferation of malignant cells, despite having modest 
anticancer activity.4  
This chapter will focus on selected aspects of the enormous Pt medicinal chemistry, 
arbitrarily excluding anticancer agents based on other metals, in light of the literature 
vastness in this field and on the nature of the research work performed during the 
thesis.  
The mechanism by which the classical platinum drugs exert their anticancer effect has 
been investigated during decades. Square planar PtII complexes are generally accepted 
to act as prodrugs per se. They contain two carrier ligands and two leaving ligands 
(Figure 2). The latters are exchanged inside cells to later interact with DNA strands via 
interstrand or intrastrand interactions, ultimately causing cell death. For instance, the 
CBDCA (cyclobutane dicarboxylate) chelating ligand bestows lower reactivity and 
slower DNA binding kinetics to carboplatin with respect to cisplatin, despite the two 
complexes form similar final reaction products. In addition, carboplatin shows 
alternative mechanisms of action, as well as other Pt complexes, which may overcome 
cisplatin drug resistance.5  
Notwithstanding the good survival rates of patients treated with PtII drugs (e.g. the use 
of cisplatin exceeds 95% cure rate survival for testicular cancer),6 systemic toxicity is 
associated to these metal-based therapies causing several side effects in patients 
(Figure 2).7 
Because of the need to tackle the clinical problems of PtII drugs, an increased interest 
of the scientific community focused on the investigation of PtIV complexes, which 
display higher stability and hydrolytic inertness. PtIV agents do not undergo fast 
hydrolysis in biological environments and reduce subsequent unspecific toxicity. This 
family of octahedral compounds incorporates axial ligands (Figure 2) into their 
chemical structure, which help modulating solubility parameters and biological effect 
in cells, as well as adding molecular vectors for targeting specifically cancer cells.7   
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Octahedral PtIV complexes act as prodrugs of PtII, they require additional step of 
activation in which they undergo reductive elimination of ligands. This reaction is 
typically triggered inside cells by intracellular reducing agents (e.g. glutathione (GSH) 
or ascorbic acid) which are able to reduce the inert PtIV into PtII, to later form reactive 
aqua species that form DNA adducts and consequently induce cell death (Figure 2).3 
Much of the research carried out on PtIV complexes has consisted in improving the 
pharmacological profiles of Pt drugs, elucidating the details of the PtIV t > PtII activation 
and its biological effects, obtaining promising toxicity profiles in vitro, and overcoming 
drug resistance caused by previous treatments. 
 
Figure 2. Schematic representation of the mechanism of activation of PtIV prodrugs and their 
biological action in cells. Scheme adapted from reference 3. 
Insights in the mechanism by which these octahedral PtIV complexes are converted into 
square planar PtII are essential for the rational design and enhancement of metal 
prodrug features. These processes are complex to elucidate and strictly depend on the 
type of ligands and their spatial distribution around the metal center. Furthermore, 
administration of inert PtIV complexes is likely to increase their circulation lifetime in 
the blood due to reduced reactions with plasma proteins.8 In particular, a way to 
increase this circulation lifetime consists in the bioconjugation of a PtIV complex with 
human serum albumin protein (HSA) which also enhances the tumor accumulation due 
to the EPR (enhanced permeability retention) effect in vivo. 9 Therefore, their 
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reduction potentials should be considered since prodrugs will be activated inside the 
cancer cells and not in the bloodstream. The biological GSH and ascorbic acid are both 
present at lower concentrations in blood plasma (900 and 50 t 150  M respectively) 
and in higher concentrations in the cells (approximately 2 and 1 mM respectively). 
Experimental studies have proposed several mechanisms for the reductive elimination 
reaction of PtIV complexes, such as outer sphere reactions, inner sphere mechanisms 
and PtII catalyzed reaction schemes.8,10 Inner sphere reactions involve the interaction 
between a reductant and the metal complex. The capacity of coordinated ligands to 
interact (e.g. via H-bonding, electrostatic or  -   stacking interactions) with the 
reductant governs dramatically the electron transfer efficiency. On the other hand, 
outer sphere reductions are less efficient and normally involve PtIII intermediate with 
one electron reductions. For example, the trans orientated chlorido ligands in the PtIV 
complex JM576 provides a reduction via the formation of an inner sphere pathway for 
electron transfer which is three orders of magnitude faster than its cis chloride isomer 
JM216 which follows an outer sphere electron transfer generating different PtII product 
(Figure 3).8,10 Many of the pharmacologically promising PtIV prodrugs incorporate two 
axial carboxylato ligands which reduce the capacity of the complex to form bridging 
moieties for electron transfer, and consequently lower their reduction potentials 
compared to chloride analogues. 
 
Figure 3. Reduction reaction for two different PtIV isomers: (Above) Fast reduction of JM576 
whith trans chlorido ligands forming a chloride bridge between the ascorbate and the metal 
center.(Below) Slower reduction of the cis isomer  through an outer sphere mechanism. Figure 
reproduced from reference 8. 
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Several Pt(IV) prodrugs have undergone clinical trials. Representative examples are 
Ormaplatin, Iproplatin, Satraplatin and LA-12 (Figure 4). Ormaplatin, also known as 
tetraplatin or tetrachloro (trans-1,2-diaminocyclohexane)platinum(IV), is rapidly 
reduced to dichloro (trans-1,2-diaminocyclohexane)platinum(II) in tissue culture 
medium (t1/2 = 5 >15 min). Toxicity is thought to arise from fast reduction to the active 
Pt(II) form because of the presence of the chloride axial ligands and finished in Phase I 
studies.7 Encouraging results have also been obtained for the PtIV complex iproplatin, 
also known as JM9, CHIP, or cis-dichlorobis(isopropylamine)trans-
dihydroxyplatinum(IV). Iproplatin is less prone to reduction and deactivation by 
biological reducing agents than ormaplatin, due to the presence of hydroxide axial 
ligands instead of chlorides, which confer higher reduction potential. This slower 
deactivation allows an easier distribution of the complex throughout the body. 
Another remarkable feature of iproplatin is its very high water solubility (44.1 mM), 
which allows simpler formulation and administration, and reached Phase II in 
combination with carboplatin for breast cancer. Satraplatin, trans,cis,cis-
bis(acetato)amminecyclohexylaminedichloroplatinum(IV) (Figure 4), was the first 
platinum agent reported to have oral activity. Remarkably, satraplatin was rationally 
designed with suitable lipophilicity and stability for oral administration. It is in Phase III 
in combination with prednisone for prostate cancer treatment and in Phase I for solid 
tumors including brain tumors in children and young adults. A Phase I clinical trial has 
also been carried out with LA-12, a derivative of satraplatin in which the 
cyclohexylamine is replaced with adamantylamine (Figure 4).7 
 
Figure 4. Chemical structures of PtIV agents that have undergone clinical trials. 
 
PtIV prodrugs have to be approved for clinical use yet, although some offer the promise 
of increased efficacy and reduced side effects. Hence, researchers have further 
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developed the PtIV prodrug strategy3,7,10,11 exploiting the axial ligand to provide the 
desired biological properties such as lipophilicity, redox stability, cancer-cell targeting, 
orthogonal or complementary bioactivity, and improved cellular uptake. The design of 
the axial ligands has been instrumental to load PtIV complexes onto a great variety of 
nanoparticles and other delivery systems.7 
An alternative and promising strategy to improve PtIV application has been the use of 
light for the PtIV activation, which is the main focus of this thesis. 
 
1.2 Photoactivatable PtIV prodrugs 
The use of light as external stimuli has been extensively investigated in drug delivery 
and theranostics. This approach is minimally invasive and allows spatio-temporal 
control of the biological activity of the therapeutic agents, avoiding systemic side 
effects. Currently, photodynamic therapy (PDT) is the most important clinically 
employed light-triggered treatment. 
PDT is a powerful procedure for the treatment of non-malignant diseases and tumors 
(e.g. skin, head, neck, lung, pancreas, esophagus, bladder, prostate and neoplasms). 
PDT drugs are photosensitizers whose typical structure is based on tetrapyrrole 
macrocycles with highly conjugated electron systems that allow efficient visible light 
absorption (Figure 5). The mechanism of action consists in the visible light-irradiation 
of a photosensitizer, whose excited triplet state is able to react with 3O2 (Type II 
reaction) or other biomolecules (Type I reaction) to finally generate cytotoxic 1O2 and 
reactive oxygen species (ROS) (Figure 5).  
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Figure 5. Chemical structure of the photosensitizer Photofrin and PDT mechanism of action. 
 
It is worth highlighting that every PDT component separately is non-toxic but their 
simultaneous combination produces cell death.12 1O2 and ROS can directly damage 
cells and/or vasculature, and induce inflammatory and immune responses.13 In 
addition, ROS produced by photosensitizers can not only induce tumor cell apoptosis 
directly, but also disrupt the cytomembrane and endolysosomes. This may be helpful 
for combinatory treatments of PDT and chemotherapy because it could prevent 
chemotherapeutic drugs from being pumped out by P-glycoprotein among others, and 
being degraded by enzymes14 Transition metal compounds also play a key role in PDT. 
A representative example is the Ru polypyridyl complex named TLD-1433, which has 
entered into clinical trials as a novel PDT photosensitizer for the treatment of non-
muscle-invasive bladder cancer.15 Furthermore, the Pd-based PDT agent TOOKAD 
(tetrahydroporphyrin) for prostate adenocarcinoma treatment has been clinically 
approved in Latin America.16 
Fostered by the success of PDT in cancer treatment,12 light-activation strategies are 
being currently applied to overcome systemic drawbacks observed for traditional 
metal-based chemotherapy. In photochemotherapy (or photoactivated 
chemotherapy), light is used to control spatio-temporally the generation of metal-
based drugs and their cytotoxic effects.17 This approach requires complexes to be non-
toxic and stable in the dark under physiological conditions, but at the same time they 
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need to be capable of generating cytotoxic metal-based species which target key 
functions in cells upon light activation. The investigation of novel photoactivatable 
metal-based prodrugs could potentially lead to overcome limitations coming from both 
PDT and chemotherapy. For instance, PDT oxygen dependency limits the effectiveness 
of the treatment since many tumors are hypoxic and O2 concentration progressively 
decreases during application of the therapy.18 On the other hand, light activation of 
prodrugs may help preventing the unspecific toxic effects associated with 
chemotherapy, which provoke severe side effects and limit drug administration. 
Among all the classes of photoactivatable metal-based prodrugs, this chapter will focus 
on PtIV complexes. This family of compounds has particularly poor absorption 
properties and strongly needs new activation approaches to advance their use towards 
preclinical settings. Nevertheless, the capacity of PtIV photoactivatable complexes to be 
converted into clinically approved PtII drugs, whose anticancer profiles is well known 
and studied, may overall ease their advance towards the clinics. 
The photochemical and photophysical processes of low spin octahedral d6 metal 
complexes, in which PtIV complexes are included, are governed by a variety of excited 
states (Figure 6). These are generated upon absorption of light and subsequent 
promotion of one electron to higher-energy unoccupied orbitals. The corresponding 
electronic transitions are generally defined:  
- Metal centered (MC) transitions: These are orbitally (Laporte)-forbiden transitions 
with weak absorptions. Typically antibonding orbitals are populated, therefore the 
excited states generated often lead to bond lengthening and favor ligand 
substitution. 
- Charge-transfer (CT) transitions: They include metal-to-ligand (MLCT), ligand-to-
metal (LMCT) or to-solvent (TS) transitions. These have higher intensity and can 
lead to redox reactions (e.g. metal reduction and radical generation). 
- Ligand-centered (LC) transitions: These generally are often seen in large 
delocalized systems and involve  -   excited states. 
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Figure 6. Simplified orbital and excited-state diagram for a d6 metal complex with octahedral 
coordination (strong crystal field is assumed). Small double colored arrows represent the 
electron involved in each electronic transition. When in the singlet state they are spin-down, 
or in the triplet state they are spin-up. Schematic representation reproduced from reference17. 
 
Time-resolved optical techniques and computational methods have often been 
employed to characterize the excited states involved in the photoactivation of metal 
complexes.17 In the case of PtIV photoactivatable anticancer agents, Density Functional 
Theory (DFT) calculations have highlighted that MC and LMCT states are responsible 
for their photochemical behavior and for the generation of PtIV and PtII photoproducts, 
often dissimilar than the ones obtained by direct chemical reduction of the 
complexes.19,20 
 
In addition to the discovery of cisplatin biological activity, Barnett Rosenberg was also 
the first to report in 1967 that light activation of PtIV compounds produced cytotoxic 
species which affected bacterial growth in E. coli.21 Thirty years later Bednarski and 
coworkers were the first in the middle and late 1990s to investigate the 
photochemistry, DNA-binding, and antiproliferative properties of the photoproducts 
originated from iodido PtIV diamine complexes. The photoactivation of these 
complexes primarily involved redox processes, but ligand substitution and 
isomerization could commonly occur.22,23 The first generation of derivatives, 
represented by cis,trans-[Pt(en)(I)2(OAc)2] (1) (where OAc = OCOCH3 and en = 
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H2NCH2CH2NH2) (Figure 7), reacts to visible light by binding irreversibly to DNA and 
forming adducts with 5'-GMP (guanosine 5'-monophosphate, used to model DNA 
binding) in the same manner as the PtII complex [Pt(en)Cl2]. Furthermore, the 
photolysis products are cytotoxic in TCCSUP human bladder cancer cells in vitro. 
However, these complexes are too reactive towards biological thiols (e.g., GSH), which 
rapidly reduced (30 min) them to cytotoxic PtII species in the dark, thus making them 
unsuitable as effective prodrugs.23,24 
The second generation of photoactivatable Pt(IV) complexes includes the diazido-PtIV 
complexes developed by Sadler and Bednarski. Representative example are the 
cis,trans-[Pt(en)(N3)2(OH)2] (2) and cis,trans,cis-[Pt(N3)2(OH)2(NH3)2] (3) (Figure 7). Light 
irradiation at 366 nm converts both complexes into cytotoxic species that effectively 
induce cancer cell death by attacking their nuclei. Photoproducts are shown to bind 
irreversibly DNA and form similar products with DNA and 5'-GMP as their 
corresponding PtII complexes with released azido ligands. However, differently from 
iodide PtIV complexes, azido PtIV complexes are stable towards GSH reduction and 
binding, which greatly decreases their dark cytotoxicity. These early studies showed 
that photoactivatable azido PtIV antitumor agents are promising candidates for new 
drug development.24 
 
Figure 7. Schematic representation of the photoactivatable PtIV complexes: trans,cis-
[Pt(OAc)2I2(en)] (1), cis,trans-[Pt(en)(N3)2(OH)2] (2), cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (3), 
trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)] (4) and trans,trans,trans-[Pt(N3)2(OH)2(py)2] (5). 
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 The complex trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)] (4)25 (Figure 7) was evaluated 
toward several human cancer cells. 14N NMR studies demonstrated that NH3, N2, and 
azide are released from 4 upon photoactivation, besides Pt-based species. The average 
IC50 values obtained after 30 minutes of UVA light irradiation (0.12 mW/cm2) was 55 ± 
28  PM. Notably, under visible light irradiation (420 nm) the complex was also effective 
(1.17 J/cm2). More remarkable, 4 showed antitumor activity in vivo in nude mice. Blue 
light (100 J/cm2 at 420 nm) was delivered through the skin for 30 minutes, followed by 
a second irradiation 6 hours later (total dose of approx. 200 J/cm2). Survival of 2 mice 
of 7 treated with 4 and light was obtained after 35 days, while no survival was reached 
for control experiments.  
Sadler and coworkers also reported on the biological activity of trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (5) (Figure 7)26, which was a potent phototoxic agent under 365-nm 
irradiation towards human several cancer cell lines such as keratinocytes (HaCaT), 
parental (A2780) and cisplatin resistant (A2780CIS) ovarian carcinoma, oesophageal 
adenocarcinoma (OE19), and hepatoma (HepG2) cells. Cells were irradiated with a low-
dose (5 J/cm2) of visible light (420 nm) obtaining for HaCaT cells a cytotoxic activity 10 
times higher than cisplatin, and a phototoxic index (PI) greater than 22. In OE19 cells, 
the IC50 value is 8.4  PM and PI also >25 when irradiated with visible light. The presence 
of pyridine ligands is crucial for the biological activity of the photoproducts. Pyridines 
remain coordinated to the platinum center upon irradiation, avoiding the typical 
condensation and fragmentation of cell nuclei caused by cisplatin. 
More recent efforts in the development of photoactivatable PtIV prodrugs aimed at 
improving cell uptake and cancer cell targeting. In 2014, the group of Sadler 
exhaustively evaluated the lipophilicity of ten photoactivatable PtIV diazido prodrugs of 
formula trans,trans,trans-[Pt(N3)2(OH)2 ~ Z~ Z[  ~`Z   Z  v   Z[     E , 3, methylamine, 
ethylamine, pyridine, 2-picoline, 3-picoline or thiazole), among which complexes 4 and 
5, in order to correlate lipophilicity with anticancer activity. Lipophilicity is an 
important feature in the design of drug because it plays a key role in the passive influx 
of drug molecules into cells. The lipophilicity of the PtIV diazido complexes investigated 
show a linear dependence based on this hydrophobic nature of the coordinated 
ligands. However, in vitro results show no correlation between lipophilicity and 
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intracellular accumulation of platinum, probably suggesting the involvement of active 
transport and favored influx of selected structures. Furthermore, no correlation 
between platinum accumulation and photocytotoxicity was observed in A2780 cancer 
cells, implying that the type of intracellular damage induced by these complexes, 
rather than their abundance, plays a key role in their cytotoxic effect.27 
Adding targeting capability to PtIV complexes was the following step in the design of 
more effective prodrug candidates. In 2015, Marchán and coworkers reported a new 
anticancer agent by conjugating a PtIV diazido complex to a cyclic RGD-containing 
peptide (6), which is selectively recognized by  DV E3 and  DV E5 integrins  (Figure 8) in 
order to increase selectivity for cancer cells.28 Upon visible light irradiation (420 nm, 5 J 
cm-2), phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells, 
which overexpress  DV  E3 integrin compared to control DU-145 human prostate cancer 
cells. This clearly indicated that peptide conjugation had a positive effect on the 
intracellular accumulation of the photoactivatable PtIV prodrug. Notably, platinum 
accumulation in SK-MEL-28 cells after exposure to conjugate was higher (about 2.8-
fold) than in control DU-145 cells. The intracellular accumulation of the conjugate in 
MBAMD-468 (breast carcinoma cell line) was also higher than in DU-145 cells (about 
3.6-fold) despite the very low expression of  DV  E3 integrin in the breast carcinoma cell 
line. These results suggest that the internalization of the Pt t c(RGDfK) conjugate 
mediated by  DV E5 integrin as well. Additionally, the phototoxicity of conjugate in SK-
MEL-28 (IC50 = 19.5  PM) was similar to that of the parent succinylated complex (IC50 = 
15.5  PM).  
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Figure 8. Trans,trans,trans-[Pt(N3)2(OH)2(py)2] conjugated with a cyclic peptide containing the 
RGD sequence ( t Argt Gly t Aspt ) (6); trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (succ = 
succinylate, py = pyridine), has been conjugated to guanidinoneomycin (7); and 
trans,trans,trans-[Pt(N3)2(Py)2(OH)(succinate)] conjugated with TEMPO (8). 
 
Sadler and Marchán also conjugated a photoactivated PtIV diazido complex with 
guanidinoneomycin (7) (Figure 8), a known RNA-binding ligand able to transport large 
bioactive cargos into cells in a selective proteoglycan-dependent manner.29 The aim of 
using this polycationic compound as ligand is to promote the intracellular 
accumulation and targeting of the phototoxic PtIV prodrug in cancer cells. Under visible-
light irradiation ( Omax= 420 nm, 5 J cm-2), 7 can potentially promote platination of RNA 
over DNA what may lead to chemotherapeutic agents with a novel mechanism of 
action. Cellular uptake studies showed that guanidinoneomycin conjugation improves 
the intracellular accumulation of the PtIV agent in two cancer cell lines, and particularly 
in SK-MEL-28 cells. Notably, the higher phototoxicity of the conjugate in SK-MEL-28 
cells than in DU-145 cells suggests a degree of selectivity towards the malignant 
melanoma cell line. Moreover, it was demonstrated that the photoactivation of the Ptt
guanidinoneomycin conjugate in the presen   }(  æ[ -GMP lead to the formation of 
trans-[Pt(N3)(py)2 ~æ[-GMP)]+, as does the parent PtIV complex. 
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Adopting a similar synthetic strategy, a stable free radical TEMPO (2,2,6,6-
tetramethylpiperidine-1-oxyl) has been incorporated in the axial position of 
trans,trans,trans-[Pt(N3)2(Py)2(OH)(succinate)] (8) (Figure 8).30 Upon 420-nm light 
irradiation, the reduction in LMCT band was monitored in aqueous solution by UV-Vis 
and EPR (Electron pamagnetic spectroscopy). Results indicate that the complex 
undergoes loss of an azido ligand and/or electron transfer from azido ligands to the PtIV 
center, resulting in the formation of azidyl radicals and PtIV/II species. The 
photocytotoxicity of 8 (50 mW at 465 nm for 1 h) increased by 1.2 times against A2780 
ovarian cancer cells compared with its parent analogue. The biological action is 
ascribed to the attack on DNA by the PtII photoproducts as well as to the activity of the 
reactive azidyl radicals and antioxidant properties of the TEMPO ligand.  
 
In 2017, the Sadler group described a new strategy to design hydrogels that can deliver 
photoactivatable PtIV anticancer complexes to cancer cells.31 Incorporation of 
trans,trans,trans-[Pt(N3)2(Py)2(OH)(succinate)] coupled with dopamine (9) into the 
non-toxic G4K+B hydrogel, a G-quadruplex formed by guanosine-borate units (Figure 9) 
dramatically increased its photocytotoxic potency toward cisplatin-resistant human 
ovarian cancer cells (cisplatin-resistant A2780Cis). The 9-G4K+B hydrogel displayed 
activity against A2780Cis in the dark (IC50 = 16  M), but was significantly more potent 
upon irradiation (1 h using blue LEDs (465 nm, 50 mW)) (IC50 = 3  M) with a PI of 5.6. In 
order to evaluate the cytotoxic selectivity between cancer and healthy cells, the same 
conditions employed for A2780Cis cells were applied to MRC-5 normal lung fibroblasts. 
Both 9 and 9-G4K+B hydrogels were nontoxic toward MRC-5 (IC50 > 50  M) giving a 
photocytotoxicity selectivity factor (ratio of the activity between normal and cancer 
cells) of >18 for the 9-G4K+B hydrogel. This result is an early indication of the possibility 
of reducing unwanted side effects by the use of the hydrogel as a delivery strategy.  
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Figure 9. a) Complex 9 obtained reacting dopamine hydrochloride with trans,trans,trans-
[Pt(N3)2(Py)2(OH)(succinate)] using amide coupling and its structural interaction with guanosin-
borate G4 quadruplex; b) Schematic incorporation of 9 into G4K+ borate hydrogel. 
 
1.3 Strategies for the enhanced photoactivation of PtIV 
prodrugs 
 
Photoactivatable PtIV anticancer prodrugs generally suffer from poor absorption 
profiles. Therefore, complementary strategies to delivery cytotoxic PtII species at 
convenient excitation wavelengths have been explored. Following an approach earlier 
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devised for Ru complexes by Alessio and coworkers,32 metal complexes can be 
conjugated with porphyrins which absorb light in the red part of the visible, acting as 
antennas. Conjugates of this type, behave both as PDT and photochemotherapy agents 
due to the presence of the metal complex. This is the case of tetraplatinated 
porphyrins described by the group of Spingler,33 whose conjugates can interact with 
DNA by both intercalation and platinum binding modes. Other delivery systems are 
based on biocompatible nanomaterials, such as inorganic or polymeric nanoparticles, 
that serve as vehicles for the photoactivatable anticancer drugs.11 
New emerging systems permit the transport and delivery of the PtIV prodrugs as well as 
their photoactivation by using light-irradiation wavelengths in the therapeutic window 
(600 t  1000 nm). In addition, they can act as a theranostic agent by combining 
therapeutic and multimodal imaging capabilities. 
 
Figure 10. Schematic representation of the QDs photoactivation of 10 upon visible light 
irradiation (630 nm). 
 
Mareque and coworkers demonstrated that core-shell CdSe t ZnS quantum dots (QDs) 
can efficiently photoactivate a series of PtIV complexes via ET (electron transfer) using 
visible light up to 630 nm, a wavelength currently in use for clinical PDT.19,34,35 The two 
PtIV complexes studied were [PtCl4(bpy)] (b   ˙ A  îUî[ -bipyridine) and cis,cis,trans-
[Pt(NH3)2Cl2(O2CCH2CH2CO2H)2] (10) (Figure 10). After 1 h in the presence of QD, 
around 2000-2200 molecules of PtII were generated per QD using low power visible 
laser light in the case of [PtCl4(bpy)].34 Concerns regarding the toxicity of these systems 
exist, but no significant toxicity was found when employing micellar QDs formulated 
for the study of radiolabelling, in the concentrations required to photogenerate 
cisplatin. Additionally, the authors demonstrated the capability of micellar QDs to be 
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radiolabelled with the fac-[99mTc(OH2)3(CO)3]+ complex, and therefore their theranostic 
capability to be used for imaging (SPECT and optical imaging) as well as for 
photochemotherapy35  
Upconverting nanoparticles (UCNPs) are also a promising multimodal tool for the 
activation of metal-based prodrugs. This type of nanomaterials is typically composed 
by an inorganic host lattice (i.e. NaYF4, NaGdF4, NaLuF4, KYF4), activator ions (Er3+, 
Tm3+, Ho3+) and sensitizer ions (i.e Yb3+). Upon near infrared (NIR) light excitation, 
these lanthanide-doped UCNPs undergo an anti-Stokes process which converts the 
absorbed low-energy NIR light into UV and visible photons. The upconverted emission 
has been used to photoactivate the NO- o]vP   Z}µ]v[   ol   ^o 36 and also to 
promote the ligand photodissociation of Ru polypyridyl complexes.37 UCNPs have also 
shown promising properties as optical, MRI, and PET/SPECT imaging probes integrating 
suitable features for theranostics.38 
Our group reported the photoactivation of the PtIV complex cis,cis,trans-
[Pt(NH3)2(Cl)2(O2CCH2CH2CO2H)2] (10) by near infrared light (980 nm) using 
NaYF4:Yb3+/Tm3+@NaYF4 core-shell upconversion nanoparticles (UCNPs) (Figure 11a).39 
The cisplatin precursor was coupled with the biocompatible PEGylated phospholipid 
DSPE-PEG(2000)-NH2 (DSPE-PEG-10) (Figure 11a), affording a promising strategy to 
decorate the surface of the nanoparticles. This hybrid photoactivatable nanomaterials 
was capable of releasing PtII species upon NIR light excitation ( Oexc = 980 nm, 7.3 W·cm-
2). 1H NMR confirmed the release of the axial succinate ligands after 3.5 h of 980-nm 
irradiation and XPS indicated that UCNPs decorated with DSPE-PEG-10 fully converted 
PtIV into PtII at the end of the photoreaction.  
Chapter 1a 
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Figure 11. a) core-shell upconversion nanoparticles (UCNP) decorated with conjugated DSPE-
PEG and complex 10; b) b1: cis,trans-[Pt(en)(I)2(O2CCH2CH2CO2H)(OH)] (where en = 
ethylenediamine) covalently linked to silica-coated UCNPs and b2: cis,trans-
[Pt(en)(I)2(O2CCH2CH2CO2)(OH)]- electrostatically anchored to UCNP. Both b1 and b2 strategies 
released the photoproduct [Pt(H2O)2(en)]2+. 
 
Bednarski et al. applied the use of UCNPs for the photoactivation of diiodido-PtIV 
complexes at 980 nm.40 Two different approaches were employed for loading the PtIV 
complexes on the UCNPs (Yb,Er- and Yb,Tm-doped t -NaGdF4): (b1) covalent 
attachment of the Pt(IV) complex via amide bonds on the silica-coated surface of the 
UCNPs; and (b2) electrostatic interactions between the UCNPs surface and 
diiodi }> PtIV carboxylato complexes (Figure 11b). 
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In vitro results on human leukemia HL60 cells indicated a substantial increase in 
cytotoxicity when both modified Pt(IV)-UCNPs were combined with five rounds of 30 
min NIR light irradiation (980 nm, 1.2 W/cm2) compared to dark controls. However, 
NIR light alone also had a significant cytotoxic effect, 70 % reduction in cell vitality, at 
the same time exposure. The activated products were able to platinate calf thymus 
DNA. The main drawback of the systems developed by Bednarski was the limited 
stability of the diiodido-PtIV complexes on the UCNP surface, where only 20% of the Pt 
loaded on the surface of both b1 and b2 UCNPs retained the Pt(IV) measured by XPS. 
These hybrid nanomaterials have the potential to overcome the poor absorption 
properties of metal complexes in the visible, particularly in the therapeutic window 
(630−700 nm).  The low toxicity (both in vitro and in vivo) of UCNPs with respect to 
other nanomaterials and their multimodal imaging capability are key advantages to 
exploit for novel applications in nanomedicine. Despite photoactivation reactions were 
accomplished employing these UCNP systems, there is still need for significant 
improvements in the upconversion yield and optimization of the surface 
functionalization. This is mandatory in order to decrease the power density employed, 
and achieve safe application of NIR light sources in vitro and future in vivo studies. 
 
  
Chapter 1a 
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1.1 Introduction 
Flavin (from Latin flavus, "yellow") is the term commonly used to define a family of 
yellow-colored compounds containing the basic structure 7,8-dimethyl-10-alkyl 
isoalloxazine. Riboflavin (Rf), also known as vitamin B2, is an essential component of 
living organisms and the precursor of all biologically relevant flavins.1 
 
 
Figure 1. Chemical structures of riboflavin (Rf), flavin mononucleotide (FMN), and flavin 
adenine dinucleotide (FAD). 
As such, Rf is an important component of our diet, found in nutrients such as milk, 
eggs, cereals and grains, some meats, and green vegetables.  Upon ingestion, Rf is 
diversely distributed in tissues, but little is present as free Rf. Once internalized into 
cells, the majority of riboflavin is found as flavin adenine dinucleotide (FAD), and in 
smaller amounts as flavin mononucleotide (FMN) (Figure 1). 
 
These flavin cofactors have the ability to participate in one and two electron transfer 
processes. Flavins exist in three forms depending on their redox state and pH: oxidized, 
one-electron reduced (semiquinone) and two-electron reduced (Figure 2). Therefore, 
flavins are very versatile being able to transfer single electrons, hydrogen atoms and 
hydride ions.2 
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Figure 2. Redox and acid-base equilibria of flavins. 
At physiological pH, the redox potential of free flavins is around Em A  >îìì   u s  ~>îí ı 
u s  (}   &   U  >î ìæ  u s  (}   & D EU  v   >îì ì  u s  (}   Z(X   dZ   À oµ   À ˙   ]Pv](]v o˙ 
(approx. from >400 mV to +60 mV) in flavin-containing proteins (flavoproteins) 
because of the protein environment. The proximity of aminoacidic residues with a 
positive charge may generally produce an increase of the flavin redox potential, while, 
a negative charge or a hydrophobic environment would reduce it.3 Furthermore, 
studies where the target residue of covalently bound FAD in flavoenzymes is mutated, 
suggest that the covalent interaction would contribute to increase the oxidative power 
of the flavin.4 
 
Oxidized flavins present good absorption (molar absorptivities > 104 M-1 cm-1) in the UV 
and visible part of the spectrum, displaying four peaks at 445, 375, 265 and 220 nm 
which all correspond to   W   * transitions. When flavins are photoexcited, the 
intersystem crossing from the singlet to their triplet state is generally efficient. The 
quantum yields for the triplet formation of Rf and FMN are high, 0.375 and 0.225 
respectively. On the contrary, in the case of FAD, the triplet quantum yield is very low 
due to efficient radiationless decay to the ground state caused by stacking between 
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the isoalloxazine and adenine moieties.5 The neutral forms of flavins exhibit an intense 
yellow-green fluorescence at around 520 nm while their anions and cations are non-
fluorescent. The fluorescence quantum yield of Rf is 0.28 in water (pH 7). 
 
Despite flavins are thermostable, they are sensitive to light excitation and have a 
tendency to photodecompose. In particular, Rf is highly sensitive to UV and visible light 
undergoing intramolecular photoreductions between the isoalloxazine ring and ribityl 
side chain, which acts as electron donor in the absence of external reducing agents. 
Several photoproducts are obtained via oxidation and further fragmentation of the 
side chain, including cyclodehydroriboflavin (CDRF), formylmethylflavin (FMF), 
lumichrome (LC), lumiflavin (LF) and carboxymethylflavin (CMF), (Figure 3). Except for 
lumichrome (LC), the photoproducts show absorption and emission properties similar 
to Rf. If further oxidized, they are totally decomposed and converted into 2,3-
butanedione. However, the Rf photostability can be increased by alkylating the ribityl 
side chain, such as in the î [Uï[Uð[Uæ[-tetrabutyril ester of Rf.1 
 
 
Figure 3. Photodegradation products of Rf in the presence of light and O2. 
 
Apart from intramolecular reduction, addition and alkylation reactions upon light 
exposure, Rf can also carry out intermolecular photoreactions.6 A great variety of 
photocatalytic processes have been developed using Rf as catalyst and organic 
substrates. A decarboxylative fluorination of aliphatic carboxylic acids was described 
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by Ye and corworkers.7 Modified Rfs were used by the group of Cibulka to perform 
photocatalytic energy transfer [2+2] cycloadditions8 and stereoselective photocatalytic 
esterification of various acids and alcohols.9 Inspired by  E µ [  (Z) to (E) 
photoisomeritazion of retinal (vitamin A aldehyde) by using Rf, Gilmour and coworkers 
demonstrated in 2015 the reversed photoisomerization from (E) to (Z) by modulating 
retinal substrate.10 
Wolf et al.  described a strategy for the enhancement of the reduction potential of 
riboflavin tetraacetate by coordinating scandium triflate. This coordinated compound 
enabled the challenging photocatalytic C t H oxidation of electron-deficient 
alkylbenzenes and benzyl alcohols.11 Same photocalysis was afforded bycoordinating 
the tetraacetate riboflavin with abiomimetic non-heme iron complex .12 Rf has been 
reported to photocatalytically perform the direct conversion from biaryl carboxylic 
acids without the need of substrate pre-functionalization into benzocoumarins. This 
photoproduct is a coumarin derivative, which has recently emerged as an interesting 
fluorophore in the bioimaging research.13  
Another remarkable example of the applicability of Rf as a photocatalyst is its use as 
photosensitizer in Mirasol Pathogen Reduction Technology System (Terumo BCT). This 
process is used to treat both platelet and plasma for blood transfusions in which Rf 
inactivates significant levels of viruses and bacteria upon UV light irradiation.14 This 
simple and direct protocol concomitantly with the inexpensive catalyst and the 
absence of external metal additives makes a promising use of vitamins in the field of 
catalysis. 
Flavins are present in multiple organisms. In particular, the human genome contains 90 
genes encoding for flavin-dependent proteins.15 Flavoenzymes can catalyze highly 
diverse reactions, such as oxidation and reduction, monooxygenation, 
dehydrogenation, and halogenation. However, more than 90% of the flavoproteins are 
oxidoreductases. Their essential and versatile role in most organisms, make 
flavoproteins a potential pharmacological target.16  
Flavoenzymes have also been reported to perform artificial reactions, such as the use 
of modified transient reactive flavin methylene iminium cofactor in enzymes to 
perform nucleotide methylation and therefore a nucleotide activation.17 Another 
example is the use of the enzyme flavocytochrome c3 (fcc3) to carry out fuel-forming 
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in an artificial photosynthesis reaction, which normally catalyzes hydrogenation across 
a C=C double bond (e.g. fumarate to succinate).18 This adaptability to other substrates 
in the reactions opens a new field of strategies with flavins as catalysts. 
In this chapter, I briefly describe four selected flavoproteins among others, because 
these have played an important role in the work I discuss in the following experimental 
chapters:  
NADH oxidase (NOX from Thermus thermophilus) catalytically produces reactive 
oxygen species (ROS) by reducing molecular oxygen to generate superoxide and 
hydrogen peroxide in many cellular compartments. The structure of this homodimeric 
enzyme consists of a central 4-stranded antiparallel beta-sheets covered by helices, a 
more flexible domain formed by two helices, and a C-terminal excursion connecting 
the subunits. The flavin moieties at the active site are easily accessible and are located 
in a deep open cleft between the subunits.19 
This flavoprotein is industrially utilized for the in-situ cofactor regeneration of 
NADH.20,21 
 
Figure 4. Crystal structure of NOX with FAD. 
 
Glucose oxidase (GOX from Aspergillus niger) is a flavin-dependent oxido-
reductase enzyme composed of two identical 80-kDa subunits with two FAD co-factors 
bound. This enzyme catalyzes the oxidation of beta-D-glucose by molecular oxygen to 
D-glucono-w-lactone and hydrogen peroxide. GOX is produced naturally in some fungi 
and insects, where the hydrogen peroxide generated by the enzyme acts as an anti-
bacterial and anti-fungal agent. GOX is an industrially important enzyme used in 
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various applications such as glucose-based enzymatic biosensors and biofuel cells due 
to its high intrinsic specificity and selectivity for glucose. Recently, its biocatalytic 
properties have been combined with nanotechnology for biosensor applications.21 
 
Figure 5. Crystal structure of GOX with FAD. 
 
Glutathione reductase (GR from S. cerevisiae) is a dimeric flavo-oxidoreductase 
involved in the cytoplasmic and mitochondrial redox regulatory systems. GR catalyzes 
the reduction of glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH), 
using NADPH (Nicotinamide adenine dinucleotide phosphate) as electron donor and 
FAD as coenzyme. GSH is a critical molecule in the cellular management of oxidative 
stress and in maintaining the reducing environment of the cell. 
 
Figure 6. Crystal structure of GR with FAD. 
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MiniSOG (for mini Singlet Oxygen Generator), is a fluorescent flavoprotein engineered 
from Arabidopsis phototropin 2 which contains 106 amino acids.22 Fluorescent 
proteins derived from light, oxygen, or voltage (LOV) domains offer advantages due to 
their small size (advantageous in protein fusions) and efficacy under anaerobic 
conditions.23 Upon light excitation, miniSOG has been reported to photosensitize 1O2 
(L = 0.47 ± 0.05) practically to the same extent as free FMN.22 Later, it was found that 
MiniSOG not only produces 1O2, but also alternative mechanisms type-I involving 
radical species, in which the photooxidation of the substrates is produced.24 These 
findings show that MiniSOG might be a potential tool as oxygen-independent 
fluorescent reporters.  
Very recently, MiniSOG has been engineered to form fluorescent flavoprotein 
heterodimers (~26kDa) with phiLOV2.1, the most photostable flavoprotein known to 
date. These heterodimers endure photodegradation significantly, in addition to the 
combination of photostable fluorescence, ROS photosensitization and/or ïUï[ -
diaminobenzidine (DAB) photo-oxidation useful for imaging tool.25 
 
 
Figure 7. Crystal structure of MiniSOG with FMN cofactor. 
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2.1 Introduction 
 
Nature has developed efficient and selective enzymes to perform a myriad of 
biological functions. Enzymes often employ metals and have inspired chemists in the 
design of abiotic catalytic processes, which are carried out by coordination or 
organometallic compounds and occur in complex biological environments. Accordingly, 
chemical activation and catalytic amplification can be harnessed to efficiently produce 
in cells bioactive species able to diagnose or cure diseases. Catalysis requires 
administration of low doses of metals to achive desired biological effects, potentially 
diminishing metal toxicity in biological enviroments. Additionally, different 
mechanisms of action are normally associated to catalytic drugs, which can in principle 
help avoiding drug resistances. Yet, performing efficient and selective abiotic catalysis 
in biological environments is a challenging task because catalysts need to survive and 
perform in extreme complex habitats, where high concentrations of biomolecules and 
reactive chemical species can easily interfere and deactivate the whole catalytic 
process. 
 
In this context, metal-based catalysis has merged with bioorthogonal chemistry to 
originate bioorthogonal catalysis, a young and thriving field, which has delivered new 
chemistry concepts and scientific breakthroughs. Bioorthogonal reactions are chemical 
modifications that can be performed within living biological systems, such as cultured 
mammalian cells or even complex organisms (e.g. zebra fishes or mice) without 
interfering with their host biochemistry. The term bioorthogonal was coined 15-years 
ago by Bertozzi to describe the use of Staudinger ligation reactions for the selective 
modification of glycoproteins with biochemical and biophysical tags.1,2 
The groups of Mascareñas and Do published this year two excellent review articles3,4 
which summarise the best achievements of bioorthogonal catalysis, specifically 
highlighting the key role played by organometallic chemistry. The labelling of proteins 
and membranes with fluorescent dyes (e.g. rhodamine)5,6 is historically the first 
scientific achievement of bioorthogonal catalysis. However, a significant portion of the 
systems developed more recently in the field focuses on the deprotection reactions of 
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allyl and propargyl groups from profluorescent dyes, a proof of concept strategy for 
demonstrating that catalysis takes place in vitro and in vivo.3  
 
Metal-based catalytic processes specifically devised for therapy are still a minority. This 
introductory chapter will look at this latter aspect in particular. Herein, I organise an 
overview of the key concepts introduced in drug development by the combination of 
catalysis, bioorthogonal chemistry and metallodrug design. Although orginated from a 
different perspective, there is a relatively small number of metallodrugs designed to 
work as enzyme mimics for the cleavage or modification of targeted biomolecules. 
They are also part of this specific field and share drug design concepts that are worth 
including in the chapter. Figure 1 is a schematic representation of the strategies that 
have been employed to introduce catalysis in the development of novel drugs. 
 
 
Figure 1. Schematic representation of the two different strategies applied for the catalytic 
metallodrugs described in this chapter. 
 
 
2.2 Catalytic metallodrugs targeting biomolecules 
 
Cells depend on fundamental biomolecules such as RNA or proteins among others, 
which carry out processes indispensable for their functioning and survival. Catalysis 
approaches and catalytic metallodrugs have been developed to target and disrupt 
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several of these essential biochemical systems for therapy purposes. The degradation 
of biomacromolecules (proteins, sugars, lipids and nucleic acids) and the perturbation 
of the redox balance in cells are the two strategies explored for the design of 
metallodrugs capable of inducing (cancer) cell death through a catalytic mechanism. 
 
Degradation of biomolecules 
Catalytic metallodrugs can exert therapeutic activity by targeting peptides and proteins 
and favouring their degradation and fragmentation via hydrolysis and oxidation 
reactions.  
The first catalytic metallodrugs capable of cleaving enzymes and shutting down their 
activity date back to the 90s. The phenanthroline CuII derivative (1) (Figure 2), for 
instance, catalyzes the hydrolytic cleavage of carbonic anhydrase enzymes, specifically 
acting within their active site upon addition of a reducing agent.7 Analogously, FeIII and 
CuII t containing EDTA-biotin conjugates (2) (Figure 2) were developed to catalytically 
produce the oxidative cleavage of streptavidin, (a protein with extraordinary high 
affinity to biotin) selectively in close proximity to its biotin (vitamin B7) binding site.8  
[CoIII(cyclen)(OH2)2]3+ (3) (Figure 2) is a peptide-cleaving catalyst that can selectively cut 
under physiologically relevant conditions the peptide deformylase, a metalloprotein 
essential in bacteria cell growth. For such reason, this CoIII derivative 3 is described as a  
potential antibiotic agent.9  Suh et al. employed the same CoIII complex 3 for the 
hydrolysis (at 310 K and pH 7.4) of amyloids,10 t 13 which are insoluble aggregates of 
peptides or  }]v    v  ]v  ]       µZ      oÌZ]u[ U   Wl ]v}v[   v    d˙    / /  
diabetes. 
 
A series of metallodrugs (CuII, NiII, FeIII and CoII) were prepared using the so called 
ATCUN motifs, metal-binding tripeptides present in the N-terminus of many naturally 
occurring proteins (Figure 2). Among these, copper complex 4a, bearing the inhibitor 
of angiotensin-converting enzyme (ACE) lisinopril, demonstrated to catalytically cleave 
such enzyme, with potential implication in the treatment of hypertension and heart 
failure.14  
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Figure 2. Chemical structures of metallodrug catalysts or ligands employed in the degradation 
of biomolecules.  
 
Cowan and coworkers redirected the use of ATCUN ligands to the catalytic cleavage of 
RNA, a process which is normally produced by oxidative stress. They designed a CuII 
ATCUN catalytic metallodrug (4b, Figure 2) to target hepatitis C via inactivation of its 
RNA.15,16 The same group also described that CuII ATCUN complexes with a Rev peptide 
(one of the cell-penetrating peptides (CPPs) derived from HIV-1 Rev protein) targeting 
sequence (4c) (Figure 2) were able to recognize and catalytically cleave HIV1 RNA in 
Escherichia Coli and in mammalian Jurkat cell lines. 17,18  
 
The Cowan group also designed artificial glycosidases (fucosidases). The artificial 
construct is based in a copper ATCUN motif incorporated into a fucose-selective 
binding domain (4d) (Figure 2), which exhibits selective carbohydrate cleavage 
reactivity towardL-fucose over D-glucose.  
This synthetic metallopeptide selectively cleave fucose from the H2-antigen 
saccharide, enabling in such a way the efficient removal of this antigen from the red 
blood cells (erythrocytes). The rare Bombay blood type lacks this H2 antigen, what 
makes extremely difficult to find compatible blood for such patients that would need 
transfusions. Therefore, the application of this artificial glycosidases on regular human 
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type-O blood with the H2-antigen converts such abundant blood type into a potential 
blood substitute for the rare Bombay blood type.19 Such strategy may also be applied 
for the selective degradation of other carbohydrates relevant in other sugar-
dependent diseases.  
Other examples of metal complexes, mainly of NiII, FeII, FeIII, CoIII and CuII , which 
contain ligands targeting specific peptides and RNA have been reported and reviewed 
elsewhere.20 t 24 
 
Redox imbalance 
Cells maintain a delicate redox balance by fine-tuning the concentration of oxidizing 
and reducing agents. This balance can be disrupted by oxidative and reductive stresses, 
which trigger a mismatch between reactive oxygen species (ROS) and/or reactive 
nitrogen species (RNS) and intracellular antioxidants. As a result, the structure of 
biomolecules such as DNA, lipids and proteins may be damaged, and the normal 
functioning of the cell altered.25 The redox conditions of cells are crucial in the 
regulation of gene expression and some signalling pathways. Thus, the modulation of 
the redox equilibria in cells is an attractive strategy in which applying metal-based 
catalysts for therapy.  
 
Photodynamic therapy (PDT) is a prototypical example of catalysis-based therapeutic 
approach that affects the cell redox balance. This clinically approved treatment relies 
on the photoinduced catalytic production of 1O2 and ROS in tumors. Despite several 
PDT agents have been approved for clinical use,26there is an emerging interest in 
extending the use to transition metal complexes as PDT agents. Metal complexes can 
be tailored to achieve optimal stability and biodistribution properties and typically 
display intense absorptions in the visible region, and good two-photon absorption 
cross-sections which enable two-photon excitation with highly-penetrating NIR light.27 
Examples of ROS generating catalysts for PDT include Ru,28 t 30 Rh,31 Ln,32,33 Tb34 
complexes35. Few have emerged as promising PDT agents and are currently under 
clinical trials including motexafin lutetium (Antrin),36 tin ethyl etiopurpurin (Purlytin),37 
and the polypyridil Ru complex TLD1433 which has completed clinical trials phase I in 
2017.30 
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The enzyme superoxide dismutase (SOD) and its catalytic antioxidant activity have also 
been investigated in clinical trials for the treatment of age-related macular 
degeneration.38 SOD is an endogenous and first-line-of-defense enzyme that 
eliminates the superoxide anion O2 t  by catalyzing its dismutation into O2 and H2O2.39  
If superoxide is not regulated, causes many types of cell damage. Analogously, H2O2 is 
also damaging but it is degraded by other enzymes such ascatalase. 
Two MnII MRI contrast agents, Mangafodipir (MnDPDP) and Calmangafodipir 
(Ca4Mn(DPDP)5) (Figure 3), have shown activity as SOD analogues. The last is in phase II 
clinical trials for the treatment of metastatic colorectal cancer.40,41 A great number of 
SOD mimiking complexes have been developed over the years stimulated by these 
clinical results.42 Among others, the M40403 (Figure 3) synthetic manganese 
containing superoxide dismutase mimetic is undergoing clinical trials for the treatment 
of metastatic melanoma and renal carcinoma.43 
 
 Figure 3. Chemical structures of manganese SOD analogues and organotelluride.  
 
Differently from the previous manganese SOD analogues, the LAB027 compound 
associates a quinone core along with two tellurium atoms. The organotelluride redox 
  o˙    ]        }}˙ ] o  uu    }(   Z   Z v }l((  } [  (u]o˙U  `Z] Z  ]     o    }  
recognize a particular intracellular state of cells, such as an oxidative stress, and 
selectively kill the cells that are under this state. In particular, LAB027 was found to 
amplify the level of ROS in human HT29 and murine CT26 colon cancer cell lines 
generating a lethal oxidative burst. LAB027 was demonstrated to be a potential drug 
to treat colon cancer either alone or in combination with oxaliplatin through a 
mechanism that involves mainly necrosis.44 
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Thiol groups significantly contribute to preserve the folding and stability of proteins 
and enzymes. Moreover, thiols also control the redox homeostasis of cells.45 
Gluthatione (GSH) is the most important, non-enzymatic antioxidant component 
together with the nicotinamide adenine dinucleotide phosphate NADPH/NADP+ 
couple.46 GSH is a cysteine-containing tripeptide (  J-L-Glu-L-Cys-Gly), which can be 
oxidized to glutathione disulfide (GSSG) preventing cellular damage by ROS and RNS.  
Sadler and coworkers reported half-sandwich RuII arene complexes with  V-donor/ S-
acceptor phenylazopyridine ligand, which confers remarkable inertness toward ligand 
substitution. In phosphate buffer, the RuII catalyst 5a and 5b (1% loading) (Figure 4) 
oxidized 10 mM GSH efficiently over 24 h, achieving a turnover number (TON) of 37 
(turnover frequency (TOF) = 0.30 h-1) and 46 (TOF = 0.37 h-1) respectively. Complexes 
5a and 5b as well as their p-cymene analogues were highly cytotoxic to A2780 human 
ovarian and the A549 human lung cancer cell lines with IC50 values of 2-6  PM, due to 
the catalytic reduction in the intracellular GSH concentration.47 
 
In addition to redox balance, GSH is responsible of other cellular processes such as 
detoxification, i.e. convertion of endogeneous and exogeneous toxins into GS-X 
adducts.48,49 RuII complexes containing redox-active o-phenylenediamine chelating 
ligands `]Z   Z  (}uµ o   ~ 6-arene)Ru(o-phenylenediamine)Cl]+ (arene = p-cymene 
(6), hexamethylbenzene or biphenyl) (Figure 4) undergo ligand oxidation producing  
their o-benzoquinonediimine. Interestingly, the benzoquinone complexes can be 
reduced by the tripeptide GSH but readily undergo reoxidation in air.50 Nevertheless, 
this family of RuII complexes show no anticancer effect in lung and ovarian cancer cells 
(IC50>100  PM), probably due to the low catalytical efficiency or because of the 
reoxidation by oxygen.50 
Recently, Therrien and coworkers demonstrated that two thiolate-bridged RuII arene 
]u   ~~ 6-arene)2Ru2(SR)3]+ (7  v  ~ 6-arene)2Ru2(SR)2Cl2]) (8) (where R comprises 
more than 20 different subtituents with variable lipophilicity) (Figure 4) were able to 
perform catalytic GSH oxidation under physiological conditions. These dimers showed 
anticancer activity against several cancer cell lines, including cisplatin-resistant ones. 
Unfortunately, such results do not correlate with the the catalytic oxidation of GSH 
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determined by NMR. A possible explanationconcerning this mismatch may be due to 
the different environmental conditions, where the study of the catalytic oxidation is 
performed in NMR tubes, while the cytotoxicity is determined within cancer cells. 
Despite of this, the catalytic GSH oxidation activity cannot be completely ruled out, 
since the cytotoxicity correlates well with lipophilicity, what would significantly vary 
the Ru uptake in cells and consequently the GSH activity.51,52  
 
The RuII cages [(p-cym)6Ru6(2,4,6-tri(pyridine-4-yl)1,3,5-triazine)2(1,4-
benzoquinoato)3]6+ (9) (Figure 4) and its naphthoquinonato analogue are normally 
synthesized to transport cytotoxic molecules into cancer cells, but their capability to 
catalytically oxidize GSH to GSSH have been also demonstrated.  The presence of the 
imidazole group of histidine, and the basic amino groups of lysine and arginine, were 
shown to break the hexanuclear metallaprism 9 and coordinate to the p-cymene RuII 
unit generating stable adducts.53,54 In competitive studies, 9 has shown to 
preferentially react to amino groups, while simultaneously oxidizing ascorbic acid, Cys, 
and GSH to dehydroascorbic acid, cystine, and GSSG. As a consequence of such 
oxidation reactions, this precatalyst displayed good cytotoxicity (IC50 = 23  M) against 
A2780 cancer cell lines. 
 
Figure 4. Chemical structures of metallodrug catalysts employed in the oxidation of thiols.  
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The abovementioned studies regarding the catalytic oxidations of thiols have shown 
promising results, yet they lack specificity and can react with other sulphur-containing 
molecules. Nonetheless, their partial preference for GSH is encouraging for the design 
of a new generation of catalytic metallodrugs. 
 
Transfer hydrogenation reactions are reduction processes in which a catalyst is able to 
transfer a hydride ion from a donor to a molecule containing a doble bond. In 
biological relevant conditions, these reductions can be carried out in aqueous solutions 
using sodium formate as hydride source.55 Such mild electron donor allows hydride 
transfer to biomolecules such as nicotinamide adenine dinucleotide (NADH/NAD+) or 
pyruvate. Importantly, cancer cells have a high metabolic rate in which high levels of 
oxidizing species are generated. This makes cancer cells more sensitive to changes in 
redox homeostasis, and therefore variation of the NAD+/NADH balance can provide an 
effective strategy to devise new therapies.  
 
Early examples of application of this strategy concerned the development of metal-
based catalysts for the generation of NADH in aqueous solution. 
Steckhan and coworkers reported the first examples of metal catalysts capable of 
regenerating NADH via NAD+ reduction in a buffered solution. RhIII bipyridine 
complexes (e.g. 10) (Figure 5) efficiently catalyzes the reduction of NAD+ to NADH up 
to 8.2 regeneration cycles.56 Süss-Fink and coworkers studied a series of complexes of 
phenanthroline-containing RuII, RhIII and IrIII catalysts able to reduce NAD+, with  RhIII 
and IrIII derivatives showing the highest catalytic activity. For example, 
[(Cp*)Rh(phen)Cl]+ (11) (Figure 5) reached the best TOF value (2000 h t 1) in aqueous 
media, twice the efficiency obtained by its bipyridine analogue [(Cp*)Rh(bipy)Cl]+.57  
A family of RuII complexes containing ethylenediamine or acetylacetonate were 
studied for the regioselective and catalytic regeneration of 1,4-NADH in the presence 
of formate. The hexamethylbenzene (hmb) RuII derivative (12) (Figure 5) provided the 
higher TOFmax value (1.46 h-1) in buffer and aireated solution, although higher rates 
were obtained under argon (TOF is 1.14 h-1 under argon compared with 0.85 h-1 under 
air condition). Remarkably, eukaryotic cells (at least human lung cancer cells) appear to 
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tolerate high levels of formate, therefore the catalytic activity of these metal 
complexes may be proven in cells.58  
Further development in the design of catalytic metallodrugs consisted in the use of 
artificial metalloenzymes in order to avoid metal poisoning. Ward and coworkers 
incorporated biotin into Noyori-type IrIII complexes [Cp*Ir(biot-p-L)Cl] and 
demonstrated that, in combination with oxidizing agents, it was able to oxidize GSH 
and the catalytic activity increased. In addition, they anchored the IrIII complex within 
streptavidin, and used the resulting compound for asymmetric transfer hydrogenation 
with different redox enzymes which depend on NADH, FADH2 (reduced flavin adenine 
dinucleotide) and haem cofactors.59 
 
Figure 5. Chemical structures of metallodrug catalysts for transfer hydrogenation reactions.  
Water-soluble Noyori-type RuII sulfonamide ethyleneamine complexes, especially 13 
(Figure 5), have demonstrated to reduce NAD+ to NADH with higher TOFs (TOF = 0.2 t 7 
h-1) than compound 12. For this reason, they were evaluated in A2780 ovarian cancer, 
where they could reduce the levels of NAD+ by co-administration of sodium formate. 
The antiproliferative potency of these Noyori-type RuII sulfonamide ethyleneamine 
complexes was comparable to that of cisplatin.60 On the contrary, the IrIII complex 
[(CpX)Ir(phen)H2O]2+ (14) (Figure 5) is able to accept hydrides from NADH prompting a 
higher NAD+/NADH ratio that alter the mitochondrial membrane potential (MMP), 
generate oxidative stress via ROS production and finally cause apoptosis in A2780 
ovarian cancer cells after 24 h of exposure (Figure 5).60 In the same manner, the IrIII 
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complex [(CpXbiph)Ir(phpy)py]+ (phpy = phenylpyridine), utilizes NADH as a biological 
hydride donor, to produce an iridium-hydride complex which generates ROS in cancer 
cells.61 
More recently, Sadler and coworkers demonstrated for the first time that the chiral 
half-sandwich OsII arene sulfonyl diamine complexes, like [Os(arene)(TsDPEN)] (TsDPEN 
= N-(p-toluenesulfonyl)-1,2-diphenylethylenediamine) (15) (Figure 5), are capable to 
carry out the enantioselective reduction of pyruvate into D-lactate enantiomer in cells 
using non-toxic concentrations of sodium formate as hydride source.62 This Os complex 
displays high stability both in aqueous and DMSO solutions, and in the presence of cell 
culture media over 24 hours (310 K). TOF values of all the osmium complexes 
described were higher than the ruthenium analogues in the cetophenone reduction 
catalysis by a factor of 3.5xTOFmax, and values reached up to 78 h-1. They showed toxic 
effect in A2780 ovarian cancer cells and more remarkably, a novel mechanism of 
anticancer activity which is not related to DNA damage. Other unsaturated substrates 
of the cytosol may be targeted to yield a multitargeted mechanism of action for the 
drug. In addition, the authors described an interesting strategy to avoid formate 
toxicity. They used N-formylmethionine as a formate precursor and simultaneously?? 
as a substrate for the enzyme peptide deformylase, which is overexpressed in some 
cancer cell lines (for example in PC3 human prostate cancer). In this way, the 
generation of intracellular formate would provide a hydride donor and a co-catalyst. 
 
2.3 Bioorthogonal metal-based catalysis towards 
extracellular substrates 
 
Different catalysis concepts have been adopted to generate organic drugs directly in 
the cellular environment for therapy purposes. 3,4,63These processes use abiotic 
substrates such as cage compounds or synthesis precursors, and typically rely on 
cleavage and deprotection reactions, as well as on cycloadditions. In situ catalytic 
generation of bioactive molecules may give a handle to control the effects of drugs via 
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chemical activation and potentially reduce systemic side effects. Ideally, catalysts are 
administred at low concetrations, eluding metal toxicity concerns. 
The earliest breakthrough in bioorthogonal metal-based catalysis was reported by 
Streu and Meggers.64 In 2006, they described the use of the Ru(II) half-sandwich 
complex [Cp*Ru(COD)Cl] (16) (where Cp* = pentamethylcyclopentadienyl and COD = 
1,5-cyclooctadiene) (Figure 6) as catalyst for the conversion of an allylcarbamate-caged 
rhodamine in Hela cells. This system was not ideal since exogenous aromatic thiols 
such as thiophenol (PhSH) were needed to attain a catalytic cycle. Furthermore, PhSH 
had non-negligible celluar toxicity which promted the exploration of alternatives for 
improving application of this strategy in vitro. 
Few years later, Meggers and coworkers reported that Ru(IV)-quinoline catalysts (17a-
b) were capable of performing allylcarbamate cleavage employing weaker nucleophiles 
such as GSH, an abundant intracellular bioreductant.65,66 This remarkable advance 
allowed performing catalysis in cell without the need of extracellular co-reactants, 
employing exclusively a prodrug (substrate) and its activator (catalyst). Compared to 
early bioorthogonal organoruthenium catalysts [Cp*Ru(COD)Cl] (16), complexes 17a-b 
greatly increased the catalytic efficiency, providing TONs up to > 300. In particular, 
higher catalytic activity was afforded under biologically relevant conditions using 
donor and acceptor substituents in the 4- (-Cl) and 5-position (-Cl,-NO2 and t COOMe) 
of the quinoline ligands. Substitution with a higher electron withdrawing methyl ester 
group to afford 18 (Figure 6) resulted in the most efficient catalyst of the series. This 
complex also demonstrated good catalytic activity in blood serum. 
Besides protected fluorophores, 17a-b catalyzed the activation of the anticancer 
prodrug N-(allyloxycarbonyl)doxorubicin inside HeLa cells, inducing cell death via 
apoptosis.65   
When cells exposed to alloc-doxorubicin (10 µM) were incubated with the Ru catalyst 
18 (1 µM), an IC50 of 2.0 µM was determined. This corresponds to an almost 
quantitative conversion of the prodrug, considering that direct administration of 
doxorubicin leads to an IC50 of 1.5 µM.66 
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Figure 6. Chemical structures of selected Ru(II) and Ru(IV)-quinoline bioorthogonal catalysts 
for the allylcarbamate cleavage reaction.  
 
The group of Mascareñas functionalized this family of Ru catalysts with the 
triphenylphosphonium (TPP) cationic ligand (19) for mitochondria targeting (Figure 6). 
The hydrophobic TPP cation drives the accumulation of functionalized molecules in the 
mitochondria in response to the mitochondrial membrane potential. Ru-catalyzed 
deprotection of profluorescent probes demonstrating that the approach could be 
applied to activate molecules in specific cellular organelles.67 
The introduction of Pd in the bioorthogonal metal catalysis toolkit has been a 
fundamental discovery in the field. In their pioneering work, Bradley and Unciti-
Broceta were the first to report on the catalytic uncaging of non-fluorescent allyl, 
propargyl, and benzyl carbamate-protected rhodamines by Pd0 nanoparticles (5 nm) 
supported on amino-functionalised polysterene microspheres. 
 
 In the context of new therapeutic approachs for controled drug release, Pd0-
microspheres were used for the extracellular activation of the drug 5-fluorouracil (5FU) 
from allyl, propargyl and benzyl caged precursors (Figure 7A). The Pd-mediated 
generation of 5FU induced apoptosis in colorectal and pancreatic cancer cells.68 
Analogously, a propargyl-masked prodrug of the anticancer agent vorinostat (histone 
deacetylase inhibitor) was also activated via Pd0 catalysis and subsequently by 
lowering the pH (Figure 7B).69  
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Figure 7. Different catalytic deprotection reactions of anticancer prodrugs by Pd NPs.  
 
Pd bioorthogonal catalysis was further extended for a controlled release of 
gemcitabine from carbamate-protected precursors (Figure 7C) in both buffered 
solution and cell culture medium.70 Using the profluorescent dyes allyl, propargyl, and 
benzyl carbamate-protected rhodamines, this specific approach was translated to 
zebrafishes to demonstrate its applicability in vivo, however without using products for 
therapy.68,71 
Recently, Unciti-Broceta and Leung demonstrated that Pd microspheres had promising 
biocompatibility when implanted in mice bearing a prostate tumor. Drug activation 
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experiments demonstrated the capacity of these catalysts to carry out ex vivo 
carbamate cleavage of a masked doxorubicin (Figure 7D).72 Zebrafish studies revealed 
that such caged doxorubicin derivative avoided the cardiotoxicity tipically produced by 
doxorubicin alone. 
 
Figure 8. Schematic representation of  Z}oo}[  Au nanorobot and the catalytic activation of a 
profluorophore and prodrug.  
Rotello and coworkers conceived nanozymes based on gold nanoparticles (AuNPs), 
integrating Ru- and Pd-mediated bioorthogonal catalysis. The protein-sized AuNPs (2 
nm of nanoparticle diameter) presented a core covered with hydrophobic alkanes for 
encapsulation of the organometallic Ru and Pd catalysts, a tetra(ethylene glycol) unit 
for improving biocompatibility and a terminal dimethylbenzylammonium group for 
imparting water solubility. Host-guest interactions between the headgroup and non-
toxic curcubit[7]uril (CB[7]) transforms this supramolecular  ˙  u  ]v    ZP   l [ 
nanozyme (Figure 8). Complexation with CB[7] inhibits the catalytic activity of Ru and 
Pd catalysts blocking the accessibility of substrates by steric hindrance. However, 
catalysis is restored as soon as the CB[7] competitive guest 1-adamantylamine (ADA) is 
added. Under these controlled conditions the Ru-catalyst [Cp*Ru(COD)Cl] (16) is 
employed to turn on the fluorescence of allylcarbamate caged rhodamine 110 dye in 
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Hela cells. The gated activation approach is also applied for the cleavage of the 
propargyl protecting group of pro-5FU (1 mM) by AuNPs embedded with the Pd 
catalyst 20 (100 nM) (Figure 8). In HeLa cells, intracellular conversion of pro-5FU into 
5FU using gated-catalysis results in a remarkable reduction of cell viability.73 
 
A different bioorthogonal catalysis concept was proposed by the Bradley group. They 
applied copper-catalyzed azide t alkyne cycloaddition (CuAAC) for the extracellular 
generation of a cytotoxic Cobrestatin derivative. Combretastatin A4 is a tubulin 
polymerization inhibitor and a highly cytotoxic agent against a variety of cancer cell 
lines. The triazole analogue synthesized in situ via CuAAC from two non-toxic (up to 10 
 PM) azide and alkyne precursors (Figure 9)74 is known to inhibit K562 leukemia cancer 
cell growth with an IC50 value of 1.3  PM.75,76 Polymeric microspheres supporting Cu 
nanoparticles (51.2 ± 4.2 nm) were employed to generate catalytically the Cobrestatin 
analogue in vitro in SKOV-3 and HeLa cells. Moreover, application of the copper 
nanostructures in zebrafish embryos triggers the unmasking of a profluorophore and 
proved the usability of this approach in a living organism.  
 
Figure 9. Formation of a Cobrestatin derivative mediated by Cu NPs catalysis.  
 
2.4. A new approach - outlook 
In catalysis, metal complexes are generally regarded as the catalyst. Specifically design 
mediators that facilitate the transformation of organic substrates in more valuable 
molecules. Of course, this also applies in the field of metal-based bioorthogonal 
catalysis. Changing this catalysis paradigm is a fine prospect in medicinal inorganic 
chemistry. There is in fact wide range of metal-based agents that can be developed as 
substrates for catalytic activation processes. This unorthodox approach may lead to 
devise new families of prodrugs and innovative strategies to exploit the rich medicinal 
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chemistry of metal complexes, simoultaneously reducing some of the unwanted 
biological effects characteristic of these systems. The experimental work of this thesis, 
described in the following chapters, is the first attempt to apply such new catalysis 
concept for therapy purposes. 
 
  
Chapter 2 
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Riboflavin As Bioorthogonal 
Photocatalyst For The Activation Of A 
PtIV Prodrug 
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3.1 Introduction 
The combination of catalysis and bioorthogonality1 t 3 promises to impact drug 
discovery and bioimaging by facilitating the execution of non-natural chemical 
reactions in living systems. Catalytic turnover can boost the efficiency of bioorthogonal 
chemical reactions, unveiling new strategies for prodrug activation and uncaging of 
molecular probes.4 t 8 
In this context, transition metal and organometallic catalysis have opened new 
avenues for the advance of bioorthogonal catalysis in cells.5,9 t 16 The laboratories of 
Meggers, Mascareñas, Unciti-Broceta and Bradley used organoruthenium and 
palladium catalysis to deprotect pro-fluorescent substrates and activate prodrugs in 
cancer cells or in their compartments and surroundings.11 t 14,16 Rotello devised 
biomimetic nanoenzymes for imaging and therapy, by encapsulating ruthenium and 
palladium catalysts into water-soluble gold nanoparticles and controlling their catalytic 
activity in HeLa cells through supramolecular chemistry.15 These pioneering studies 
exploited metal-based catalytic uncaging of allylcarbamate- and propargyl-protected 
amines as viable strategies for bioorthogonal catalysis, however new biocompatible 
transformations are highly needed to further advance this extremely challenging field 
that is still in its infancy.  
 
Scheme 1 Transition metal complex acting as substrate and its bioorthogonal activation by 
riboflavin which functions as photocatalyst. 
Herein, we describe an original photocatalysis approach to control the reactivity of 
transition metal complexes in a bioorthogonal fashion. In a new type of light-driven 
reaction, the exogenous biological molecule riboflavin (Rf) functions as a 
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bioorthogonal photocatalyst and a metal complex as unconventional substrate 
(Scheme 1).  
This unusual catalyst/substrate pair relies on the photoredox properties of Rf to enable 
the selective activation of a PtIV prodrug of cisplatin with exceptionally low doses of 
blue light, and induce apoptotic death in PC-3 human prostate cancer cells. 
Metal complexes are typically regarded as catalysts which convert organic substrates 
in more valuable compounds, whereas catalytic transformations of metal complexes 
are, to date, practically unknown and represent a paradigm shift in catalysis.17,18 Their 
development can expand the scope of bioorthogonal chemical reactions to inorganic 
substances and metal-based prodrugs, fostering the creation of new inorganic 
chemistry toolkits for biology and medicine. 
 
3.2  Results and Discussion 
As part of our ongoing efforts to design innovative light-activation modes for 
anticancer platinum complexes,19 we reasoned that Rf and its rich photochemistry 
would facilitate the photoreduction of cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2)2]2 t  
(1) to cisplatin by means of excitation wavelengths appropriate for use in biological 
systems (Scheme 2). Complex 1 is a cisplatin prodrug suitable for photochemotherapy 
because of its high dark stability in aqueous solutions and its negligible dark 
cytotoxicity in several cancer cell lines, e.g. prostate cancer PC-3 cells.20,21 
 
 
Scheme 2 Light-induced reduction of cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2)2]2 t  (1) 
promoted by riboflavin (Rf) in MES buffer. 
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Upon UVA light excitation (385 nm) 1 undergoes photochemical activation. However, 
UVA light is of limited use in therapy and PtIV complexes such as 1 rarely display 
satisfactory absorption features at wavelengths longer than 400 nm (Figure 1a). 
Rf is vitamin B2 and the precursor of biologically important cofactors such as FMN and 
FAD, which are essential to humans and animals due to their redox activity.22 The 
yellow-colored Rf  }   ]v   µ}µ   u]  `] Z  P}}  ˘]v ]}v   }((]]v   ~x 446 > 
104 M >1  cm >1)23 as far as ca. 500 nm (Figure 1a), and can promote a great variety of 
light-induced reactions which depend on its 7,8-dimethyl-10-alkylisoalloxazine 
fragment.22 Rf has been adopted as photocatalyst in several organic reactions, 
including the photooxidation of benzyl alcohols and alkyl benzenes or the [2+2] 
cycloaddition of styrene dienes and bis(arylenones).24 t 26 
 
3.2.1  Photocatalytic activation of a PtIV prodrug by riboflavin in solution 
After confirming blue light has not direct effects on 1 (Figure S1t 3), we investigated 
the capability of Rf to photoactivate the complex upon 460-nm excitation in MES 
µ((X   h]vP  o}`  ˘] ]}v  }`   v]˙  ~îXæ  u tu t 2), 120 µM solutions of 1 were 
photolysed in the presence of Rf at various concentrations (12 t 120 µM, Figure S4t 7). 
The process was monitored via 1H NMR by the evolution of diagnostic peaks 
corresponding to the Pt-bound (triplets) and free (singlet) succinate ligands (Figure 1b). 
Sub-stoichiometric quantities of Rf are capable to produce full conversion of 1 into its 
photoproducts under light excitation, demonstrating that Rf does not act as a simple 
photosensitizer but is indeed a photocatalyst. The efficiency of this catalytic process is 
remarkable since 12 µM Rf converts 100% of 120 µM 1 in 5 minutes (light dose 0.75 
 : u t 2). A Rf concentration as low as 0.13 µM still photocatalyses the transformation of 
1 (120 µM), however more than 2 hours are required to achieve 27% of conversion 
(Figure S8). No reaction between 1 and Rf occurs in the dark within 1 week (Figure S9). 
Interestingly, photoconversion of 1 takes place in pure water (pH 5) or in phosphate 
buffer (PB, 100 mM, pH 5.5), but never reaches completion due to poor photostability 
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of Rf in these media (vide infra). Thus, MES buffer plays a key role in the catalytic 
process preventing Rf from undergoing photodecomposition reactions.  
Figure 1. (a) Absorption spectrum of riboflavin (Rf) and cis,cis,trans-
[Pt(NH3)2(Cl)2(O2CCH2CH2CO2)2]2 t  (1) in aqueous solution. (b) Rf-catalysed photoreduction of 1 
in MES buffer (18 mM, pH 6) monitored by 1H NMR. Spectra were recorded for a MES/D2O 
(9:1) solution of 120 µM 1 and 50 µM Rf upon t = 0 sec, 30 sec, 1 min and 2.5 min of 460-nm 
o]PZ  ]]]}v  ~îXæ  u t u t 2). 1  ,   E D Z  ]Pvo  ooo]vPW  •   W t OCOCH2CH2CO2 t U  •   W t
OCOCH2CH2CO2 t U • uZ˙o P}µ }(  Rf ]}oo}˘Ì]v ]vPU • (  t O2CCH2CH2CO2 t . 
In order to assess the rate law for the Rf-catalysed photoreduction of 1 to PtII species, 
we studied the reaction rate at different substrate concentrations (120 µM t 1.92 mM, 
i.e. 2.4t 38.4 mol equiv of 1 compared to Rf) in 18 mM MES buffer during 30 sec of 
irradiation at 298 K (Figure S10). The effect of MES on the reaction rate was evaluated 
in a separate set of experiments, in which MES concentration was varied in the 3 t 20 
mM range (Figure S11). Results demonstrate that the rate of the reaction linearly 
increases with the concentration of 1 and MES, corresponding to a first-order reaction 
for both species. Importantly, the reaction shows a stronger dependency on the 
concentration of 1 than on MES, suggesting that PtIV reduction is limiting step of the 
reaction. 
Since our experiments employ a large excess of MES and all reaction steps are 
irreversible, the rate constant can be described using the pseudo-first order model 
(ESI  ). Using 50 µM Rf, we obtained a pseudo-first order reaction constant (kobs = 10.0 
± 0.05·10 t 3 s t 1) that increases with the catalyst concentration (Figure S12 and S13) and 
depends on MES concentration. 
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A turnover frequency (TOF) value of 0.22 ± 0.06 s t 1 was determined for the conversion 
of 1 (1.92 mM) by Rf (50 µM) under light irradiation at 298 K in 18 mM MES buffer. 
Under such reaction conditions, the maximum total turnover number (TTN) value is 38 
after 3 minutes of light irradiation, and no decomposition of catalyst is observed by 1H 
NMR. The Rf/1 catalyst/substrate pair achieves approx. 700 t 70 times higher TOF 
compared to ruthenium(II) organometallic catalysts, which catalytically convert NAD+ 
in NADH or transform O-allyl carbamates into their respective amines under 
biologically relevant conditions and in cells.9,8 High TOF is crucial for application in 
photochemotherapy since it guarantees rapid and sufficient conversion of 1 with short 
irradiation times and low light doses. 
 
3.2.2  Mechanism of photocatalytic activation 
Rf is extremely light sensitive and its photochemical reactivity strongly depends on the 
surrounding environment. Electron transfer and proton-coupled reactions or singlet-
oxygen generation take place upon light excitation of Rf, depending on the availability 
of electron donors. In addition, light decomposes Rf into several fragments through 
intramolecular reactions in which the ribityl chain can be used as the electron source.27  
Direct energy transfer from Rf to 1 can be ruled out since there is no overlap between 
 Z u]  ]}v v }(  Z (oÀ ]v  ~ em = 535 nm) and the absorption spectrum of 1.  
Hence, the sensitizing and catalytic capacity of Rf in MES buffer reasonably relies on 
electron transfer processes triggered by light. In the triplet excited state (3Rf*), Rf is a 
strong oxidant (Eº = 1.77 V)22 capable of efficiently extracting electrons from the 
abundant MES molecules, and generate the two-electron reduced RfH2/RfH t  species 
(pKa ~ 6) together with morpholino radicals28 which eventually evolve to the oxidized 
N-oxide form of MES (Figure S14).29  
Employing ferrioxalate actinometry,30 we determined the photochemical quantum 
yield for Rf/1 (50 µM / 1.0 mM, 18 mM MES) obtaining a value of 1.4  r  0.1 (Figure S15 
and S16).  
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Yield values > 1 are rather common in photoredox catalysis where radical chain 
propagation cycles form part of the catalytic mechanism.31 
Figure. 2 Proposed mechanism for the photocatalytic activation of 1 by Rf. (a) Computed 
structure and frontier molecular orbitals (DFT:PBE0/def2-SVP) of a selected 1-RfH2 adduct. 
Intermolecular H-bonds in 1-RfH2 are highlighted with magenta lines (top). Isodensity surfaces 
are plotted with the isovalue of 0.02 e > bohr >3. Atoms color code: Pt grey, Cl green, O red, N 
blue, C pale brown (1) or yellow (Rf), H white. (b) Rf absorbs 460-nm photons to generate the 
triplet excited state (3Rf*) which oxidizes two MES molecules to give the reduced species 
RfH2/RfH t . Next, complex 1 forms stable adducts with either RfH2 (shown in Figure 2a) or RfH t  
and undergoes photoreduction and elimination reactions upon absorption of more photons, 
liberating cytotoxic PtII species and regenerating the Rf catalyst. 
 
As a result, MES buffer dramatically improves Rf photostability by preventing that the 
isoalloxazine unit reacts with the ribityl moiety or with molecular oxygen.NMR and UV-
Vis show that MES substantially preserves Rf from decomposition for over 30 min, 
whereas the catalyst is fully converted to the photoproduct lumichrome in water 
within 1 min of light irradiation, and then to 2,3-butanedione at longer irradiation 
times (Figure S17t 19).32 
71 
The role of the buffer was confirmed using HEPES (18 mM, pH 6), an analogue 
zwitterionic buffering agent (Figure S20 and S21), in which Rf and 1 behave similarly to 
MES in terms of photocatalytic activity. 
The presence of sodium azide (singlet oxygen scavenger) in water and PB also 
improves the efficiency of the photocatalytic reaction of Rf with 1 (Figure S22 and 
S23). When added to MES buffer, sodium azide does not improve Rf/1 (Figure S24), 
excluding the participation of 1O2 and other oxygen radicals as major actors in the 
catalytic mechanism. On the other hand, O2 partially deactivates Rf, since under inert 
Ar atmosphere the photoconversion of 1 is faster (Figure S25). 
Importantly, complex 1 (1.8 mM) does not affect the fluorescence lifetime of Rf in MES 
(Figure S26 and S27), indicating that the active catalyst is not likely to be a Rf excited-
state species. Therefore, photooxidation of MES ultimately leads to the formation of 
reduced (ground-state) RfH2/RfHt , whose low redox potential (ca. t 0.2 V)22 cannot 
directly promote reduction of 1 (t 0.9 V).33 
Yet, as suggested by density functional theory (DFT) modelling (PBE0/def2-SVP) and 
consistently with the results obtained under Ar atmoshpere, 1 is capable to form 
adducts with either RfH2 (Figure 2a) or RfH t  (Figure S28t 30) by means of H-bonding 
interactions between its succinate and amino ligands, and the isoalloxazine and ribityl 
groups of Rf. FMN and FAD also photocatalyze the PtIV conversion of 1, displaying an 
efficiency comparable to Rf (Figure S31t 34). FAD, however, is somewhat less active, 
possibly due to steric constrains introduced by its adenine moiety which would 
disfavour H-bonding between the complex and the flavin. 
These computed adducts have HOMO localized on the Rf isoalloxazine rings, while 
LUMO and LUMO+1 are  V-antibonding orbitals of 1. Absorption of a second photon 
and subsequent light-induced population of the dissociative LUMO orbitals can trigger 
photoreduction and ligand elimination reactions,34 ultimately promoting the formation 
of cisplatin and other PtII species. Nevertheless, we cannot exclude that these strong 
and specific interactions could significantly lower the redox potential of 1 and cause 
direct reduction of the prodrug once the Rf-adducts are formed.35,36 Calculated binding 
energy for 1-RfH2 and 1-RfH t  adducts are in range 52 t 69 kcal·mol t 1, indicating that 
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these transient species are strongly stabilized and may bestow unique selectivity to the 
Rf/1 catalyst/substrate pair (vide infra).  
A pH-dependency profile for the photoreaction at fixed light-irradiation time (2.5 min) 
shows that complete photoconversion of 1 occurs above pH 6 in MES, whereas at 
lower pHs the photocatalysis is less efficient (Figure S35). The finding is in agreement 
with the prevalence of the RfH2/RfH t  forms of reduced Rf at pHs higher than 6.22 
On the basis of the described evidence, we have schematized a tentative 
photocatalytic mechanism for the Rf/1 catalyst/substrate pair in Figure 2b, although 
further investigations will be needed for its complete elucidation. 
 
3.2.3  Photocatalysis in the biological environment 
To test the potential of Rf photocatalysis as a bioorthogonal tool for 
photochemotherapy, we studied next the activation of 1 by Rf in cell culture medium 
and its effects in PC-3 cancer cells (in which 1 has no dark toxicity). At first, 
photocatalysis experiments and controls (Figure S36 and S37) were performed in 
Ham's F-12K medium supplemented with fetal bovine serum, in which biological 
components such as growth factors, antibodies, aminoacids, vitamins, and inorganic 
salts are present at concentrations ranging from µM to mM. 
1H N D Z      Z}`   Z   ï   u]v  }(   oµ  o]PZ   ] ] ]}v  ~o]PZ   }    íXìô    : u t 2) can 
fully convert 1.92 mM 1 to PtII species in the presence of 50 µM Rf and 3 mM MES, 
without any significant side reaction affecting either medium components or the 
catalyst (Figure S38). Under such conditions the TOF and TTN for the Rf catalyst are as 
good as in pure MES buffer solutions, indicating that the catalytic process is 
bioorthogonal in cell culture medium. 
The antiproliferative activity of Rf/1 against PC-3 cancer cells was investigated in the 
dark and under 460-nm light irradiation by co-administering the catalyst/substrate pair 
at a molar ratio of 1:4 and using three different concentrations of complex (40, 80, 120 
 DX   /v  }µ   oo  ˘ ]uv U  Rf prevalently activates 1 in the extracellular space since 
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we performed light irradiation after a short pre-incubation period and replaced culture 
medium after 6 h. MES is well tolerated by cells (Figure S39) and was hence employed 
during cell viability assays as an electron donor. Under these conditions, a short light 
irradiation period (1 min) and an extremely low light dose (0.36 J·cm t 2) are sufficient 
for the full photoconversion of 1 by Rf (Figure S40 and S41). In the absence of MES the 
photoactivation of 1 still takes place, although less efficiently (Figure S42), likely 
because other biological components of the medium act as electron donors. Against 
PC-3 cells, the Rf/1 catalyst/substrate pair displays dose- dependent light-induced 
toxicity compara o   }   ] o ]v  ]v   Z  lX   Z ulo˙U  í îì   D  1 v  ïì   D  Rf 
induce a 55 ± 5% reduction in cell biomass under light irradiation, against a 65 ± 5% 
caused by cisplatin at the same concentration. Control experiments indicate that Rf/1 
does not reduce viability of PC-3 cells when kept in the dark, neither does any of the 
components when irradiated individually (Figure 3a).  
The antiproliferative action of Rf-activated 1 is associated with the formation of 
cisplatin as one of the major cytotoxic photoproducts. Initial evidence was gathered 
(}u  ]v]vP  ˘ ]uv   `]Z   Z   Z E    v     E      u}o  æ; -guanosin 
monophosphate (GMP). 1H NMR shows that irradiated Rf/1 solutions incubated with 
GMP (0t 24 h) present the diagnostic peak, corresponding to the cisplatin mono GMP-
PtII adduct (Figure S43 and S44).37 When incubated with the pET28b as model of 
double stranded circular DNA (24 h, MES 1.5 mM, pH 6), light-activated Rf/1 (2.5:10 
µM) inhibits the polymerase chain reactions (PCR). Thirty sec of light irradiation are 
sufficient to stop DNA amplification and reach PCR inhibition level comparable with 
cisplatin (10 µM), hence confirming the capacity of this bioorthogonal system to target 
DNA (Figure S45).38,39 
Fluorescence microscopy of PC-3 cells treated with either irradiated Rf/1 (30:120 µM) 
or cisplatin (120 µM) is in agreement with this scenario (Figure 3b and Figure S46). In 
both cases, images obtained after 48 h of incubation show increased percentage of 
apoptotic versus viable cells, together with changes in cell morphology that are 
characteristic of apoptosis, i.e. cell shrinkage and rounding.  
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Non-treated cells and cells treated with Rf/1 in the dark included as controls do not 
induce appreciable cell death.Consistently, flow cytometry results confirm that PC-3 
cells exposed to the Rf/1 mixture and light (30:120 µM) die through apoptosis 48 hours 
after irradiation. Cisplatin induces comparable levels of apoptosis under the same 
conditions. 
 
Figure. 3 Antiproliferative activity in human prostate cancer PC-3 cells. (a) Percentage cell 
viability of PC-3 cells following treatment with Rf, 1, Rf/1 and cisplatin with and/or without 
o]PZ  ]À]}v  ~ðòì  vuU  ìXïò   : u t 2). (b) Fluorescence microscopy images showing the effects 
of Rf/1 on PC-3 cells upon light irradiation. (A, B) untreated PC-3 cells, (C, D) Rf/1 (30:120 µM) 
in the dark, (E, F) Rf/1 (30:120 µM) activated by 460-nm light and (G, H) cisplatin (120 µM) in 
the dark. Top row: cell nuclei (green); bottom row: apoptotic cells (red). (c) Quantification of 
early apoptotic PC-3 cells (Annexin V+ / SYTOX t ) treated by Rf (30 µM), Rf/1 (30:120 µM) and 
cisplatin (120 µM) with and/or without light activation. Cell viability and flow cytometry data 
are presented as mean ± SEM of at least three independent measurements. ***P < 0.001, **P 
< 0.01, ns = non-significant by two-`˙    E K s   (}oo} `  ˙   }v(}v][    ~  }  ˙  }v -way 
   E K s  (}oo}` ˙  dµl˙[  ~X  
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  }µo    ]v]vP `]Z  W ](]   oµ¡  vv˘] n V / SYTOX® allowed differentiating between 
early-stage and late-stage apoptosis. Upon treatment with irradiated Rf/1, the 
percentage of early apoptotic cells is 16.7 ± 2.8 % against 19.9 ± 1.3 % obtained for 
cisplatin. Rf, 1 and Rf/1 in the dark exhibit no significant population of cells in either 
stage of apoptosis after 48 h of incubation (Figure 3c). 
 
3.3  Conclusions 
In summary, we have described the first photocatalytic activation of a metal-based 
prodrug in solution and in a biological environment. Co-administration of the Rf/1 as 
catalyst/substrate couple enables photoconversion of 1 into biologically active species 
by light irradiation at 460 nm, a wavelength that is ineffective when directly applied to 
the prodrug. In addition, the Rf/1 prodrug activation strategy induces an anticancer 
 ]À ]˙  }u o    }  ]  o ]v  `]Z  o]PZ   }        o}`     ìXïò   : u t 2, that is ca. 15 t 35 
times lower than what is typically used for UVA and blue light activation of analogue 
platinum complexes.40,41  
The photocatalytic turnover of PtIV into PtII species is an attractive prospect to amplify 
the antineoplastic action of metal-based prodrugs in a locoregional manner. This is 
particularly relevant for platinum anticancer agents, which have some of the poorest 
absorption properties amongst photoactivatable metal complexes, but are widely 
tested in preclinical work and nearly indispensable in clinical practice.  
In principle, photocatalysis can help expanding the therapeutic potential of platinum 
prodrugs. Efficient light activation of PtIV complexes through catalysis may help localize 
the cytotoxic effects of Pt drugs, increase their dosing at the tumour target and reduce 
their systemic toxicity. Rf (vitamin B2) is a highly biocompatible molecule and its 
capacity to function in a bioorthogonal fashion may serve to enhance the selectivity of 
metal-based drugs by minimizing side reactions. 
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3.4  Experimental details 
Methods. NMR, UV-Vis and fluorescence characterization of light-irradiated Rf/1 and 
controls, PCR and microscopy data, photochemical quantum yield by actinometry, 
setup for cell work under light irradiation, computational methodology and 
instrumentation details are described in the ESI  . 
Light-irradiation experiments in solution. Photocatalysis studies on Rf/1 were 
performed under different solution conditions (buffers, cell culture medium and in 
presence of co-reactants). All reactions were carried out in air at 298 K and pH 6, 
uo}˙]vP  v   >     o]PZ   }µ  ~ exc = 460 nm, 2.5 mW  cm t 2). Reaction kinetics, law 
rates of the reaction, turnover frequency (TOF) and total turnover number (TTN) were 
calculated by varying both reactants and catalyst concentration and quantifying via 1H 
NMR the amount of photoconverted 1. 
Cell viability studies. The antiproliferative activity of Rf/1 was determined in human 
prostate cancer cells PC-3 (ATCC) in the dark and under light irradiation by co-
administering Rf and 1 at a fixed molar ratio (1:4), and using three different 
concentrations (Rf/1: 10/40 µM, 20/80 µM, 30/120 µM). MES was employed in all cell 
experiments at a final concentration of 2 mM. PC-3 cells were seeded 24 h before the 
experiment in 96-well plates with a density of 4000 cells per well and grown under 
standard conditions (Ham's F-12K medium supplemented with 10% fetal bovine serum 
v  í9   v] ]oo]vl   }u˙]v     ïó  U  æ9     K 2 and 90% humidity). Stock solutions of 
Rf/1 were added and incubated with cells for 1 h, light irradiated for 1 min at 460 nm 
~o]PZ  }   ìXïò   : u t 2), and then incubated for other 6 h. Finally, cells were washed in 
fresh medium and grown for other 42 h. The Sulforhodamine B (SRB) colorimetric 
assay was used for cell density determination. As controls, Rf and 1 were tested under 
identical conditions, while parallel experiments were performed with Rf/1 and cisplatin 
kept in the dark. A home-made LED plate was employed to irradiate cells in 96-well 
plates (Figure S47). 
Fluorescence microscopy assays. PC-3 cells exposed to 30:120 µM Rf/1 were viewed 
using a Zeiss Axio Observer wide field fluorescence microscope (Carl Zeiss). Cells were 
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plated in an ibidi µ-Slide 0.4 (13500 PC-3 cells/channel) and allowed to adhere 
overnight before they were treated with Rf/1 as described for cell viability experiments 
(2 mM MES, 6 h of treatment plus 42 h incubation). Analysis of cellular morphological 
alteration was performed using a cell-u  o  P v  (oµ} v   ˙  (}u   Z  ^ >]À  
v         oo   ^]v]vP   <]_  ~ u  (}   ell nuclei (green channel) and SYTOX® 
    À v¡  ~ /vÀ]}Pv¡  (}       oo  ~    ZvvoX    oo  `    ]v   (}oo}`]vP 
commercial protocols and using binding or 10 mM PBS buffer at the end of the 
incubation period (48 h). Images were acquired with a Plan Apochromat 20× objective 
and a multi-band pass Colibri filter to collect fluorescence emission signals. Control 
experiments in the dark (no light irradiation) were performed on untreated cells and 
on cells exposed to 30:120 µM Rf/1 or 120 µM cisplatin. 
Flow cytometry analysis. PC-3 cells were seeded in 96-well plates (2000 cells per well) 
and treated with Rf/1 (30:120 µM) and MES (2 mM) as described above. After 48 hours 
of incubation, 7 wells for each sample were pooled into cytometer tubes, cells were 
w  Z  `]Z  íì  u D   W  ^  v    ]v  µ ]vP  íì ì   >      µ  }(   Z   W ](]    oµ ¡ 
Annexin V/SYTOX®     À v¡  (o}`  ˙}u ˙  l]  ~ /vÀ]}Pv¡X    o˙  v  o   
apoptosis were measured using a FACS Canto II (BD Biosciences) and results analysed 
using the FlowJo, LCC software. The PC-3 population was electronically gated based on 
the forward and side scatter parameters and the non-single events leaved out based 
on forward area and height scatter parameters. Inside this final population, live cells 
were gated as negative for both dyes; early apoptotic cells were defined as Pacific 
Blue-Annexin V positive cells and SYTOX® negative; and late apoptotic cells were gated 
as double positive for both dyes. Non-labelled and singly labelled samples were 
included as control and as compensation samples, respectively. Experiments were 
repeated three times. Besides untreated cells, control experiments included cells 
treated with 30:120 µM Rf/1 and 120 µM cisplatin in the dark (no light irradiation), and 
light-irradiated Rf and 1 alone. 
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4.1 Introduction 
The Riboflavin (Rf), vitamin B2, is an essential exogenous biomolecule for our 
metabolism. Rf is rapidly converted intracellularly into flavin mononucleotide (FMN) 
and flavin adenine dinucleotide (FAD), which are then incorporated into a multitude of 
flavoproteins and flavoenzymes. These have motivated an enormous interest in 
research due to their key role in biological systems where they catalyze the oxidation 
of a broad range of substrates (sugars, alcohols or aminoacids), participate in 
oxidation/reduction processes involved in detoxification, and play a photocatalytic role 
in DNA repair.1,2 
Rf has outstanding photophysical and photochemical features that make this natural 
photosensitizer a good candidate for light-triggered applications in medicine. A 
noteworthy use of Rf is the Mirasol  W Z d¡    }    uo}˙    }        o}}  (}  
transfusion, in which Rf inactivates significant levels of viruses and bacteria in platelets 
and plasma upon UV light irradiation.3 Besides, Rf has been investigated for application 
in photodynamic therapy (PDT). This clinically approved treatment for cancer and 
other diseases employs light to activate a photosensitizer and generate singlet oxygen 
and other reactive oxygen species (ROS) capable to induce cell death locally in 
irradiated areas.4 Under light irradiation, Rf generates singlet oxygen in aerated 
solutions with higher quantum yields ~L
4 = 0.54 ± 0.07) than other exogenous 
photosensitizers used in the clinics, such as Photofrin.5 
A current limitation in PDT is the absolute O2-dependency, which reduces the 
effectiveness of this treatment in hypoxic tissues.4 The search for newer O2-
independent strategies with improved photosensitizers is an emerging focus in PDT 
and transition metal complexes have raised significant interest as photoactivatable 
prodrug candidates.6 Despite their encouraging profiles as antineoplastic agents, light-
switchable metal complexes often suffer from modest absorption properties and 
innovative approaches have been explored to turn on their activity at more convenient 
wavelengths. 7 t 9 
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In our search for novel activation strategies, we recently showed that Rf and other 
flavins, including flavoproteins, can act as photosensitizers and unconventional 
photocatalysts for the selective activation of anticancer metal-based prodrug 
candidates such as PtIV complexes. These photocatalytic reactions efficiently take place 
by means of blue rather than UV-A light in the presence of zwitterionic buffers such as 
MES (2-(N-morpholino)ethanesulfonic acid), as well as with biological electron donors 
such as NAD(P)H.  
 
Figure 1. (a) Proposed photocatalytic mechanism for the bioorthogonal activation of PtIV 
prodrugs by Rf (and other flavins); (b) UV-Vis absorption spectra of Rf, 1 and 2; and (c) 
Schematic structures of the PtIV prodrugs employed in this study (1 and 2), and chemical 
species involved in their photocatalytic activation. 10,11  
According to our current understanding of the process (Figure 1),10 light excitation of 
Rf at 460 nm results in the formation of its triplet excited state, which is a highly 
oxidant species able to extract electrons from sacrificial electron donors (e.g. MES) to 
give the reduced riboflavin forms RfH2 or RfHt . Afterwards, RfH2 or RfH t  catalytically 
affords the conversion of PtIV complexes into biologically active PtII species. 
Importantly, low doses of blue light are sufficient to fully convert high concentrations 
of PtIV prodrugs in buffer solution and in cell culture medium. The Rf selectivity for PtIV 
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complexes demonstrated in the biological environment defines the bioorthogonal 
nature of these photocatalytic reactions.10,11 
This report provides new insights on the cytotoxic effect and mechanism of action of 
two PtIV prodrugs, namely cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2H)2] (1) and 
cis,cis,trans-[Pt(NH3)2(CBDCA)(O2CCH2CH2CO2H)2] (2, where CBDCA = cyclobutane 
dicarboxylate), upon flavin-mediated photocatalytic activation. In particular, we 
describe here how the cisplatin prodrug 1 can be used in combination with Rf and 
extremely low doses of blue light to erradicate human pancreatic adenocarcinoma 
cells (Capan-1). This cell model was chosen because of its relatively high tolerance 
against PDT which allows establishing the interplay between this type of treatment 
and photoactivatable PtIV prodrugs.  
Pancreatic cancer is the 4th leading cause of cancer-related deaths, and its 5-years 
survival rate is lower than 5%. Recent studies reveal alternative treatments may 
change this dreadful prognosis.12 t 14 For example, a prospective chemotherapeutic 
option consists on the combinatory treatment of gemcitabine with cisplatin, which 
revealed a significant improvement in the 6-months survival rate compared to the 
administration of gemcitabine alone.14 In the treatment of pancreatic cancer, PDT also 
receives special attention since it is not accompanied by the heavy side effects of 
systemic chemotherapy.15 Moreover, both platinum drugs16 and PDT17 have been 
shown to activate immune responses against pancreatic tumors and even 
immunogenic cell death.18,19The photochemistry of Rf may be a new tool to integrate 
singlet oxygen sensitization and bioorthogonal photocatalysis towards PtIV prodrugs for 
exploiting some of these advantages introduced by PDT and combination therapies in 
the treatment of pancreatic cancer. A combined strategy for PDT and platinum drug 
activation may lead to synergistic antitumor drug and immune responses localized in 
the malignant tissue.14 
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4.2  Results and Discussion 
4.2.1 Antiproliferative properties of PtIV complexes photocatalytically 
activated by riboflavin 
The potential of Rf in PDT is well documented.15 t 17 We reasoned that our 
bioorthogonal photocatalytic strategy would be a worthy strategy to test in those 
cancers in which PDT is of limited efficiency or might become ineffective because of 
oxygen consumption.20 Hence, we initially screened Rf photocytotoxicity in a number 
of human cell lines derived from different tumors including colon (SW480 and 
HTC116), ovarian (A2780 and A2780cis), cervix (HeLa t derivative KB-3-1), and 
pancreatic (Capan-1) carcinomas as well as a melanoma (VM47), and glioblastoma 
(H35 and H52).  
In this preliminary screen, cells were treated with Rf concentrations up to 20 µM. MES 
(1% vol., 2 mM) was added to the culture medium to prevent Rf photodecomposition1 
and mimic the conditions used for the catalytic activation of PtIV prodrugs (vide infra). 
It is worth pointing out that no toxicity was observed due to the addition of MES alone 
(data not shown). 
Cell viability experiments consisted in a drug-to-light interval of 1 h following 
administration, 1 min of blue light irradiation (460 nm, 0.36 J   cm t 2) and 6 h of 
incubation. Afterwards, media was renewed and cells were incubated for a total of 72 
h in the dark. Non-irradiated controls were directly incubated 7 h in the dark and then 
handled as described above for light-activated samples. After the 72 h, cell viability 
was determined by the MTT assay.  
Among the panel of cell lines tested, Capan t 1 showed the greatest survival and 
resistance against the Rf photosensitizing effects, retaining > 75% viability at 25 µM Rf 
under light exposure. The low sensitivity of Capan-1 cells to PDT is enigmatic but can 
be ascribed to the high levels of antioxidant molecules (such as glutathione) and 
enzymes (such as superoxide dismutase, catalase and glutathione peroxidase) present 
in this cell line.4 Moreover, Capan-1 cells harbor a mutated p53 tumor suppressor 
causing general cell death resistance20 but also a BRCA2 mutation leading to enhanced 
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cisplatin sensitivity.22 Conversely,23 all the other cell lines displayed a cell viability 
below 10% at concentrations ranging between 5 and 15 µM Rf (Figure S1).  
In light of the capacity of Capan-1 cells to endure PDT at the light dose employed, we 
extended the concentration range of Rf and studied how the co-administration of MES 
(1% vol., 2 mM) affected Rf phototoxicity. In the absence of MES, no toxicity was 
observed for concentrations of Rf up to 75 µM, both in dark and under light 
irradiation. However, addition of MES favors Rf phototoxic action, significantly 
decreasing cell survival (40 % cell death at 75 µM Rf, Figure S2). On the basis of our 
previous work, this finding was anticipated. MES, as well as other zwitterionic buffers, 
preserves Rf from photodecomposition acting as electron donor, hence, extending the 
generation of singlet oxygen and other ROS.10 In an analogous manner, acetylation of 
ribityl chain was demonstrated to improve Rf photostability and the PDT capacity of 
this photosensitizer.17  
For sake of comparison, we also tested FAD under similar experimental conditions, 
observing a less pronounced but comparable behavior to Rf, and confirming the key 
role of MES as PDT enhancing agent for flavin photosensitizers (Figure S3). 
Taking into consideration these results, we selected Capan-1 cells to evaluate the 
bioorthogonal Rf-mediated photocatalytic activation of two PtIV prodrug candidates 
(Figure 1). The compounds investigated were cis,cis,trans-
[Pt(NH3)2(Cl)2(O2CCH2CH2CO2H)2] (1) and cis,cis,trans-
[Pt(NH3)2(CBDCA)(O2CCH2CH2CO2H)2] (2), which have deprotonated at carboxylic 
groups at physiological pH,10 and are prodrugs of cisplatin and carboplatin respectively. 
Only a 10% load of the Rf catalyst was used in this set of experiments.  
Both Rf-1 and Rf-2 catalyst-substrate pairs showed improved photocytotoxic profiles 
with respect to Rf alone under a light dose of only 0.36 J   cm t 2. In fact, Rf-1 and Rf-2 
induced reductions in cell viability analogous to the direct administration of the 
corresponding PtII drugs (Figure 2). At low PtIV concentrations, Rf-1 is less effective in 
inducing cell death than cisplatin whereas light-irradiated Rf-2 and carboplatin had 
similar cytotoxicity profiles. As shown previously by the Keppler group24 and us25, this 
result may be ascribed to the fact that (photo)reductive elimination reactions of Pt IV 
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complexes are more likely to lead to single PtII products in the case of carboplatin 
derivatives rather than for cisplatin ones. Control samples, which included 1 and 2 
under light irradiation and in the dark, and Rf-1/2 in the dark, showed minimal toxicity. 
The Pt-induced phototoxicity was lower for both Rf-1 and Rf-2 in the absence of MES 
(Figure S4 and S5). When employed as photocatalyst, FAD affected cell viability in a 
less efficient manner compared to Rf and even less without MES (Figure S6-9).
Figure 2. Photocatalytic effect of Rf-1 and Rf-2 against Capan-1 cells. Cell viability following 
exposure to (a) 1 and Rf-1 and (b) 2 and Rf-2 in the dark and under light irradiation (460 nm, 
0.36 J   cm t 2) compared to dark controls and cisplatin (dark). 
Motivated by the activity of Rf-1 upon light irradiation, we investigated in Capan-1 the 
role of catalyst loading and the O2-dependency on the prodrug activation. Fixing the 
concentration of 1 at 150 µM, we modified the catalyst-substrate ratio using 15 and 75 
µM Rf (Figure S10). Rf-1 showed high antiproliferative capacity and a small difference 
(10%) in cell viability between the two Rf:1 ratios was found. Such disparity can be 
assigned to Rf phototoxicity at higher concentrations (>25 µM, Figure S2). Under 
hypoxic conditions (pO2< 1%), light-irradiated Rf alone does not produce any 
cytotoxicity, meanwhile Rf-1 retains the biological activity exhibited in normoxia. For 
example, Rf-1 at the catalyst-substrate ratio of 15:150 µM reduced Capan-1 cell 
viability to ca. 30% in both normoxic and hypoxic conditions (Figure S11). Therefore, 
flavin-based photocatalysis towards PtIV complexes is an O2-independent strategy that 
could function in hypoxic environments where PDT generally does not work and in 
treatments where PDT has lost effectiveness because of O2 depletion. 
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A remarkable aspect of this strategy is the low light dose needed for the PtIV prodrug 
activation. Only 0.36 J   cm t 2 of 460-nm light was already sufficient to switch on 
cytotoxicity and provide antiproliferative effects resembling free cisplatin and 
carboplatin. In the case of analogue PtIV complexes, the light dose needed for UV-A 
and blue light activation was more than 15 times higher than for Rf-mediated 
photocatalysis.26 
4.2.2 Insights in the mechanism of action 
The remarkable light-induced activity of Rf-1 in Capan-1 cells prompt us to select this 
prodrug system for further investigations of its mechanism of action. Additional 
experiments included 195Pt NMR speciation studies, DNA interaction experiments by 
circular dichroism spectroscopy (CD), cell uptake by ICP-MS, Western blotting analysis 
and immunofluorescence microscopy. 
1H,195Pt-HSQC NMR experiments were performed to determine the speciation of 1 
upon Rf-mediated photocatalytic activation. The photoreduction of PtIV metal 
complexes often results in multiple products, including PtII and PtIV species.24 A sample 
solution of 1 (7.2 mM) and Rf (260 µM) in 2 mM MES (pH 6) was irradiated during 10 
min (ratio Rf:1 1:27) and its 195Pt NMR spectrum collected. The concentration of 1 in 
these experiments was increased compared to cell viability studies in view of the low 
sensitivity of 195Pt NMR. Rf concentration was limited to 260 µM by its modest 
aqueous solubility.  
1H,195Pt-HSQC NMR spectroscopy (Figure 3a) revealed that 1 was not completely 
converted under the adopted experimental conditions (signal of 1 at around 2720 
ppm). Nevertheless, two new Pt species were generated by the photocatalytic process. 
The signal at 1310 ppm corresponded to an unknown PtIV species, while the PtII 
complex detected at around -520 ppm was identified as cisplatin, demonstrating that 
the photoreduction of the prodrug indeed took place. Control spectra of cisplatin and 
1 with Rf (dark) were employed for assignment and are reported in Figures S12-15. 
Considering that cisplatin anticancer activity mainly depends on its binding to DNA,27 
we investigated the interaction of the Rf-1 catalyst-prodrug pair with a double 
stranded DNA model by circular dichroism, a technique used to monitor minor 
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variations on the DNA double helix.28 We selected the oligodeoxyribonucleotide ds26, 
an auto-complementary sequence structured in a hairpin-duplex B-DNA fashion,29 
which is ideal for characterizing the formation of DNA-cisplatin adducts (Figure 3b) 
such as: i) intrastrand crosslinks between neighbouring guanine residues (accounting 
for 90% of the adducts);30 t 32 ii) monofunctional adducts; iii) interstrand cross-links.33,34 
CD spectra were collected (Figure 3c and Figure S16) in the dark and after light 
irradiation (460 nm, 0.36 J   cm t 2) using MES buffered solutions of cisplatin and 1. These 
were incubated with ds26 for 48 h at 37 °C, either in the presence or absence of Rf. 
 
Figure 3. (a) 1H,195Pt-HSQC NMR spectra of light irradiated Rf-1. Spectra were obtained using 
7.2 mM 1 and 267 uM Rf (ratio Rf:PtIV 1:27) in 2 mM MES buffer (pH 6) and irradiating at 460 
nm for 10 min; (b) Schematic representation of the selected B-DNA model ds26 and the 
possible Pt-DNA adducts formed upon treatment with cisplatin. (c)        }(  í   D  ds26 
`]Z ï  D ]o]v v  Rf-1 ~ìXïlï  D ( ]]]}v v ]vµ]}v (} ðô  Z   ïó  £ X  
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Overall the global B-conformation of the DNA was retained upon complexation with 
PtII species. However, spectroscopy data revealed a local perturbation of the DNA 
structure in the case of DNA treated with light-activated Rf-1 and cisplatin. In 
particular, platinum species generated upon irradiation of Rf-1 led to a decrease of the 
positive band of the B-DNA at around 275 nm, accompanied by a red shift in the 250 t
275 nm range. Such spectral change was previously interpreted for cisplatin as a B to 
C-like DNA conformational change involving the base pairs surrounding the platinated 
nucleosides. This feature is typical of intrastrand crosslinks which do not disrupt the 
Watson-Crick hydrogen bonding pattern.32,35,36 On the other hand, the small increase 
of the negative band at 250 nm observed for cisplatin and Rf-1 upon light activation 
ruled out the formation of interstrand crosslinks in ds26. This spectroscopic feature 
might be associated to a non-severe oxidative damage of DNA induced by light, as 
previously observed by Nowicka et al.37 In fact, interstrand binding typically leads to a 
pronounced reduction of this negative CD band as a consequence of the disruption of 
the hydrogen bonds between the platinated guanines and the complementary 
cytosines.38  
Importantly, when compared to controls (Figure S16), only irradiated Rf-1 presented 
the same effects as cisplatin. These results further demonstrate the efficacy of our 
prodrug activation approach to deliver PtII species capable of binding DNA bases. It is 
worth pointing out that the impact on the DNA CD bands induced by Rf-1 
photoproducts, although following the identical patterns, is less marked. This 
difference is most probably due the faster formation of the diaqua active species cis-
[Pt(NH3)2(H2O)2]2+ upon direct addition of cisplatin. On the contrary, 1 can undergo 
aquation only after photoreduction. Although obtained under different experimental 
conditions, 1H-195Pt NMR indicated that photocatalytic activation of 1 can lead to the 
formation of more than one Pt species, one of which is a PtIV derivative, supporting a 
significantly lower DNA binding capacity compared to an equimolar solution of 
cisplatin. 
Cellular accumulation is a key aspect in the biological activity of a drug candidate. 
Therefore, Pt cell uptake experiments in Capan-1 cells were performed under different 
incubation regimes and irradiation protocols (Figure S17). The amount of Pt 
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accumulated in cells was quantified using ICP-MS. Cisplatin and 1 alone or in 
combination with Rf (10  D ) were used at a concentration of íìì   DX   
The quantity of Pt in Capan-1 cells found after the first hour of incubation in the dark is 
similar for cisplatin, 1 and Rf-1. After light was administered, the content of Pt found 
for 1 and Rf-1 rapidly reached a plateau and did not change further between 3 h and 6 
h of additional incubation. Crucially, no significant difference was observed for cells 
treated with 1 and Rf-1 in the dark and upon light irradiation. On the contrary, cisplatin 
accumulated to a higher extent over time compared to 1 and Rf-1, both in the dark 
and when exposed to light. 
The behaviour of light-irradiated Rf-1 suggests that the antiproliferative action of the 
prodrug complex triggered by Rf under our general protocol (1h preincubation before 
irradiation) can be principally ascribed to a photocatalytic intracellular activation. In 
fact, extracellular production of PtII species would lead to a progressive increase of the 
Pt content over time, as observed for cisplatin, which is not the case for 1 
photocatalytically converted by Rf. To confirm this scenario, we performed additional 
cell viability experiments in which the Pt agents were removed by washing cells with 
fresh media immediately after 1h of preincubation and 1 min of light irradiation 
(Figure S18). This approach excluded that any toxicity effect could originate from 
species formed extracellularly. Differently from controls, light-activated Rf-1 under 
such conditions reduced cell viability in a significant manner confirming the capacity of 
Rf to catalyse intracellularly the formation of cisplatin from 1. In another control 
experiment, a higher Pt content was detected in Capan-1 cells in comparison to control 
samples when Rf-1 was irradiated at 460 nm just after administration and then 
incubated for overall 7 h. Using such a modified irradiation treatment, the generation 
of cisplatin occured completely outside the cell and the viability profile of Rf-1 more 
closely resembles the one obtained for cisplatin (Figure S17 and S19). 
Internalization of Rf in cancer cells is extremely rapid (in the order of minutes) due to 
active and passive transport mechanisms.39 As demonstrated in previously reported 
studies, there is a predominance of passive transport over protein-mediated cellular 
uptake at Rf concentrations above normal human plasma levels (ca. 12 nM),40,41 which 
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could support co-localization of 1 and Rf in the cytosol. Furthermore, the gene 
expression profile42 of Capan-1 cells indicate that this cell line overexpresses riboflavin 
transporter proteins (solute carrier family 52), hence improving their ability to 
internalize the vitamin. So, the great majority of the Rf photocatalyst is only available 
within the cell after the first hour of preincubation and its extracellular concentration 
as well its capacity of generating cisplatin from extracellular 1 should be minimal. This 
is well in agreement with cell uptake and cytotoxicity results. 
4.2.3 Induction of a light-dependent DNA damage response 
We next analyzed the expression and phosphorylation of characteristic proteins in the 
DNA damage response and cell death induction pathways by Rf-1 under light 
irradiation (Figure 4a). Capan-1 cells were treated with Rf-1 at a concentration of 10 
and 100 µM respectively and 2 mM MES under 1 min of 460-nm irradiation (0.36 J   cm t
2). Control experiments included the mixture Rf-1 in the dark and cisplatin (100 µM), Rf 
(10 µM), 1 (100 µM) as well as an untreated sample all in the dark and under light 
irradiation.  
As a general remark, light is per se affecting the phosphorylation of the DNA-damage 
repair-initiating histone H2AX. Consequently, H2AX phosphorylation was slightly 
enhanced in all the irradiated samples compared with their corresponding dark 
analogues, probably suggesting low-level light-mediated DNA damage. Treatment with 
irradiated Rf-1, however, led to clear-cut hyperphosphorylation of H2AX compared to 
Rf-1 in the dark, indicating the induction of double strand breaks (DSBs) in DNA. These 
DSBs in chromatin promptly initiated the phosphorylation of the histone H2A variant 
to generate p-H2AX. This result correlates with the extensive up-regulation observed 
for cisplatin samples. Nuclear foci in chromatin with accumulated p-H2AX can be 
conveniently detected by immunofluorescence microscopy and serve as beacons of 
DSB lesions. The respective photomicrographs clearly demonstrated an enhanced 
number of nuclear p-H2AX foci in irradiated cells in presence of Rf-1 indicating efficient 
cisplatin release (Figure 4b, S21 and S22). Controls of untreated, Rf, 1, Rf-1 and also 
the photoreaction for 2 and Rf-2 are shown in the supporting information (Figure S23 
and S24). For complex 2, a similar trend was observed.  
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Figure 4. (a) Expression/phosphorylation of DNA damage and cell death proteins in Capan-1 
cells analysed by Western blotting. Cells were: untreated (lane 1), or treated by 10 µM Rf (lane 
2), 100 µM 1 (lane 3), 100 µM cisplatin (lane 4) and Rf-1 10:100 µM (lane 5) in the dark. Same 
treatments from lane 6 to 10 but under 460-nm light irradiation (460 nm, 0.36 J   cm t 2). 
Membranes were probed for the indicated proteins or phosphorylation-specific epitopes. full-
length blots/gels are presented in Supplementary Figure S20. (b) Immunofluorescence 
microscopy images of the DNA damage marker p-H2AX induced by Rf-1 (10:100) in the dark 
and under 460-nm light irradiation. Treated and fixed Capan-1 cells were stained with DAPI 
(blue) to localize the nucleus, TRIC-phalloidin to visualize actin filaments (red), and p-H2AX 
(green) indicative for DNA DSBs.43 
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Rad51 and rad52 are essential proteins for repair of DNA breaks via homologous 
recombination44 and normally upregulated by DNA damage e.g. by cisplatin.45 
However, in our experiment both rad51 and rad52 were rather downregulated in 
Capan-1 cells upon treatment with free cisplatin or Rf-1 under light exposure. The 
cisplatin-induced downregulation of this repair proteins might be explained by the 
BRCA2-mutated background of Capan-1 cells, blocking accumulation of rad1/rad2 
within DNA damage foci in the cell nucleus.46,47 This is related to the distinct cisplatin 
sensitivity of BRCA2-mutant cancer cells.45 Nevertheless, all these changes 
demonstrated efficient release of cisplatin upon photoactivation from Rf-1. 
Expression of the DNA damage sensor p53 was already strongly detectable in 
untreated control cells reflecting the p53 mutated background of Capan-1 cells.21 
Accordingly, p53 levels remained widely stable after the diverse drug exposure 
regimes. This also explains why the p53 downstream cell cycle regulator p2148 was not 
up- but rather downregulated by DNA-damaging cisplatin and by Rf-1 after light 
exposure. On the contrary, the levels of cleaved PARP were down-regulated for 
irradiated Rf-1 but up-regulated for cisplatin compared with controls. Caspase-
mediated cleavage of PARP protein is a marker for apoptosis induction e.g. following 
DNA damage. Hence, upregulation in case of cisplatin confirmed induction of an 
apoptotic cell death pathway, while down-regulation for irradiated Rf-1 would instead 
suggest that the prodrug system activated a caspase-independent cell death, a 
possible mechanism reported previously for PDT.40 However, combined activation of 
apoptosis (by cisplatin) and non-apoptotic cell death (by PDT) might be postulated for 
Rf-1 since cleaved PARP as well as total PARP were strongly diminished in the 
irradiated Rf-1-treated cells compared to the untreated and cisplatin-exposed samples.  
Additionally, we investigated the impact of our therapeutic approach on the levels of 
major vault protein (MVP, also known as lung resistance protein LRP) upregulated by 
cisplatin and implicated in cisplatin resistance before.49 MVP levels were generally 
sensitive to light with reduced expression levels in light-exposed samples. In addition, 
light exposure abrogated cisplatin-induced MVP upregulation. Interestingly, irradiated 
Rf-1 samples were, in contrast to the corresponding cisplatin sample, completely 
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devoid of MVP. This suggests that photocatalytic activation strategy for Pt IV prodrugs 
might help overcoming MVP/LRP-mediated cisplatin resistance.50 
 
4.3 Conclusions 
The photocatalytic activation of PtIV complexes by Rf is an efficient strategy to control 
the delivery of active PtII drugs with low light doses. Cell viability and uptake results 
obtained in this work evidence for the first time that Rf can act as bioorthogonal 
catalysts towards PtIV substrates inside the cell. The details of this process within the 
cellular milieu still require further investigation due to the complexity of Rf 
homeostasis and Pt drugs uptake. Nevertheless, Capan-1 cells, with mutated p53 and a 
distinct antioxidant cell biology were effectively treated with our prodrug system Rf-1 
based on efficient cisplatin release after only 1 minute of light activation. The induced 
cell death was clearly mediated by the release and subsequent DNA-damage of 
cisplatin but also included some additional features. Hence, Rf-1-mediated cell death 
seems to include caspase-dependent and independent mechanisms and specifically 
suppressed the platinum drug resistance protein MVP/LRP. This treatment strategy has 
the potential to be further developed and tested in a photodynamic therapy setting in 
vivo.  
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4.4 Experimental details 
Cell culture. Cell lines SW480 (Dukes' type B, colorectal adenocarcinoma; ATCC® CCL-
228 ¡ ), HCT-116 (colorectal carcinoma; ATCC® CCL-247 ¡ ), A2780 and A2780cis (ovarian 
carcinoma, Sigma), KB-3-1 (Human papillomavirus-related endocervical 
adenocarcinoma; HELA derivative, obtained from Dr. D. W. Shen, Bethesda, Maryland) 
VM47 (primary melanoma as described previously51), H35 and H52 (primary 
glioblastoma as described previously52) and Capan-1 (liver metastatic pancreatic 
cancer; ATCC® HTB-79¡  ) were grown as a monolayer at 37 °C in a humified 5 % CO2 
atmosphere. RPMI growth medium was supplemented with 10% fetal bovine serum 
(PAA, Linz, Austria). Cell cultures were periodically checked for Mycoplasma 
contamination. All media were supplemented with 2 mM MES buffer (pH 6, 1% vol) or 
H2O (1% vol). 
MTT assay of the cell viability. In a typical experiment, 4 x 104 cells/ml (5 x 104 cells/ml 
in the case of Capan-1 only) were seeded in 96-well plates in 100 µL of cell culture 
medium. After 48 h, cells were administered with the anticancer agents at the chosen 
concentrations, under dark conditions. After 1 h, cells were irradiated during 1 min at 
460 nm (6 mW  cm t 2, corresponding to a light dose of 0.36 J   cm t 2) and left in the 
incubator for 6 h. Dark analogues were directly incubated 7 h. Cell culture media was 
replaced by fresh media and incubated for a total of 72 h. After this incubation period, 
cell viability was determined by means of the MTT assay following the instructions of 
the manufacturer (EZ4U Cell Proliferation and Cytotoxicity assay, from Biomedica 
Medizinprodukte GmbH & Co KG). 
Pt uptake in Capan-1 cells measured by ICP-MS. Capan-1 cells in 6 well-plate with a 
concentration of 3 x 105 cells/well were seeded and after 48 h exposed to cisplatin, 1 
and Rf-1 under different incubation conditions. In different set of experiments, cells 
were exposed to Pt agents as follows: a) 1 h in the dark, b) 1 h preincubation in the 
dark + 1 min of 460-nm light irradiation + 3 h in the dark, c) 1 h preincubation in the 
dark + 1 min of 460-nm light irradiation + 6 h in the dark, d) 1 min of 460-nm light 
irradiation + 7 h in the dark. All dark controls were not light irradiated and protected 
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from ambient light. The digestion protocol adopted was described by Keppler and 
coworkers previously.53 
Circular Dichorism. Circular dich }] u      `  }   }v    Z] v¡        ~˙ 
Applied Photophisics) using 1 cm path-length quartz cuvettes, at 25 °C. The lyophilized 
ds26 was firstly diluted in IDTE buffer (10 mM Tris, pH 7.5, 0.1 mM EDTA, Integrated 
   E    dZv}o}P]    }  } ]v  íì ì   D  stock solution. The annealing process to ensure 
the 100% formation of the B-DNA conformation was performed by heating the ds26 
stock solution to 95 °C for 5 min, followed by slowly cooling to room temperature 
overnight. Stock solution of ds26, together with stock solutions of cisplatin, riboflavin, 
1, succinic acid, were used to prepare the final mixtures at the required concentrations 
diluting them with MES buffer. After irradiation for 5 minutes, the final solutions have 
been incubated at 37 °C for 24 or 48h and then measured. 
The oligonucleotide ds26 æ[-CAATCGGATCGAATTCGATCCGATTG-ï[  ~ ’   }vv  ð òXî9  
was purchased from IDT (Integrated DNA Technologies) in HPLC purity grade.  
Pt-NMR. NMR measurements were recorded on a Brucker Avance III 500 MHz 
spectrometer at 500.32 (1H) and 107.38 (195Pt) MHz at 25 °C. 195Pt resonances were 
referenced relative to external K2[PtCl4]. 
Western blot analysis. Preparation of samples: total cell protein extracts were 
separated by 10% sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-
PAGE) and blotted onto polyvinylidene difluoride membranes (PVDF, Thermo Fisher 
Scientific). Anti-ß-actin antibody (AC-15) was purchased from Sigma, anti-PARP 
(#9542), anti-cleaved PARP (Asp214, #5625), anti-rad51 (#8875), anti-rad52 (#3425), 
anti-p21 (#2947) and anti-p-H2AX (#9718) from Cell Signaling Technology, anti-p53 
(DO-1) from Thermo Fisher Scientific and anti-MVP (#ALX-801-005) from Enzo Life 
Science. Secondary anti-mouse (#7076) and anti-rabbit (#7074) horseradish 
peroxidase-labeled antibodies were obtained from Cell Signaling Technologies. 
Immunofluorescence Microscopy. 3 × 104 cells/well were seeded in 8-well spot slides 
(Thermo Fisher Scientific). After 48h, cells were co-incubated for 1 h with the different 
concentrations of cisplatin, 1, Rf, Rf-1 in darkness, in duplicates. Then, one slide was 
kept in the dark for 6 hours more and the other was irradiated during 1 minute at 460 
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nm with an LED light source (6 mW   cm t 2), and also kept in the dark for 6 hours. Cells 
were rinsed with PBS and fixed with MeOH/Acetone 1:1 during 20 min at -20 °C, rinsed 
again with PBS and blocked with PBS + 10% BSA for 1 h. Blocking solution was 
aspirated and the diluted primary antibody p-H2AX Antibody 1:200 was applied and 
incubated at 4 °C overnight. After rinsing with PBS, secondary antibody goat anti-rabbit 
antibody conjugated to AlexaFluor488 (1:500) (Thermo Fisher) was co-incubated with 
phalloidin (1:500) and DAPI (1.5µg/mL) for 1 h. Images were acquired on an inverted 
point scanning confocal microscope with PMTs (LSM700, Zeiss, Jena, Germany) using a 
63× Plan-Apochromat 63×/1.4 oil immersion objective with Zen2010® software (Zeiss) 
using 405 nm (DAPI), 488 nm (AlexaFluor488) or 555 nm (phalloidin) solid state laser 
lines for excitation and 555 nm short pass (for DAPI and AlexaFluor488) and 560 nm 
long pass (phalloidin) emission filters, respectively.  
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5.1 Introduction 
The latest advancements in bioorthogonal chemistry1 demonstrate how 
organometallic compounds and inorganic materials are capable of catalyzing the 
activation of profluorescent substrates and prodrugs with remarkable efficiency in 
biological environments.2-10 These selective catalysts carry out non-natural reactions 
dodging the interference of biological molecules, using in some cases endogenous 
cellular components as co-reactants.3, 9 
In this context, we recently reported a new bioorthogonal reaction in which riboflavin 
photoactivates a PtIV prodrug with extremely low doses of blue light through a catalytic 
mechanism in the presence of zwitterionic electron donors. Light activation of the 
riboflavin-prodrug pair triggers cisplatin-related antiproliferative activity in PC3 cancer 
cells.[11] Unlike classic organometallic catalysis, where metals act as catalysts, in this 
reaction the metal complex is an unconventional substrate12 and the biocompatible 
riboflavin is the catalyst. 
Herein, we report fundamental discoveries in this new type of bioorthogonal chemistry 
by (i) investigating the catalytic behavior of various flavin catalysts, including four 
flavoproteins with diverse biological functions and flavin binding pockets, (ii) increasing 
the pool of inorganic reactions to different PtIV and RuII prodrug complexes and (iii) 
evaluating the efficiency of (bio)organic electron donors (Figure 1). Furthermore, our 
work shows for the first time that certain flavoproteins may be directly implicated in 
the activation of metallodrugs under biologically relevant conditions in the absence of 
light. 
 
Figure 1. Structures of catalysts, substrates and electron donors employed in this study. 
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5.2 Results and Discussion 
Initially we investigated the capacity of FAD (flavin adenine dinucleotide) as catalyst for 
the photoactivation of two classes of anticancer metal complexes, namely Pt IV 
octahedral and RuII-arene piano-stool complexes. Complexes 1t 3 are prodrugs of 
cisplatin and carboplatin,13 and complexes 4 and 5 are photoactivatable scaffolds 
capable of generating reactive Ru t OH2 species, which can bind to biomacromolecules 
(Figure 2a).14-17 Importantly, these PtIV and RuII complexes have poor absorption 
properties in the visible (Figure 2b) compared to other photoactivatable complexes, 
e.g. Ru polypyridyls. Therefore, novel strategies to prompt their photochemistry at 
longer wavelengths are pivotal for use in photochemotherapy. Complexes 1t 5 are 
stable towards hydrolysis in the dark, and have either no or poor photoreactivity under 
blue light excitation.11, 17-18 
FAD photocatalysis towards 1t 5 `    (}u  uo}˙]vP  íì   D  }(   o˙   v  îìì  
 D  }(  u o   µ     ~æ9   o˙   o}X   /v  oo  ] ] ]}v  ˘]uv U  `  µ    v 
 >     o]PZ   }µ   ~ò  u tu t 2) with an emission maximum at 460 nm and 1H NMR to 
monitor and quantify the evolution of the photoreactions. Description of experimental 
methods and a complete set of dark and light-irradiation experiments are provided in 
the Supporting Information (Figure S1 t S76). 
 
Figure 2. (a) Flavin-mediated photoactivation reactions of complexes 1t 5; (b) absorption 
spectra of FAD and 1t 5. 
In first instance, we evaluated the effect of electron donors on the catalytic process 
using complex 1, with the aim of optimizing reaction conditions. Three concentrations 
(0.2, 2 and 20 mM) of MES (as buffer, pH 6) or NADH (pH 7, 100 mM PB, i.e. phosphate 
buffer) were employed for this purpose. MES was selected as electron donor to follow 
up our previous work on riboflavin,11 while NADH for its relevance as biological 
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cofactor in numerous reactions catalyzed by flavoenzymes.19 Moreover, metal-based 
catalytic drugs have been recently shown to kill cancer cells by interfering with the 
cellular NAD+/NADH homeostasis.20-22 
Upon 460-nm light excitation, FAD photoconverted the PtIV substrate and showed a 
catalytic efficiency which increased linearly alongside the MES concentration. FAD was 
fully inactive in the dark at any tested MES concentration. In the absence of light, 0.2 
and 2 mM NADH did not induce any reaction for 1, whereas light irradiation switched 
on the generation of photoproducts at 2 mM when FAD was present. At 2 mM NADH, 
FAD photocatalyzed the full conversion of 1 in only 2.5 min against the 5 t 10 min 
required by 20 mM MES. At the lowest concentration (0.2 mM), NADH was 
instantaneously photooxidized to NAD+ by molecular oxygen (O2), precluding any 
catalytic reaction between FAD and the complex. Conversely, reduction of 1 at 20 mM 
NADH took place readily in the dark when FAD was present, or under light irradiation 
when the flavin was absent (Figure S1 t 8). 
On this basis, we used 20 mM MES and 2 mM NADH to determine FAD photocatalytic 
activity towards 1t 5 (Figure 2).23 All complexes underwent photochemical activation in 
the presence of catalytic quantities of FAD (Figure S1 t 38). Consistently with their 
redox chemistry in the biological context,24 FAD photoactivation of 1t 4 with NADH was 
approximately twice as fast as MES. The only exception was 5, towards which FAD 
displayed 3.4 times lower turnover frequency (TOF) using NADH than using MES (Table 
1). 
The kinetics of these catalytic reactions showed clear dependency on the substrate 
nature. Complexes 1, 2 and 4 were the best substrates, having the highest TOFs and 
total turnover numbers (TTNs). Remarkably, FAD was able to complete the conversion 
of 1 and 2 into its corresponding photoproducts regardless of the electron donor used. 
FAD allowed employing a convenient excitation wavelength (460 nm) and an extremely 
low light dose for the photoactivation of 1t 5. In the case of 1, 2 and 4, a light dose of 
ca. 1  : u t 2 was sufficient to fully convert the complexes in their activated 
photoproducts. RuII-arene derivatives such as 4 and 5 typically require irradiation times 
exceeding 1 hour to reach ca. 50% conversion (Figure S24 and S32).14-17 
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Herein, we show that less than 15 min are sufficient to achieve comparable effects in 4 
and 5 when FAD was used as photocatalyst. 
Table 1. Turnover frequency (TOF, min-1) and total turnover number (TTN) for the FAD- and 
flavoprotein-catalyzed photoactivation of complexes 1t 5 in the presence of MES and NADH. 
   
 
Complex 
MES (20 mM) NADH (2 mM)[a] 
TOF TTN % Conv. TOF TTN % Conv. 
 FAD 
1 2.3 ± 0.2 20 100 5.0 ± 1.7 20 100 
2 4.0 ± 0.5 20 100 7.1 ± 1.8 20 100 
3 0.6 ± 0.1 11 55 2.3 ± 0.6 14 70 
4 4.5 ± 0.6 16 80 9.0 ± 2.3 20 100 
5 2.2 ± 0.5 16 80 0.6 ± 0.1 14 70 
 miniSOG 
1 1.0 ± 0.2 20 100 7.1 ± 0.4 20 100 
2 1.2 ± 0.1 20 100 8.6 ± 2.2 20 100 
 NOX 
1 0.62 ± 
0.01 
20 100 4.3 ± 1.6[b] 20 100 
2 4.7 ± 1.2 20 100 8.3 ± 1.6[b] 20 100 
 GOX 
1 Not active 
2 <0.1 5 20 <0.2 7.4 37 
 GR[a] 
1 <0.1 10 50 0.42 ± 0.07 20 100 
2 Not active 1.2 ± 0.3 20 100 
[a] = experiments for GR were run using NADPH; [b] = in the dark 
In the cell milieu, flavins are bound to proteins through covalent and non-covalent 
interactions,19 which control their (photo)redox properties.24 Exploiting flavoproteins 
as selective catalysts is therefore an exciting prospect for the design of bioorthogonal 
activation strategies for metal-based prodrugs. Accordingly, we selected four 
flavoproteins for their diverse flavin-binding pockets and explored their capacity to 
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catalyze the photoreduction of 1 and 2 as substrates. This part of the study was limited 
to these derivatives for their relevance as anticancer compounds13, 25 with respect to 
the RuII complexes 4 and 5. Furthermore, FAD had superior activity towards these PtIV 
substrates with respect to 3. The use of 2 was also aimed at gauging the role played by 
the charge of the substrates on the catalysis, having this complex a neutral alkyl chain 
at the axial position compared to the negatively charged succinate of 1. 
The flavoprotein catalysts tested were miniSOG (mini Singlet Oxygen Generator),26 
NOX (NADH oxidase from Thermus thermophilus),27 GOX (glucose oxidase from 
Aspergillus niger)28 and GR (glutathione reductase from S. cerevisiae).29 MiniSOG is an 
FMN-containing (flavin mononucleotide) small protein investigated as a genetically 
encodable photosensitizer for the selective generation of singlet O2.30-32 The bacterial 
NOX enzyme generates hydrogen peroxide (H2O2) from O2 oxidizing NADH, while the 
eukaryotic GOX naturally oxidizes glucose to H2O2 and D-glucono-w-lactone. NOX and 
GOX have been both widely exploited in biocatalysis.27, 33 GR is a NADPH-dependent 
oxidoreductase exerting a central role in glutathione metabolism for most aerobic 
organisms.34 Conversely from the other flavoproteins, GR was selected because does 
not generate reactive oxygen metabolites. 
Different chemical environments surround the flavin binding-pocket in these four 
flavoproteins, controlling solvent and substrate accessibility to the active site. As 
shown in Figure 3, miniSOG35 and NOX, have more exposed flavins than GOX and GR, 
in which FAD is deeply buried into the protein scaffold. Solvent accessible surface 
areas of the flavins are 45.50 Å2 for miniSOG, 67.92 Å2 for NOX, while only 2.39 Å2 for 
GOX and 4.01 Å2 for GR. Moreover, they display different electrostatic surfaces in the 
proximity of the flavin binding-pocket (Figure S39 t 43). At pH 6t 7, the NOX and GR 
active sites are neutral, whereas miniSOG and GOX display positive and negative 
electrostatic charges respectively. 
Unless otherwise stated, photocatalysis experiments (Figure S44 t 76) were performed 
uo}˙]vP  íì   D  (oÀ } }]v   o˙  U  îìì   D  1 or 2 and either 20 mM MES or 2 
mM NADH, in order to directly compare activities with the corresponding free flavin. 
Concentrations of flavins bound to proteins were calibrated by optical methods using 
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FAD and FMN (for miniSOG) absorbance at 460 nm. Catalysis results for flavoproteins 
are summarized in Table 1. 
As anticipated from inspecting their flavin active site, GOX and GR showed the lowest 
catalytic activity towards the PtIV substrates. GOX presented no catalytic activity 
towards 1 under none of the experimental conditions tested. Lack of activity was also 
found when glucose (20 mM), a natural substrate for the enzyme, was employed as 
source of electrons instead of MES or NADH. Conversion of 2 by GOX occurred in the 
presence of both electron donors, however reactions were slow and did not reach 
completion after 1 h of light irradiation (conversion < 40%). In MES, GR was poorly or 
no active towards 1 and 2. On the contrary, NADPH prompted significantly higher TOF 
values and complete substrate conversion within few minutes of light exposure. 
 
Figure 3. Electrostatic surface potential of the binding sites of (a) miniSOG, (b) NOX, (c) GOX 
and (d) GR (calculated using Bluues server). Red and blue colors represent anionic and cationic 
residues, respectively.36 
In MES, miniSOG and NOX converted 1 and 2 into their photoproducts exclusively upon 
blue light excitation. Whereas miniSOG showed no preference between the two 
substrates, NOX was ca. 7 times more efficient towards 2 than 1. Light irradiation also 
switched on the catalytic activity of miniSOG in PB/NADH. The flavoprotein achieved 
full conversion of îìì   D  1 and 2 in ca. 4 min. In the case of 1, this is approximately 5 
times less efficient than free FMN (TOF 35.6 ± 4.3 min-1, Figure S50).  
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To our surprise, NOX behaved differently, activating 1 and 2 in the dark when co-
incubated with 2 mM NADH. Under  µZ   }v ]]}vU íì   D  E K y }uo o˙  }vÀ   
1 in less than 7.5 min, while free FAD did not give any reaction with 1 over 3 h (vide 
supra). The TOF values of 1 and 2 for NOX were estimated to be 4.3 ± 1.6 min-1 and 8.3 
± 1.6 min-1   ]À o˙U µ ]vP o    Zv î   D }(  (oÀ }}]v  }  oo}` u}v]}]vP }(  Z  
reaction by NMR. 
The discovery of NOX catalytic activity in the dark has broad relevance for 
understanding the mechanism of action of PtIV anticancer agents. It is common 
assumption that PtIV complexes are converted into active species by biological 
molecular reductants, such as glutathione or ascorbic acid, under physiological 
conditions.37 Nevertheless, NOX-catalyzed activation of 1 and 2 in the presence of 2 
mM NADH is significantly rapid and suggests that flavoproteins can provide alternative 
and highly efficient activation pathways for metallodrugs.38 
Considering that the cellular concentration of NADH is in the 0.1 t 0.2 mM range,39 we 
À oµ    Z   ]˙  }(   E K y   }  }vÀ   îì ì   D  1 with an equimolar quantity of 
NADH in PB (Figure S64). NOX naturally uses O2 as electron acceptor to generate H2O2 
in the presence of NADH.27 At such low concentration, the enzyme consumed NADH 
too rapidly, precluding any catalytic conversion of 1. For this reason, the reaction was 
studied under N2 atmosphere. Accordingly, we determined that NOX could activate 
approximately a third of 1 in the absence of O2, revealing that indeed flavoenzymes 
may turn on Pt drug activity under certain cellular conditions, i.e. hypoxia. Although 
the PtIV conversion did not reach completion, the concentration of activated 1 should 
reasonably be sufficient to induce cell death in cancer tissues. 
At higher concentrations of electron donor in aerated solution, the enzyme reaction 
pathway is altered by 1, which effectively competes with O2 and intercepts electrons 
from the reduced flavoenzyme. In fact, the activity of NOX was increased by 2.3 fold 
while the production of H2O2 simultaneously lowered (Figure 4a) when 1 mM 1 was 
incubated with equimolar NADH. Under these conditions, the enzyme worked faster 
because it had access to higher concentrations of electron acceptors (1 and O2), and 
produced lower amounts of H2O2 because the hydride of NADH ought to be shared 
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between O2 and the metal complex reduction reactions. Conversely, miniSOG 
production of H2O2 is independent of the presence of 1 (Table S1), as it is likely 
occurring via photosensitization.40 
The capacity of miniSOG and NOX to act as bioorthogonal catalysts towards Pt IV 
prodrugs was investigated using 1 in cell culture medium, where components such as 
proteins, vitamins and salts can interfere with the activation process. Reactions in the 
presence of NADH (2 mM) showed that miniSOG converted 1 in the biological 
environment only under light irradiation, while the same reaction occurred already in 
the dark with NOX (Figure 4b and Figure S75). The flavoproteins retained practically 
the same selectivity and efficiency of free FAD under the same conditions (Figure S76). 
 
Figure 4. (a) NOX catalytic consumption rate of NADH (magenta) and generation of H2O2 (blue) 
measured employing a 1:1 ration of 1 and NADH at a concentration of 1 mM; (b) Dark catalytic 
activity of NOX in cell culture medium (pH 7) in the presence of NADH. 1H NMR spectra were 
recorded for solutions of 200 µM 1 and 10 µM NOX and 2 mM NADH. 1H NMR signal labelling: 
 S  Ptt OCOCH2CH2CO2 t ,  S  Ptt OCOCH2CH2CO2 t ,   free t O2CCH2CH2CO2 t . 
A molecular description of the catalytic mechanism through which free flavins and 
flavoproteins activate PtIV and RuII complexes requires further investigations and is out 
of the scope of this manuscript. Our previous study suggests the catalysis is linked to 
the generation of the reduced forms of FAD and FMN (e.g. FADH2 and FMNH2), either 
through photoinduced electron transfer (MES) or by hydride transfer (NADH/NADPH). 
High levels of electron donors and light help increasing the catalytic efficiency of the 
flavins by stabilizing their active species and consequently enhancing reaction rates. 
Metal complexes may form transient adducts with the reduced flavins and undergo 
chemical and photochemical transformations.11 
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Nevertheless, it is clear from the results of this study that protein scaffolds play a 
crucial role in governing the accessibility of the metal substrate to the flavin catalytic 
site. So, the negative electrostatic surface of GOX and the shielded channel in which its 
FAD is bound prevent any interaction with the negatively charged 1. Consistently, we 
observed that the consumption of glucose by GOX was not affected by the presence of 
equimolar 1 (Table S2). Although with poor efficiency, GOX activated 2 in agreement 
with the absence of charged chemical groups in the complex and its lower reduction 
potential compared to 1.41 
In the case of miniSOG and NOX, however, the protein scaffold enables the artificial 
catalysis by facilitating the formation of reduced FMN/FAD and favoring its 
stabilization for the subsequent electron transfer interaction with the Pt IV substrates. 
Actually, miniSOG and NOX have more solvent exposed flavins and suitable 
electrostatic surfaces to allow metal substrates to access the active site. The role 
played by the protein scaffold is dramatic for NOX, which is an enzyme optimized by 
nature to transfer hydrides from NADH to electron acceptors. Consistently, NOX 
activity towards 1 and 2 is observed almost instantaneously in the dark with NADH. On 
the contrary, miniSOG, a protein derived from phototropin 2, which naturally does not 
use NADH as cofactor, requires light activation. Similarly to NOX and in contrast to 
GOX, GR has a mostly neutral FAD binding pocket and slightly positive surface charge, 
which allow catalytic activation of the 1 and 2. Nonetheless, GR requires light 
triggering for the catalysis likely due to the limited accessibility of its FAD with respect 
to NOX. 
5.3 Conclusions 
In conclusion, we show that free flavins and flavoproteins can catalyze artificial 
reactions of PtIV and RuII complexes, operating either in the dark or upon light 
excitation. Some of these unconventional reactions have promising catalytic efficiency 
and bioorthogonal selectivity. These findings open new opportunities for the design of 
chemically- and light-activated metal-based prodrugs, whose biological effects could 
be triggered endogenously by bioorthogonal flavoprotein catalysts. 
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5.4 Experimental details 
Materials 
Flavin adenine dinucleotide disodium salt hydrate (FAD), ]}(oÀ ]v  æ; -monophosphate 
sodium salt hydrate (FMN), 2-(N-morpholino)ethanesulfonic acid (MES), t -
nicotinamide adenine dinucleotide reduced disodium salt hydrate, sodium phosphate 
monobasic monohydrate, glucose oxidase from Aspergillus niger, glutathione 
reductase from S. cerevisiae and ABTS (î Uî; -Azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid) diammonium salt) were purchased from Sigma Aldrich. Sodium phosphate dibasic 
was obtained from PANREAC and K2PtCl4 and RuCl3  3H2O from Precious Metals Online. 
All chemicals were used as received without additional purification. Ham’s F-12K 
(Kaighn’s) medium nutrient mixture and fetal bovine serum (FBS) were purchased from 
Invitrogen. Penicillin-Streptomycin mixture was purchased from Teknovas. 
Synthesis of complexes 1 t 5.  
Complexes cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2H)2] (1), cis,cis,trans-
[Pt(NH3)2(Cl)2(O2C(CH2)3CH3)2] (2) and cis,cis,trans-
[Pt(NH3)2(O4C6H6)(O2CCH2CH2CO2H)2] (3) were synthetized as described previously.42-44 
Complexes [({ 6-p-cym)Ru(bpm)(m-COOMe-Py)](PF6)2 (4) and [({ 6-p-cym)Ru(bpy)(m-
COOMe-Py)](PF6)2 (5) (where p-cym = para-cymene, bpy = 2,2’-bipyridine and bpm = 
2,2’-bipyrimidine) were prepared as described by us elsewhere.45  
Nuclear Magnetic Resonance and catalysis experiments. 1H NMR spectra of the 
various samples were recorded on an AVANCE III Bruker 500 NMR spectrometer using 
standard pulse programs. Chemical shifts were reported in parts-per-u]oo]}v  ~wU  u  
and referenced to the residual solvent peak. Catalysis studies were performed under 
different solution conditions (MES and PB buffers and cell culture medium). All 
reactions were carried out in air at 298 K and pH 6 (MES) or 7 (PB and NADH1). Light 
irradiation experiments were performed employing an LED light source ( max = 460 nm, 
6 mW cmt 2).11 Turnover frequency (TOF), total turnover number (TTN) and % 
                                                    
1
 NADH was chosen in all experiments since the NOX enzyme used in this work is approx. 10 
times more efficient with this cofactor/electron donor than with NADPH (Park, H.-J ; et al., Eur. 
J. Biochem. 1992, 205, 881-885). 
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conversion for the catalytic reactions were determined by quantifying the amount of 
converted 1t 5 via 1H NMR. Integration of the free succinate and hexanoate ligand 
signals (singlet at 2.25 t 2.35 ppm and triplet at 2.04 ppm) were used for monitoring the 
reaction progress of 1t 3. In the case of 4 and 5, either the signals of the p-cymene 
methyl groups (doublet at 0.6 t 1.20 ppm) or of the p-cymene ring (doublets at 5.9 t 6.5 
ppm) were employed for the same purpose with equivalent results. TOF values were 
 u]v   uo}˙]vP  íì    D  }(  (oÀ ]v  ~]Z   ]v  ]   (   }    }]v -bound forms) and 
îìì    D  }(  u o   µ     ~æ9   o˙   o}   ]v   Z   v   }(  î ì  u D   D  S or 2 mM 
NADH. Values were calculated for substrate conversion not exceeding 40%. In the case 
}(   E K yU     }vv ]}v  }(   }]v     o}`     í  }  î   D  `   µ   ]v  }   }  oo}` 
monitoring the reaction progression by NMR. 
NOX expression, purification and FAD loading 
Plasmid harboring the gen of NADH from Thermus thermophilus HB27 (NOX) was 
transformed into the expression strain E. coli BL21(DE3), which carries the RNA 
polymerase gene from the T7 phage under the control of an inducible promoter.27 The 
transformed cells were grown at 37°C in LB broth supplemented with ampicillin until 
the culture reached an optical density of 0.6 at 600 nm. Then, the expression of NOX 
was induced by addition of iso-propyl-1-thio- t -D-galactopyranoside (IPTG) to a 
concentration of 1 mM. The bacterial culture was incubated at 37°C for further 2 h, 
and then the cells were harvested and washed in sodium phosphate buffer by 
centrifugation (10000 × g, 10 min). Afterwards, cells were lysed by sonication, and the 
cell debris was eliminated by centrifugation (10,000 × g for 10 min). Crude protein 
extracts were diluted 10 fold in 10 mM sodium phosphate at pH 7 and incubated at 
80°C and pH 7 for 45 min. Protein aggregates were discarded after centrifugation 
(10,000 × g for 10 min), and the clarified supernatant. Finally, the pure protein was 
reconstituted with free FAD to assure that all NOX molecules contain at least 1 
molecule of FAD. The pure protein was incubated with 0.15 mM of soluble FAD+ in 100 
mM sodium phosphate at pH 7 for 30 min. Afterwards, this solution was passed 
through a gel-filtration column (NAPTM-10 column, GE life sciences) to remove the 
excess of unbound free FAD+ and change the buffer of the protein solution. Depending 
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on the experiments where NOX was used, the enzyme was exchanged with 0.1 M MES 
at pH 6 or 25 mM sodium phosphate at pH 7. 
MiniSOG expression and purification 
miniSOG gene was amplified from the pBAD-Myc-HisA plasmid encoding miniSOG 
(from Tsien Lab) by polymerase chain reaction (PCR). The gene encoding miniSOG was 
cloned into a pPRO-EX-HTa bacteria expression vector (Invitrogen), using the restriction 
sites BamHI and HindIII in order to generate a His-tagged miniSOG version. The pPRO-
EX-HTa vector contains a TEV recognition site before the his-tag sequence. The 
plasmids encoding miniSOG protein was transformed into Escherichia coli C41 cells. 
Bacteria cultures were grown in LB medium with ampicillin, at 37°C to an OD600 of 0.6-
0.8, then induced with 0.6 mM IPTG and grown 5 h at 30°C. The cells were harvested 
by centrifugation and the pellets re-suspended with lysis buffer (300 mM NaCl, 50 mM 
phosphate pH 7.4) supplemented with protease inhibitor cocktail (Roche, Basel, 
Switzerland). Cells were lysed by sonication and the lysate was cleared by 
centrifugation during 30 min at 4ºC and 15.000xg. His-tagged miniSOG was purified 
from the supernatant using a Nickel-agarose affinity column (Jena bioscience, Jena, 
Germany). The eluted fractions with protein were dialyzed into 150 mM NaCl, 50 mM 
phosphate pH 7.4 (PBS buffer). The His-tag was cleaved by overnight TEV protease 
digestion in 5mM EDTA, 1 mM DTT, 10 % glycerol, 50 mM Tris pH = 8.0 at 4oC. MiniSOG 
was purified from the His-tag and the tagged TEV protease by a second nickel affinity 
chromatography. Protein purity was determined by SDS-PAGE gel and MALDI-TOF mass 
spectrometry. Purified protein was concentrated by centrifugation using Millipore 
concentration devices and aliquots at the appropriate concentrations are frozen and 
stored at -20°C. The total protein concentration was determined by measuring the 
absorbance at 280 nm, using extinction coefficients calculated from amino acid 
composition and the total concentration of the flavin mononucleotide (FMN) 
chromophore was determined by absorbance at 448 nm using an extinction coefficient 
of 16760 M-1·cm-1.  
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MiniSOG molecular model 
The miniSOG molecular model was generated as described previously.31 Briefly, the 
model is based on the structure of the homologous protein iLOV (PBD ID: 4eet),46 and 
generated by manual modelling by automated homology modelling using Swiss-Model 
(http://swissmodel.expasy. org//SWISS-MODEL.html).47 The model was minimized 
using GROMOS 43B1 force field included in Swiss-PdbViewer program and YASARA 
minimization server (http://www.yasara.org/minimizationserver.htm).48 The geometry 
and stereochemical properties of the final model were checked and validated with 
Molprobity (http://molprobity.biochem.duke.edu/).49 
Protein electrostatic surface 
The electrostatic surfaces were calculated using Bluues server based on the Poisson 
Boltzmann equation.36 Firstly the .pdb file of each protein was converted into .pqr file 
to assign the electrostatic charges at pH 7 using PDB2PQR server.50 The .pqr file is then 
upload in the Bluues server obtaining a .pdb file where the b-factor columns have been 
replace by the corresponding electrostatic charge for each atom. The images were 
created using pymol 0.99 (DeLano, USA). 
Protein quantification 
 W}]v  `   µv](]  ˙   (} [   u Z} 51 adapted to 96-well plates. Briefly, 5 µL 
of enzyme solution were mixed with 200 µL of Bradford reagent, incubated at room 
temperature for 5 min. Then the absorbance was measured at 595 nm and the protein 
content was estimated employing a calibration curve using BSA as a standard. 
Enzyme activity assays 
The activity of NOX was analyzed spectrophotometrically recording the absorbance at 
340 nm ( xNADH= 6.22 mM t 1 cm t 1) promoted by the oxidation of in presence of different 
electron aceptors. Enzyme solution at different concentration was incubated with 
1mM NADH and different concentrations of 1 (0 t 1 mM) in 25 mM sodium phosphate 
at pH 7 and 25 ºC. The assay was adapted to 96-`oo   o   µ ]vP  îì ì   >      }o 
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reaction volume. One NOX international unit (IU) was defined as the amount of 
vÌ˙u v   } }˘]]Ì í  u}o }(  E    ,   u]vµ     , ó  v  îæ Ñ  X   
The activity of GOX was analyzed spectrophotometrically recording the absorbance at 
414 nm ( xABTS= 36.8 mM t 1 cm t 1) which results from the oxidation of î Uî; -Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), by coupling the 
peroxidase to the assay according to Bateman. Briefly, the assay was adapted to 96-
`oo  u] } o   `]Z    (]v o    ]}v  À }oµu  }(  îìì   >  }v]v]v]vP  ïì   D     d ^U  ï ì  
u D  }(  Poµ } U  îı  Plu >  }(  Z}  ] Z   }˘]    ~ , Z W  v   ìXìæ  uPlu >  }(   ’ K y  ]v 
25 mM sodium phosphate at pH 7 in presence and absence of 0.2 mM 1. One GOX 
]vv ]}vo  µ v]  ~ / h  `    (]v       Z   u}µ v  }(  vÌ˙u  v     }  }˘]]Ì   í   u}o  
of ABTS per minute at pH 7 and 25  qC.  
H2O2 spectrophotometric determination 
Once NOX quantitatively oxidized the NADH, the resulting H2O2 concentration was 
u  µ  ˙    Z}  ] Z  }˘]   ~ , Z W    ˙  }µo    }  ïUï;UæUæ; -
Tetramethylbenzidine (TMB). 150  L of NOX reaction were incubated with 50  L of 
TMB solution containing 0.035 mg/mL of HRP, 2.1 mM TMB and 8.8 % (v:v) of DMSO. 
The reaction was incubated for 5 minutes and measure at 650 nm. The assay was 
calibrated with H2O2 (0t 0.1 mM) to quantify the H2O2 produced by the action of NOX 
in presence of different electron acceptors.  
A similar approach was employed for miniSOG. After light irradiation (460 nm, 5 min), 
50 µL of a solution containing 200 µM 1 and 10 µM miniSOG were mixed with 50 µL of 
a solution containing horseradish peroxidase (HRP, 60 µg/mL) and 2 mM ABTS in 20 
mM MES at pH 6. The generation of H2O2 was determined by spectrophotometrical 
analysis measuring the absorbance at 414 nm ( xABTS= 36.8 mM t 1 cm t 1), which results 
from the oxidation of ABTS. 
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Conclusions 
 
The use of photoactivatable metal complexes as anticancer prodrugs is a promising 
approach that merges the benefits of light as spatio-temporal trigger, with the well-
known antineoplastic effects of metal-based drugs. In particular, photoactivatable PtIV 
complexes attract much attention since they can be transformed into clinically 
approved PtII drugs (e.g. cisplatin, carboplatin). Nevertheless, photoactivatable PtIV 
complexes generally suffer from poor absorption profiles. For this reason, a 
complementary strategy to efficiently deliver cytotoxic PtII species at more convenient 
excitation wavelengths (i.e. 460 nm) has been explored by introducing flavin cofactors 
and flavoproteins as photosensitizers. This allows excluding the use of UVA light, a 
range of wavelengths that is unsuitable for biomedical applications since it directly 
damages cellular components. Additionally, flavins are good candidates for use in 
biology and medicine since they take part in a great variety of processes occurring in 
living organisms. Nonetheless, flavins are more than simple photosensitizers in the 
activation chemistry of these metal-based prodrugs. They simultaneously act as 
unconventional catalysts and metal complexes, typically considered as catalysts, 
behave as substrates. 
This Ph.D. project has exploited such an atypical reactivity to devise a new prodrug 
activation approach, in which bioorganic flavin catalysts are able of photocatalyzing 
the transformation of anticancer metal agents with high efficiency and without being 
disrupted in biological media. Few other catalysis-based strategies have been reported 
to successfully deliver biologically active species in a bioorthogonal fashion. However, 
none of them is applied to metal-based prodrugs. They typically use metal complexes 
as catalysts for the activation of organic drugs and often suffer from metal poisoning 
or interferences by other biomolecules. 
Fundamental for the development of my Ph.D project has been the initial discovery 
that the co-administration of the riboflavin (Rf) and the photoactivatable PtIV complex 
cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2)2]2 t  as catalyst/substrate couple enables 
photoconversion of PtIV into biologically active species by light irradiation at 460 nm. 
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This Rf-PtIV pair induces an anticancer activity comparable to cisplatin in prostate 
cancer PC3 cells with light doses as low as 0.36 J·cm t 2. The need of only such a small 
light dose is valuable since long expositions to blue light have non-negligible tissue 
damage. The remarkable photocatalytic turnover obtained for the conversion of PtIV 
into PtII species is an attractive prospect to amplify the antineoplastic action of metal-
based prodrugs specifically in the tumor tissue.  
During the Ph.D stay in the group of Dr. Walter Berger at the Medical University of 
Vienna, more insights into the photocytotoxic activity and mechanism of action of this 
prodrug system have been obtained. Cell viability and uptake results in pancreatic 
carcinoma Capan-1 cells evidence for the first time that Rf can act as bioorthogonal 
catalyst towards PtIV substrates intracellularly. Capan-1 cells, which are characterized 
by a mutated p53 and a distinct antioxidant cell biology, are effectively induced into 
cell death after treatment with Rf-PtIV and only 1 minute of blue light activation. This 
photocytotoxic effect is clearly mediated by the release of cisplatin and subsequent 
DNA-damage, but other pathways are targeted as well, such as the specifically 
suppressed platinum drug resistance protein MVP/LRP.  
The last part of this Ph.D thesis has aimed at further expanding this chemistry by 
exploring the capability of flavoproteins to catalyze artificial reactions on two different 
classes of anticancer metal complexes, specifically PtIV octahedral and RuII-arene 
piano-stool complexes. The latter are photoactivatable scaffolds that generate reactive 
Rut OH2 species, which can bind to biomacromolecules and exert anticancer activity. 
Free FAD displays good catalysis features for all the metal-based substrates in the 
presence of two different electron donors (MES and NADH). Flavoproteins showed as 
well the capacity to function as photocatalysts, however a disparity in their catalytic 
efficiency and bioorthogonal selectivity is observed, depending on the accessibility of 
the flavin binding pocket and the protein electrostatic surface potential. As a result, 
GOX and GR have lower reactivity while miniSOG and NOX are more efficient catalysts. 
Interestingly, NOX in the presence of its natural cofactor NADH was able to activate 
the PtIV prodrugs also in the dark.  
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These findings are relevant since they support that enzymes of this type may also be 
involved in the activation of PtIV prodrugs. Besides, the discovery may open new 
designs of metal-based prodrugs which can be bioorthogonally activatated by 
endogeneous flavoprotein catalysts. 
Overall, my Ph.D work represents the starting point of a long-term project that aims at 
developing unconventional photocatalysis approaches for drug activation. Many 
details of the flavin-based catalysis process still require elucidation and their 
understanding would help to improve the design of photoactivatable prodrug systems. 
At this stage, I envision that the following points are crucial to further advancing the 
bioorthogonal catalytic activation of anticancer metal complexes towards preclinical 
studies: 
a) Obtaining insights in the catalysis mechanism such as thorough determination 
of reaction kinetics and detection/isolation of key intermediates. In this 
context, I believe modeling methods (i.e. Density Functional Theory DFT) can 
provide useful information on the nature of catalyst-substrate adducts which 
appear to play a key role in the catalysis.  
b) Performing biological studies to elucidate which cell death pathways follow the 
flavin-activated Pt drugs (e.g. caspase dependent or independent). Such work 
serves to assess the potential of our strategy to combine the benefits of PDT 
and chemotherapy (i.e. generation of 1O2 and liberation of toxic metal-
containing species). In addition, the use of intracellularly or/and artificially 
expressed flavoproteins as bioorthogonal catalysts would be an intriguing 
approach to employ cellular components to selectively activate anticancer 
metal complexes in specific compartments. 
c) Introducing as photocatalyst the flavin derivative roseoflavin (max = 505 nm) 
for its improved absorption properties, with the aim further red-shifting the 
excitation wavelength employed to trigger the photoactivation.  
d) Formulating viable delivery systems for in vivo applications, as for example, by 
the incorporation of catalysts and/or substrates into nanoparticles (e.g. 
upconverting nanoparticles) or other bioorganic platforms (e.g. polymeric 
micro-beads). 
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Figure S1. Photostability of 1 in H2O (pH 6). 1H NMR control spectra of a H2O/D2O 
solution (9:1) of 1 under 460-vu  o]PZ  ] ] ]}v ~îXæ u tu t 2) for 1 h. 
 
Figure S2. Photostability of 1 in phosphate buffer (PB). 1H NMR control spectra of a 
PB/D2O solution (9:1, PB 100 mM, pH 5.5) of 1 under 460-nm light irradiation (2.5 
u tu t 2) for 1 h. 
 
Figure S3. Photostability of 1 in MES buffer. 1H NMR control spectra of a MES/D2O 
solution (9:1, MES 18 mM, pH 6.0) of 1 under 460-nm light irradiation (2.5 mW  cm t 2) 
for 1 h. 
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[Rf] = 12 µM 
 
Figure S4. Photolysis of 1 in MES buffer in the presence of 12 µM Rf. 1H NMR spectra 
of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 12 µM Rf under 460-
vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 sec, 30 sec, 1 min, 2.5 min and 5 min. 1H 
NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of 
Rf isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
 
[Rf] = 24 µM 
 
Figure S5. Photolysis of 1 in MES buffer in the presence of 24 µM Rf. 1H NMR spectra 
of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 24 µM Rf under 460-
vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 sec, 30 sec, 1 min, 2.5 min and 5 min. 1H 
NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of 
Rf isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
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[Rf] = 50 µM 
 
Figure S6. Photolysis of 1 in MES buffer in the presence of 50 µM Rf. 1H NMR spectra 
of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 50 µM Rf under 460-
vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 sec, 30 sec, 1 min and 2.5 min. 1H NMR 
signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of Rf 
isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
 
[Rf] = 120 µM 
 
Figure S7. Photolysis of 1 in MES buffer in the presence of 120 µM Rf. 1H NMR spectra 
of a MES/D2O solution (9:1, MES 18 mM, pH = 6.0) of 120 µM 1 and 120 µM Rf under 
460- vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 sec, 30 sec, 1 min and 2.5 min. 1H 
NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of 
Rf isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
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[Rf] = 0.13 µM 
 
Figure S8. Photolysis of 1 in MES buffer in the presence of 0.13 µM Rf. 1H NMR spectra 
of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 0.13 µM Rf under 
460- vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0, 5, 35 and 120 min. 1H NMR signal 
labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t  •  free t O2CCH2CH2CO2 t . Methyl 
groups of Rf isoalloxazine ring are not detectable by NMR at this concentration. 
 
 
Figure S9. Stability control in the dark for Rf/1 in MES buffer. 1H NMR spectra of 
MES/D2O solution (9:1, MES 18 mM, pH 6.0) containing 120 µM 1 and 50 µM Rf in the 
dark for t = 0, 24 h, 48 h and 1 week. 1H NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  
Pt t OCOCH2CH2CO2 t , and •  methyl groups of Rf isoalloxazine ring. 
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Figure S10. Dependency of photocatalytic rate on substrate (1). Study of the 
photocatalytic activation of 1 at increasing substrate concentrations ([1] = 60, 120, 
240, 480, 960 and 1920 µM) and fixed concentrations of Rf (50 µM) and MES (18 mM). 
 v  ] ] ]}v   ]u  }(  ï ì     `   µ   (}  oo   Z   uo   ~ exc A  ðò ì  vuU  îXæ  u tu t
2).  
 
Figure S11. Dependency of photocatalytic rate on MES concentration. Photocatalytic 
activation of 1 at increasing concentrations of MES ([MES] = 3, 5, 7, 10, and 20 mM) 
and at a fixed concentration of Rf (50 µM) and 1 (500  PM). An irradiation time of 30 
sec was set fo  oo  Z   uo  ~ exc A  ðòì  vuU îXæ u tu t 2). 
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Figure S12. Dependency of photocatalytic rate on Rf concentration. Study of the 
photocatalytic activation of 1 at three different concentrations of Rf (12, 50 and 120 
 D v   (]˘  }vv ]}v  }(  1 (1î ì   D  v  D  ^ ~íô u DX  dZ   ]((v  }o}µ  
lines corresponds to the fitting of the corresponding experimental data to the pseudo-
first order equation   >s ? L >s ?
4 A? Þ Ú˝Þ ç , where t = time and kobs = observed kinetic 
constant defined as kobs = k[MES] where k = constant of the second order reaction. 
 
Figure S13. Dependency of photocatalytic rate constant kobs on MES concentration. 
Study of the photocatalytic activation of 1 at increasing concentrations of MES ([MES] 
= 3, 5, 7, 10, and 20 mM) and at a fixed concentration of Rf (50 µM) and 1 (500  PM). 
 v ]  ] ]}v  ]u }( ï ì   `     (} oo  uo  ~ exc A ðò ì vuU îXæ u tu t 2). 
139 
 
 
Figure S14. Light-induced MES oxidation by Rf. 1H NMR spectra of a MES solution (3 
mM) containing 500 µM 1 and 50 µM Rf under 460-vu  o]PZ  ]  ] ]}v  ~îXæ  u tu t 2) 
for tirr = 0 and 30 sec. The newly formed peaks are assigned to oxidized MES species. 
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Figure S15. Plot of Fe(II) mol vs. irradiation time at 460 nm. The ferrioxalate 
actinometer (K3[Fe(C2O4)3]) (0.15 M) was irradiated with a 460-nm light source in a 
plate reader and a phenatroline-based developing solution was then added to 
determine spectrophotometrically the amount of Fe(II) ions generated by irradiation, 
as described by S. L. Hopkins et al.3 Data were fitted with the equation y = (3.12·10 t 9  r  
0.17·10 t 9)x + (1.60·10 t 8  r  4.52·10t 9). R-Square = 0.998. Being the absolute quantum 
yield 
Jc : MM;   for (K3[Fe(C2O4)3]) (0.15 M) at 460 nm equal to 0.65,
3 a photon flux of 
8.09·10 t 9  r  0.94·10 t 9 mol photon·sec t 1 was obtained for the light source using the 
equation: 

Jc : MM; L  
D
Jc : MM;
 
_‘q
 
where D
Jc : MM;  the moles of Fe(II) produced photochemically and   _‘q  the absorbed 
photon dose by the Fe-oxalate complex.4 
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Figure S16. Moles of photodissociated succinate ligand vs. irradiation time at 460 nm. 
MES (18 mM) solutions of 1 (1.00 mM) and Rf (50 µM) placed in a plate reader were 
irradiated at 460 nm for different time intervals and using the same setup employed 
for the ferrioxalate actinometry. The amount of photodissociated succinate was 
quantified by 1H NMR spectroscopy and data were fitted with the equation   L
  : F wä tx I sr  ;    r   v ä t I sr  < ;  
7 n
/. ä 45    r   2 ä 01  + (-5.44·10t 7  r  2.9·10 t 8). R-Square = 0.969. 
By employing the equation 
 L  
                                  
:
              
;
                                                          
                                                                    
L  
 
     
>            ?
t
                    
 
 
a quantum yield   of 1.4  r  0.1 was determined. 
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Figure S17. Photostability of Rf in MES buffer. 1H NMR spectra of a MES/D2O (9:1, MES 
18 mM, pH 6.0) solution of 240 µM Rf under 460-vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) 
for tirr = 0, 30 and 60 min. 1H NMR signal labelling: •  methyl groups of Rf isoalloxazine 
ring. 
 
 
Figure S18. Photostability of Rf in MES buffer and water. UV-Vis spectrum of Rf (50 
R D  ]v   D  ^   µ((   ~îì  u DU   ,  ò  v  ]v  `   ~  ,  ó       ](( v  ] ] ]}v   ]u   ~ irr 
= 460 nm, 2.5 u tu t 2; MES: violet tirr = 0, magenta tirr = 2.5 min, and pink tirr = 5 min; 
Water: dashed-blue tirr = 1 min). The absorption profile obtained after light irradiation 
in water (dashed blue line) corresponds to lumichrome, a common photoproduct of Rf 
photolysis. 
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Figure S19. Photostability of Rf in Phosphate Buffer (PB). 1H NMR spectra of a PB/D2O 
(9:1, 100 mM, pH 5.5) solution of 240 µM Rf under 460-nm light irradiation (2.5 
u tu t 2) for tirr = 0, 30 and 60 min. Changes in the 1H NMR signal at 3.5 t 3.8 ppm 
indicate the ribityl side chain is undergoing intramolecular photodegradation. 
Appearance of the peak at at 2.33 ppm ( • ) is consistent with the formation of 2,3-
butanedione, a photoproduct obtained by O2-oxidation of the isoalloxazine ring. 
 
 
Figure S20. Photolysis of 1 in HEPES buffer in the presence of 50 µM Rf. 1H NMR 
spectra of a HEPES/D2O solution (9:1, HEPES 18 mM, pH 6.0) of 120 µM 1 and 50 µM Rf 
under 460-vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 sec, 30 sec, 1 min. 1H NMR 
signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of Rf 
isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
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Figure S21. Stability control in the dark for Rf/1 in HEPES buffer. 1H NMR spectra of 
HEPES/D2O solution (9:1, HEPES 18 mM, pH 6.0) containing 120 µM 1 and 50 µM Rf in 
the dark for t = 0 and 3 h. 1H NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t
OCOCH2CH2CO2 t  and •  methyl groups of Rf isoalloxazine ring. 
a 
 
b 
 
Figure S22. Photolysis of 1 in the presence of Rf and NaN3 in water. (a) 1H NMR spectra 
of a H2O/D2O (9:1, pH 3) solution of Rf/1 (50/120 µM) with 3 mM NaN3 under 460-nm 
o]PZ  ]  ] ]}v  ~îXæ u tu t 2) for tirr = 0 and 30 min; (b) 1H NMR spectra of a H2O/D2O 
(9:1, pH 2.7) solution of Rf/1 (240/120 µM) without NaN3 irradiated under the same 
conditions. In all experiments, HCOOH was added (3 mM and 24 mM for a and b 
respectively) to improve the photoconversion of 1 and slightly reduce the 
photodecomposition of Rf. 1H NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t
OCOCH2CH2CO2 t , •  methyl groups of Rf isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
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Figure S23. Photolysis of 1 in the presence of Rf and NaN3 in Phosphate Buffer (PB).  1H 
NMR spectra of a PB/D2O (9:1, 100 mM, pH 5.5) solution of Rf/1 (240/120 µM), with 
(a) or without (b) 1 mM NaN3 under 460-vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 
and 30 min. In all experiments, 24 mM HCOOH was added to improve the 
photoconversion of 1 and slightly reduce the photodecomposition of Rf. 1H NMR signal 
labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of Rf 
isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
 
Figure S24. Photolysis of 1 in MES buffer in the presence of Rf and NaN3. 1H NMR 
spectra of a MES/D2O (9:1, 18 mM, pH 6.0) solution of Rf/1 (50/120 µM) with 18 mM 
NaN3 under 460-vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0, 2.5, 5 and 10 min. 1H 
NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of 
Rf isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
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Figure S25. Photolysis of 1 in MES buffer in the presence of Rf under Ar atmosphere or 
in air. 1H NMR spectra of a MES/D2O (9:1, 18 mM, pH 6.0) solution of Rf/1 (50/200 µM) 
under 460- vu  o]PZ  ] ] ]}v  ~ò  u tu t 2) for tirr = 0 and 30 sec. 1H NMR signal 
labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of Rf 
isoalloxazine ring, •  free t O2CCH2CH2CO2 t . 
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Figure S26. Lifetime decay profile for Rf. Fluorescence lifetime measurement for a 5 
 D  Rf solution in MES buffer (10 mM) measured in a time-correlated single photon 
counting (TCSPC) setup. Rf exhibits a mono-exponential decay with a lifetime of 4.60 
nm (green dots). IRF (grey dots) = instrument response function (prompt). 
 
Figure S27. Lifetime decay profile for Rf in the presence of 1. Fluorescence lifetime 
u  µuv  (}     æ   D  Rf solution in MES buffer (10 mM) measured in the presence 
of 1.8 mM of 1 in a time-correlated single photon counting (TCSPC) setup. Rf exhibits a 
mono-exponential decay with a lifetime of 4.63 nm (blue dots). IRF (grey dots) = 
instrument response function (prompt). 
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Figure S28. DFT-optimized structure and frontier orbitals of a selected 1-RfH2 adduct. 
(a) Conformation of a selected 1-RfH2 adduct optimized by DFT at the PBE0/def2-SVP1,2 
level (H-bond contacts highlighted with violet lines). (b t d) Frontier orbitals for the 
optimized conformation of the 1-RfH2 adduct (isodensity surfaces plotted with the 
isovalue of 0.02 e > bohr >3). The stabilization energy for 1-RfH2 is t 52.0 kcal·mol t 1 and is 
calculated using the form µ o 4  A    1-RfH2 t  (E1 + ERfH2). 
 
 
149 
a 
 
b 
 
HOMO 
c 
 
LUMO 
d 
 
LUMO+1 
Figure S29. DFT-optimized structure and frontier orbitals of a selected RfH t  adduct 
(N5). (a) Conformation of a selected 1-RfH t  adduct (N5-protonated) optimized by DFT 
at the PBE0/def2-SVP1,2 level (H-bond contacts highlighted with violet lines). (b t d) 
Frontier orbitals for the optimized conformation of the 1-RfH t  adduct (isodensity 
surfaces plotted with the isovalue of 0.02 e > bohr >3). The stabilization energy for 1-RfH t  
is t 68.8 kcal·molt 1 v  ]  o µo   µ ]vP  Z (} uµo 4  A   1-RfH t  (E1 + ERfH). 
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Figure S30. DFT-optimized structure and frontier orbitals of a selected RfH t  adduct 
(N1). (a) Conformation of a selected 1-RfH t  adduct (N1-protonated) optimized by DFT 
at the PBE0/def2-SVP1,2 level (H-bond contacts highlighted with violet lines). (b t d) 
Frontier orbitals for the optimized conformation of the 1-RfH t  adduct (isodensity 
surfaces plotted with the isovalue of 0.02 e > bohr >3). The stabilization energy for 1-RfH t  
is t 61.2 kcal·molt 1 v  ]  o µo   µ ]vP  Z (} uµo 4  A   1-RfH t  (E1 + ERfH). 
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Figure S31. Photolysis of 1 in MES buffer in the presence of 50 µM FMN. 1H NMR 
spectra of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 50 µM FMN 
under 460-vu  o]PZ  ] ] ]}v  ~îXæ u tu t 2) for tirr = 0 sec, 30 sec and 1 min. 1H NMR 
signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of FMN 
isoalloxazine ring and •  free t O2CCH2CH2CO2 t . 
 
 
Figure S32. Stability of 1 in MES buffer in the presence of 50 µM FMN. 1H NMR control 
spectra of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 50 µM FMN 
in the dark for 3 h. 1H NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t
OCOCH2CH2CO2 t , •  methyl groups of FMN isoalloxazine ring. 
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Figure S33. Photolysis of 1 in MES buffer in the presence of 50 µM FAD. 1H NMR 
spectra of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 50 µM FAD 
under 460-vu  o]PZ  ] ] ]}v  ~îXæ  u tu t 2) for tirr = 0 sec, 30 sec and 2.5 min. 1H 
NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t , •  methyl groups of 
FAD isoalloxazine ring and •  free t O2CCH2CH2CO2 t . 
 
 
Figure S34. Stability of 1 in MES buffer in the presence of 50 µM FAD. 1H NMR control 
spectra of a MES/D2O solution (9:1, MES 18 mM, pH 6.0) of 120 µM 1 and 50 µM FAD 
in the dark for 3 h. 1H NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t
OCOCH2CH2CO2 t , •  methyl groups of FAD isoalloxazine ring. 
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Figure S35. Dependency of photocatalytic prodrug activation on pH. Photocatalytic 
activation of 1 at different pHs (4-10) and at a fixed concentration of Rf (50 µM), 1 (120 
 PM) and MES (18 mM). An irradiation time of 2 min and 30 sec was set for all the 
 uo  ~ exc A ðò ì vuU îXæ u tu t 2). 
 
 
Figure S36. Photostability of cell culture medium. 1H NMR spectra of cell culture 
medium (Ham's F-12K supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin) before and after 1 min of irradiation with 460-nm light (6 
u tu t 2). 
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Figure S37. Photostability of Rf in cell culture medium. UV-Vis spectra of Rf ~æì   D  ]v 
cell culture medium (Ham's F-12K supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin) with 3 mM MES in the dark (violet line), after 1 min of 
] ] ]}v  ~]vl  o]v     ðò ì  vu  ~ò  u tu t 2) and after 1 min of irradiation in the 
 v }(  D  ^ ~oµ o]v    ðòì  vu ~ò u tu t 2). 
 
 
Figure S38. Photolysis of 1 in cell culture medium in the presence of Rf and MES. 1H 
NMR spectra of cell culture medium/MES/D2O (7.5:1.5:1, 3 mM MES) solution 
containing 1.92 mM 1 and 50 µM Rf under 460-vu  o]PZ  ] ] ]}v  ~ò  u tu t 2) for tirr 
= 0, 30 sec, 2.5 min and 3 min. Cell culture medium corresponds to Ham's F-12K 
medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. 
1H NMR signal labelling: •  Pt t OCOCH2CH2CO2 t , •  Pt t OCOCH2CH2CO2 t  •  free t
O2CCH2CH2CO2 t . 
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Figure S39. MES toxicity in PC-3 cells. Control experiments performed treating PC-3 
cells with MES (2 mM) under light irradiation, using two different incubation 
conditions. Cells were plated in 96-well plates with a density of 4000 cells per well 
supplemented with serum and antibiotics and left to grow for 24 h at 37 °C with 5% 
CO2 and 90% humidity. MES was then dissolved in the cell culture medium to reach a 2 
mM concentration and cells were incubated for 1 h and then irradiated for 1 min with 
460- vu  o]PZ  ~o]PZ   }   ìXïò   : u t 2). Afterwards, cells were either incubated for other 
i) 6 hours or ii) 24 h before medium was replaced and cells grown of a total of 48 h. 
The SRB assay was employed for both incubation conditions to evaluate cell density. 
 
Figure S40. Assessment of the presence of 1 in cell culture medium without MES 
buffer. 1H NMR spectra of cell culture medium/D2O (9:1) solution containing 120 µM 1. 
Cell culture medium corresponds to Ham's F-12K medium supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin. 1H NMR signal labelling: •  Pt t
OCOCH2CH2CO2 t . 
cell culture medium and 1 
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Figure S41. Photolysis of 1 in cell culture medium in the presence of Rf and MES. 1H 
NMR spectra of cell culture medium/MES/D2O (7.5:1.5:1) solution containing 120 µM 1 
and 40 µM Rf under 460-vu  o]PZ  ] ] ]}v  ~ò  u tu t 2) for tirr = 0 and 1 min. Cell 
culture medium corresponds to Ham's F-12K medium supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin. 1  ,   E D Z   ]Pv o  ooo]vPW  •  (   t
O2CCH2CH2CO2 t  (compared to Figure S30, the triplet signal of 1 at 2.55 ppm is here 
buried under one of the MES signals). 
 
Figure S42. Photolysis of 1 in cell culture medium in the presence of Rf. 1H NMR 
spectra of cell culture medium/H2O/D2O (7.5:1.5:1) solution containing 120 µM 1 and 
40 µM Rf under 460-vu  o]PZ  ] ] ]}v  ~ò  u t u t 2) for tirr = 0 and 1 min. Cell culture 
medium corresponds to Ham's F-12K medium supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin. 1  ,   E D Z   ]Pvo  ooo]vPW  •   W t OCOCH2CH2CO2 t , 
• (   t O2CCH2CH2CO2 t . 
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Figure S43. Light- ]À     o ]v ]}v  }(  æ; -guanosin monophosphate (GMP) by Rf/1. 
1H NMR spectra of a MES/D2O (9:1) solution (1.5 mM, pH 6.0) of 120 µM 1, 50 µM Rf 
after 460- vu  o]PZ  ] ] ]}v ~í  u]vU îXæ u tu t 2) and incubation with GMP (0.5 mM) 
for t = 0, 12 and 24 h. 1H NMR signal labelling: : v  mono-adduct cis-[Pt(NH3)2(N7-
GMP)2]2 t . 
 
Figure S44.  Wo ]v ]}v  }(  æ; -guanosin monophosphate (GMP) by cisplatin. 1H NMR 
spectra of a MES/D2O (9:1) solution (2 mM, pH 6.0) of 120 µM cisplatin and incubation 
with GMP (0.5 mM) for t = 0, 12 and 24 h. 1H NMR signal labelling: v  mono-adduct cis-
[Pt(NH3)2(N7-GMP)2]2 t . 
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               DNA     DNA + Rf    DNA + Rf/1  Cisplatin 
Light          t     +   t  +  t        +       t  
 
 
 
 
 
 
 
 
1342 bp 
            1.0 1.2   1.2    1.1       0.7         0.04         0.02 
Figure S45. Inhibition of the polymerase chain reaction (PCR) using as template pET28b 
incubated with Rf (2.5 µM), Rf/1 (2.5:10 µM) and cisplatin (10 µM) in the dark and 
µv   ïì      }(  o]PZ  ] ] ]}v     ðò ì  vu  ~îXæ u t u t 2, 1.5 mM MES and pH 6). Values 
below the gel indicate intensities of amplified DNA fragment normalized by that of the 
DNA control in the dark. 
 
 
Figure S46. Morphological analysis of PC-3 cells. Merged DIC (Differential Interference 
Contrast) and fluorescence microscopy images showing the effects of Rf/1 on PC-3 
cells upon light irradiation. (A) untreated PC-3 cells, (B) Rf/1 (30:120 µM) in the dark, 
(C) Rf/1 (30:120 µM) activated by 460-vu o]PZ ~o]PZ }  ìXïò   : u t 2) and (D) cisplatin 
(120 µM) in the dark. All samples were treated in the presence of 2 mM of MES. Cells 
were stained at the end of the incubation period (48 h) using the dye SYTOX® 
    À v¡ ~ /vÀ]}Pv¡ (}     oo ~ Z vvoX   
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Figure S47. LED setup for cell work and emission profile. (a) Custom-made array of 
blue emitting LEDs used for irradiation of 96-well plates. (b) Emission profile of the LED 
˙ ~ðòì vuU ò  u tu t 2) employed in the cell work experiment. 
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Experimental details 
 
Materials 
(-)-Riboflavin (Rf), formic acid, 2-(N-morpholino)ethanesulfonic acid (MES), sodium 
phosphate monobasic monohydrate, Pµv}]v  æ; -monophosphate disodium salt 
hydrate (GMP), cisplatin were purchased from Sigma Aldrich, sodium phosphate 
dibasic from PANREAC and K2PtCl4 from Precious Metals Online. All chemicals were 
used as received without additional purification. Ham's F-12K (Kaighn's) medium 
nutrient mixture and fetal bovine serum (FBS) were purchased from Invitrogen. 
Penicillin t  Streptomycin was purchased from Teknovas. The pET28b plasmid was 
purchased from Novagen, DNA primers from Sigma and the Dream Taq polymerase 
and SYBR Safe dye from Thermo-Fisher. 
 
Synthesis of cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2H)2] (1) 
The platinum complex was synthesized by following the procedure described by M. 
Reithofer et al.5 
 
Instrumentation 
Nuclear Magnetic Resonance (NMR). 1H NMR spectra of the various samples were 
recorded on an AVANCE III Bruker 500 NMR spectrometer using standard pulse 
programs. Chemical shifts were reported in parts-per-u]oo]}v  ~wU  u   v    (v  
to the residual solvent peak. 
UVt Vis absorption spectroscopy (UV-vis). All spectra of 1 and Rf were acquired in 
aqueous solution or buffers using a Varian Cary 5000 spectrophotometer.  
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Photoirradiation experiments 
Photoirradiation experiments were performed on aqueous and buffer solutions 
obtained dissolving 1 and Rf at different concentrations in a 1 mL glass vial and 
] ] ]vP   Z  `Z}o   À }oµu   `]Z     >     o]PZ   }µ   ~ irr A  ðòì   vuU  îXæ  u tu t 2, 
Prizmatix LED Multi-Wavelength MWLLS-11). 
In the case of cell experiments, black 96-well plates were photoirradiated using the 
oµ   >      ˙   Z}`v  ]v   &]Pµ   ^ï ó  ~ irr A  ðòì  vuU  ò  u tu t 2). Power densities were 
measured with a Ophir photonics power meter. 
 
Quantum yield determination by actinometry. 
Ferrioxalate actinometry was employed to determine the photon flux of the blue LED 
˙  ~ irr A  ðòì  vuU  ò  u tu t 2) and the yield of the photochemical activation for the 
Rf/1 system. Samples were irradiated in 96-well plates as described in the modified 
method of Bonnet and co-worker.3 1H NMR was employed to quantify the 
concentration of succinate ligand photoreleased and determine the yield of the 
photochemical reaction. Actinometry experiments were repeated three times. 
 
Computational details 
All calculations were performed with the Gaussian 09 program.6 The systems were 
analyzed with Density Functional Theory, using the PBE0/def2-SVP combination, which 
was previously used in similar studies.7 Solvent was considered by means of the 
polarized continuum model (PCM) with water as implicit solvent, and dispersion 
interactions were taken into account using Grimme's dispersion correction with Becke 
and Johnson's damping.8 The geometries were optimized and frequency calculations 
were run to ensure the lack of imaginary modes. Several isomers were found for each 
of the complexes presented; only the global minima are presented in this work. The 
binding energy was calculated as the electronic energy balance of the reaction Rf + 1 
W  Rf/1. 
Chapter 3 Supporting Information 
162 
Polymerase chain reaction (PCR)-inhibition assay using Rf/1-treated DNA. 2 ng/µL 
  dî ô   `   o]PZ  ] ]       ð òì   vu  (}   ï ì     ~îXæ u tu t 2) in presence of 2.5 µM of 
Rf and 10 µM of 1 in 1.5 mM MES at pH 6. As negative controls, DNA and DNA 
incubated with 2.5 µM Rf were also irradiated. Moreover, non-irradiated controls were 
run for each sample. As positive control, DNA was also incubated with 10 µM cisplatin. 
After incubating irradiated and non-irradiated mixtures for 24 h in the dark, 2 ng of 
plasmid DNA were used as template for the amplification of 1342 bps fragment by 
using the following primers: AACTTAATGGGCCCGCTAACAG (primer forward) and 
CGTCCCATTCGCCATCC (primer reverse). PCR was performed using the Dream Taq 
polymerase according to the manufacturer´s protocol. PCR was run for 30 cycles and 
its products were analysed by DNA electrophoresis using 1% agarose gels and SYBR 
Safe as dye to visualize DNA. The DNA bands were quantified using Image J. 
 
Photocatalysis kinetic model 
Assuming the reaction scheme reported below in which Rf acts as a photocatalyst, we 
have adopted a simplified kinetic model in which the reaction rate depends on both 1 
and MES Eq. (1) (Figure S10 and S11). Nevertheless, such rate can be approximated 
with as a pseudo-first order reaction considering that the initial concentration of MES 
is much larger than the initial concentration of 1. Thus, the concentration of MES 
remains constant during the chemical reaction. Within this approach, a pseudo-first 
order reaction constant (kobs = 10.0 ± 0.1·10 t 3 s t 1) can be calculated fitting 
experimental data to Eq (2) (Figure S12) or to Eq (3) (Figure S10). Moreover, a second 
order reaction constant (k = 1.3 ± 0.1 M t 1s t 1) can be calculated using Eq (4) by fitting 
the experimental data for kobs at different [MES]o (Figure S13). 
Reaction scheme 
2[MES] + [Rf   W î  D  ^ • =] + [RfH2/RfH t ] 
[RfH2/RfHt ] + [1  W  Rf]+ [PtII] 
2[MES] + [1  W î D  ^ • =] + [PtII] 
163 
Kinetic Model 
rate(v) = k[MES][1]     (1) 
[𝟏] = [𝟏]0𝑒
−𝑘𝑜𝑏𝑠𝑡     (2) 
v = kobs [1] [MES]o >> [1]o   (3) 
kobs = k[MES]o     (4) 
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Cytotoxicity 
 
 
Figure S1. Phototoxic effect of Rf (2 mM MES) on the cell viability of different cell lines after 72 
h with and without light irradiation (460 nm, 0.36 Jcm t 2). Cisplatin was employed as positive 
control (10x [Rf]). 
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Figure S2. Rf phototoxic effect on the cell viability of Capan-1 after 72 h in the absence (1% 
H2O) and in the presence of 2 mM MES (1%). Experiments were performed in the dark and 
under light irradiation (460 nm, 0.36 Jcm t 2). 
 
 
Figure S3. FAD phototoxic effect on the cell viability of Capan-1 after 72 h in the absence (1% 
H2O) and in the presence of 2 mM MES (1%). Experiments were performed in the dark and 
under light irradiation (460 nm, 0.36 Jcm t 2). 
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Figure S4. Photocatalytic Rf-1 effect against Capan-1 cells. Cell viability of Capan-1 upon 
incubation with Rf-1 (1:10) and 1 in the absence of MES under light irradiation (460 nm, 0.36 
Jcm t 2) and in the dark. Cisplatin is shown as positive control. 
 
 
Figure S5. Photocatalytic Rf-2 effect against Capan-1 cells. Cell viability of Capan-1 upon 
incubation with Rf-2 (1:10) and 2 in the absence of MES under light irradiation (460 nm, 0.36 
Jcm t 2) and in the dark (n = 2). Carboplatin is shown as positive control. 
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Figure S6. Photocatalytic FAD-1 effect against Capan-1 cells. Cell viability of Capan-1 upon 
incubation with FAD-1 (1:10) and 1 in the absence of MES under light irradiation (460 nm, 0.36 
Jcm t 2) and in the dark. Cisplatin is shown as positive control. 
 
Figure S7. Photocatalytic FAD-1 effect against Capan-1 cells. Cell viability of Capan-1 upon 
incubation with FAD-1 (1:10) and 1 in the presence of 2 mM MES under light irradiation (460 
nm, 0.36 Jcm t 2) and in the dark. Cisplatin is shown as positive control. 
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Figure S8. Photocatalytic FAD-2 effect against Capan-1 cells. Cell viability of Capan-1 upon 
incubation with FAD-2 (1:10) and 2 in the absence of MES under light irradiation (460 nm, 0.36 
Jcm t 2) and in the dark. Carboplatin is shown as positive control. 
 
Figure S9. Photocatalytic FAD-2 effect against Capan-1 cells. Cell viability of Capan-1 upon 
incubation with FAD-2 (1:10) and 2 in the presence of 2 mM MES under light irradiation (460 
nm, 0.36 Jcm t 2) and in the dark. Carboplatin is shown as positive control. 
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Figure S10. Cell viability of Capan-1 cells treated with two different Rf-1 ratios (1:10 and 1:2) 
with 2 mM MES, under light irradiation (460 nm, 0.36 Jcm t 2) and in the dark. Cisplatin is 
shown as positive control. 
 
Figure S11. Photocatalytic Rf-1 effect against Capan-1 cells in hypoxia conditions. Cell viability 
of Capan-1 cells upon incubation with Rf-1 (1:10), Rf and 1 in the presence of 2 mM MES, 
under light irradiation (460 nm, 0.36 Jcm t 21 min at 6 mW cm-2) and in the dark. Cisplatin is 
shown as positive control. 
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 Pt NMR 
 
Figure S12. 195Pt-NMR spectrum of cisplatin. A solution of 2.7 mM cisplatin dissolved in 2 mM 
MES buffer pH 6 was measured. 
 
Figure S13. 195Pt-NMR spectrum of cisplatin. A solution of 2.7 mM cisplatin and 267 µM Rf 
(ratio Rf:cisplatin 1:10) dissolved in 2 mM MES buffer pH 6 was measured. 
 
 
Figure S14. 195Pt-NMR spectrum. A solution of 7.2 mM 1 and 267 µM Rf (ratio Rf:cisplatin 
1:26.7) were dissolved in 2 mM MES buffer pH 6 was measured in the dark. 
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Figure S15. 1H,195Pt-HSQC NMR spectrum. A solution of 7.2 mM 1 and 267 µM Rf (ratio 
Rf:cisplatin 1:27) dissolved in 2 mM MES buffer pH 6 was measured in the dark. 
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CD DNA interaction 
Figure S16. CD     }(    í   D  ds26 ]v   Z  l  v  (  ] ] ]}vV   í   D  ds26 in 
}u]v ]}v  `]Z  ìXï   D  Rf ]v   Z  l   v   (   ]  ] ]}vV    í   D  ds26 in 
}u]v ]}v  `]Z  ò    D   µ ]v]   ]   ]v   Z   l  v  (   ] ] ]}vV    í    D  ds26 in 
}u]v ]}v `]Z  ï  D  1 in the dark and (  ] ] ]}vV   í   D  ds26 in combination 
`]Z  ï   D  cisplatin ]v   Z   l  v   (  ] ] ]}vV  (  í   D  ds26 in combination with 
ï   D  1 and ìXï   D  Rf in the dark. Incubation: 48h at 37 °C. Buffer: MES 20 mM 
(pH=6.0). Light irradiations were performed at 460 nm (0.36 Jcm t 2). 
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ICP cell uptake 
Figure S17. Pt accumulation in Capan-1 cells measured by ICP-MS at different time points. Cells 
treated with 100 µM cisplatin, 100 µM 1 and 10:100 µM Rf-1 were incubated a) 1 h in the dark, 
b) 1 h preincubation in the dark + 1 min of 460-nm light irradiation + 3 h in the dark, c) 1 h 
preincubation in the dark + 1 min of 460-nm light irradiation + 6 h in the dark, d) 1 min of 460-
nm light irradiation + 7 h in the dark. All dark controls were not light irradiated and protected 
by ambient light. 
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Figure S18. Photocatalytic Rf-1 effect against Capan-1 cells. Cell viability of Capan-1 cells upon 
incubation with Rf-1 (1:10), Rf and 1 in the presence of 2 mM MES during 1 h and followed by 
light irradiation (460 nm, 0.36 Jcm t 2). Media was renewed immediately after irradiation. Dark 
controls were performed accordingly. Cisplatin is shown as positive control. 
 
 
Figure S19. Photocatalytic Rf-1 effect against Capan-1 cells. Cell viability of Capan-1 cells upon 
incubation with Rf-1 (1:10), Rf and 1 in the presence of 2 mM MES were irradiated (460 nm, 
0.36 Jcm t 2) and incubated for 7 h. Media was renewed after these 7 h. Dark controls were 
performed accordingly. Cisplatin is shown as positive control. 
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Figure S20. Original films for protein detection by Western blot analyses. Bands shown in 
Figure 4a of the main manuscript are indicated in bold face and by arrows. 
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Supplemental figure legend:		original	films	for	protein	detection	by	Western	blot	analyses.	
Bands	shown	in	Figure	3a	of	the	manuscript are	indicated	in	bold	face	and	by	arrows.		
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Immunofluorescence 
Figure S21. Immunofluorescence microscopy images of Capan-1 cells. Images correspond to 
control samples: Rf (15 µM), Rf-1 (10t 100 µM and 15 t 150 µM) and cisplatin (150 µM) under 
dark conditions. Cells were stained using DAPI for nuclei localization (blue channel), TRIC-
phalloidin to visualize actin filaments (red channel) and primary antibody histone H2AX 
antibody (green channel). 
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Figure S22. Immunofluorescence microscopy images of Capan-1 cells. Images correspond to 
control sample: Rf-1 (10t 100 µM and 15t 150 µM) and 1 (150 µM) irradiated 1 min at 460 nm 
(0.36 Jcm t 2). Cells were stained using DAPI for nuclei localization (blue channel), TRIC-
phalloidin to visualize actin filaments (red channel) and primary antibody histone H2AX 
antibody (green channel). 
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Figure S23. Immunofluorescence microscopy images of Capan-1 cells. Images correspond to 
control samples: Rf (15 µM), Rf-2 (15t 150 µM) and carboplatin (150 µM) in the dark. Cells 
were stained using DAPI for nuclei localization (blue channel), TRIC-phalloidin to visualize actin 
filaments (red channel) and primary antibody histone H2AX antibody (green channel). 
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Figure S24. Immunofluorescence microscopy images of Capan-1 cells. Images correspond to 
control samples: Rf (15 µM), Rf-2 (15t 150 µM) and 2 (150 µM) irradiated 1 min at 460 nm 
(0.36 Jcm t 2). Cells were stained using DAPI for nuclei localization (blue channel), TRIC-
phalloidin to visualize actin filaments (red channel) and primary antibody histone H2AX 
antibody (green channel). 
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Complex 1 
a 
 
 
b 
 
 
Figure S1. Dark stability of 0.2 mM 1 in (a) MES (pH 6, 20 mM, 10% D2O) and (b) PB buffer (pH 7, 
100 mM, 10% D2O) over 24 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–
OCOCH2CH2CO2–. 
a 
 
 
b 
 
Figure S2. Photostability of 0.2 mM 1 in (a) MES (pH 6, 20 mM, 10% D2O) and (b) PB buffer (pH 7, 
100 mM, 10% D2O). 1H NMR spectra were recorded upon 460-nm light irradiation (6 mW·cm–2) for 
1 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
Figure S3. 1H NMR spectra showing the PB buffer (pH 7, 100 mM, 10% D2O) stability of 1 under 
light irradiation (460 nm, 6 mW·cm–2) in the presence of 2 mM NADH. 1H NMR signal labelling:  
Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–.  
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a 
 
b 
 
Figure S4. 1H NMR spectra showing the PB buffer (pH 7, 100 mM, 10% D2O) stability of 1 in the 
dark (a) and under light irradiation (b, 460 nm, 6 mW·cm–2) in the presence of 20 mM NADH. 1H 
NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
 
 
Figure S5. Dark stability of 0.2 mM 1 in MES (pH 6, 20 mM, 10% D2O) in the presence of 10 µM 
FAD over 3 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
a 
 
b c 
 
Figure S6. FAD-catalyzed photoreduction of 1 in MES buffer (a 200 µM; b 2 mM; c 20 mM) 
monitored by 1H NMR. Spectra were recorded for MES (10% D2O) solutions of 200 µM 1 and 10 
µM FAD upon t = 0 sec, 2.5 min, 5 min and 10 min of 460-nm light irradiation (6 mW·cm–2). 1H 
NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
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Figure S7. Dark stability of 1 in the dark and in PB buffer (pH 7, 100 mM) in the presence of NADH 
(a, 2 mM; b, 20 mM) and FAD monitored by 1H NMR. Spectra were recorded for PB (10% D2O) 
solutions of 200 µM 1 and 10 µM FAD. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–
OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
 
 
a 
 
b 
 
Figure S8. FAD-catalyzed photoreduction of 1 in PB buffer (pH 7, 100 mM) in the presence of 
NADH (a, 200 µM; b, 2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O) 
solutions of 200 µM 1 and 10 µM FAD upon t = 0 sec and 2.5 min of 460-nm light irradiation (6 
mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –
O2CCH2CH2CO2–. 
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Complex 2 
a 
 
b 
 
Figure S9. Photostability of 0.2 mM 2 in (a) MES (pH 6, 20 mM, 10% D2O, 1% dmso-d6) and (b) PB 
buffer (pH 7, 100 mM, 10% D2O, 1% dmso-d6) with 2 mM NADH. 1H NMR spectra were recorded 
upon 460-nm light irradiation (6 mW·cm–2) for 1 h. 1H NMR signal labelling:  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3. 
 
Figure S10. Photoactivation of 0.2 mM 2 in water (10% D2O, 1% dmso-d6) upon 365-nm light 
irradiation for 10 min. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –
OCOCH2CH2CH2CH2CH3. 
 
Figure S11. Dark stability of 0.2 mM 2 in MES (pH 6, 20 mM, 10% D2O, 1% dmso-d6) in the 
presence of 10 µM FAD over 2 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
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Figure S13. Dark stability of 2 in the dark and in PB buffer (pH 7, 100 mM) in the presence of NADH 
(2 mM) and FAD monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 10 µM FAD. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  
Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
 
 
Figure S14. FAD-catalyzed photoreduction of 2 in MES buffer (pH 6, 20 mM) monitored by 1H 
NMR. Spectra were recorded for MES (10% D2O, 1% dmso-d6) solutions of 200 µM 2 and 10 µM 
FAD upon t = 0, 1 min and 4 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal labelling: 
 Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3, ● free –OCOCH2CH2CH2CH2CH3,  acetone impurity. 
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Figure S15. FAD-catalyzed photoreduction of 2 in PB buffer (pH 7, 100 mM) in the presence of 
NADH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 10 µM FAD upon t = 0, 0.5 min, 1.5 min and 4 min of 460-nm light 
irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –
OCOCH2CH2CH2CH2CH3. 
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Figure S16. Dark stability of 0.2 mM 3 in (a) MES (pH 6, 20 mM, 10% D2O) and (b) PB buffer (pH 7, 
100 mM, 10% D2O) over 24 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–
OCOCH2CH2CO2–. 
a 
 
 
b 
 
 
Figure S17. Photostability of 0.2 mM 3 in (a) MES (pH 6, 20 mM, 10% D2O) and (b) PB buffer (pH 7, 
100 mM, 10% D2O). 1H NMR spectra were recorded upon 460-nm light irradiation (6 mW·cm–2) for 
1 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
a 
 
b 
 
Figure S18. Stability in the dark (a) and under light irradiation (b) of 0.2 mM 3 in the presence of 2 
mM NADH (PB buffer pH 7, 100 mM) monitored by 1H NMR. Light source: 460 nm, 6 mW·cm–2. 1H 
NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
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Figure S19. Dark stability of 3 in PB buffer (pH 7, 100 mM, 10% D2O) in the presence of NADH and 
FAD over 3 h. 1H NMR spectra were recorded for solutions of 200 µM 3 and 10 µM FAD and 2 mM 
NADH. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
Figure S20. Dark stability of 0.2 mM 3 in MES (pH 6, 20 mM, 10% D2O) in the presence of 10 µM 
FAD over 3 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
Figure S21. FAD-catalyzed photoreduction of 3 in MES buffer (pH 6, 20 mM) monitored by 1H 
NMR. Spectra were recorded for MES (10% D2O) solutions of 200 µM 3 and 10 µM FAD upon t = 0 
min, 4 min, 16 min 46 min and 1 h and 46 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR 
signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
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Figure S22. FAD-catalyzed photoreduction of 3 in PB buffer (pH 7, 100 mM) in the presence of 
NADH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O) solutions of 200 µM 
3 and 10 µM FAD upon t = 0 sec, 30 sec, 3 min and 5 min of 460-nm light irradiation (6 mW·cm–2). 
1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
192 
Complex 4 
a 
  
b 
 
Figure S23. Dark stability of 0.2 mM 4 in (a) MES (pH 6, 20 mM, 10% D2O, 3.3% dmso-d6) and (b) 
PB bufer (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) over 24 h. 1H NMR signal labelling: ⬣ and ⬣ Ru–
(p-cymene). 
a 
 
b 
 
 
Figure S24. Photostability of 0.2 mM 4 in (a) MES (pH 6, 20 mM, 10% D2O, 3.3% dmso-d6) and (b) 
PB buffer (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6). 1H NMR control spectra were recorded upon 
460-nm light irradiation (6 mW·cm–2) for 1 h. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 
4, ⬣ and ⬣ Ru–(p-cymene) of the corresponding aqua complex. 
a 
 
b 
 
Figure S25. Stability in the dark (a) and under light irradiation (b) of 4 in the presence of 2 mM 
NADH (PB buffer pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) monitored by 1H NMR over time. Light 
source: 460 nm, 6 mW·cm–2. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 4, ⬣ Ru–(p-
cymene) of the corresponding aqua complex, ● NADH. 
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Figure S26. 1H NMR spectra showing the PB buffer (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) 
stability of 4 in the dark in the presence of NADH and FAD over 3 h. Spectra were recorded for 
solutions of 200 µM 4 and 10 µM FAD and 2 mM NADH. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-
cymene) of 4, ● NADH. 
 
Figure S27. Dark stability of 0.2 mM 4 in MES (pH 6, 20 mM, 10% D2O, 3.3% dmso-d6) in the 
presence of 10 µM FAD over 3 h. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 4. 
 
Figure S28. FAD-catalyzed photoreduction of 4 in MES buffer (20 mM, 10% D2O, 3.3% dmso-d6) 
monitored by 1H NMR. Spectra were recorded for MES (10% D2O) solutions of 200 µM 4 and 10 
µM FAD upon t = 0 min, 2 min, 6 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal 
labelling: ⬣ and ⬣ Ru–(p-cymene) of 4, ⬣ and ⬣ Ru–(p-cymene) of the corresponding aqua 
complex. 
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Figure S29. FAD-catalyzed photoreduction of 4 in PB buffer (pH 7, 100 mM, 10% D2O, 3.3% dmso-
d6) in the presence of NADH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% 
D2O) solutions of 200 µM 4 and 10 µM FAD upon t = 0 sec, 1min and 3 min of 460-nm light 
irradiation (6 mW·cm–2). 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 4, ⬣ and ⬣ Ru–(p-
cymene) of the corresponding aqua complex, ● NADH, ● NAD+. 
 
a 
 
b 
 
 
Figure 30. Speciation of 4 and [(η6-p-cym)Ru(bpm)Cl][PF6] in (a) MES (20 mM, 10% D2O, 3.3% 
dmso-d6) and (b) PB (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) with 2 mM NADH under different 
conditions. 1H NMR spectra show the chemical shift range corresponding to the isopropyl group of 
the p-cymene ligand (methyl resonances). 1H NMR signal labelling: ⬣ 4, ⬣ [(η6-p-cym)Ru(bpm)Cl]+, 
⬣ [(η6-p-cym)Ru(bpm)(dmso)]2+, ⬣ [(η6-p-cym)Ru(bpm)(H2O)]2+, ⬣ [(η6-p-cym)Ru(bpm)(H2O)]2+-
NADH adduct, * not assigned.[1-2] 
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Figure S31. Dark stability of 0.2 mM 5 in (a) MES (pH 6, 20 mM, 10% D2O, 3.3% dmso-d6) and (b) 
PB buffer (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) over 24 h. 1H NMR signal labelling: ⬣ and ⬣ 
Ru–(p-cymene). The 1H NMR spectrum in (c) was recorded in pure D2O without using the 1D 
excitation scultping sequence (zggpw5, Bruker Avance III) for the suppression of the water signal 
and shows an extra doublet at 9.71 ppm due to the bpy H6/H6′ protons. This signal does not 
appear in all the spectra recorded for 5 in buffers (90/10 H2O/D2O). 
 
a 
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Figure S32. Photostability of 0.2 mM 5 in (a) MES (pH 6, 20 mM, 10% D2O, 3.3% dmso-d6) and (b) 
PB buffer (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6). 1H NMR control spectra were recorded upon 
460-nm light irradiation (6 mW·cm–2) for 1 h. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 
5, ⬣ and ⬣ Ru–(p-cymene) of the corresponding aqua complex. 
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Figure S33. Stability in the dark (a) and under light irradiation (b) of 5 in the presence of 2 mM 
NADH (PB buffer pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) monitored by 1H NMR. Light source: 460 
nm, 6 mW·cm–2. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 5, ● NADH. 
 
Figure S34. Dark stability of 0.2 mM 5 in MES (pH 6, 20 mM, 10% D2O, 3.3% dmso-d6) in the 
presence of 10 µM FAD over 3 h. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 5. 
 
Figure S35. FAD-catalyzed photoreduction of 5 in MES buffer (20 mM) monitored by 1H NMR. 
Spectra were recorded for MES (10% D2O, 3.3% dmso-d6) solutions of 200 µM 5 and 10 µM FAD 
upon t = 0 sec, 5 min, 13 min and 35 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal 
labelling: ⬣ and ⬣ Ru–(p-cymene) of 5, ⬣ and ⬣ Ru–(p-cymene) of the corresponding aqua 
complex. 
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Figure S36. 1H NMR spectra showing the PB buffer (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) 
stability of 5 in the dark in the presence of NADH and FAD over 3 h. Spectra were recorded for 
solutions of 200 µM 5 and 10 µM FAD and 2 mM NADH. 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-
cymene) of 5, ● NADH. 
 
Figure S37. FAD-catalyzed photoreduction of 5 in PB buffer (pH 7, 100 mM) in the presence of 
NADH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 3.3% dmso-d6) 
solutions of 200 µM 5 and 10 µM FAD upon t = 0, 15, 25 and 85 min of 460-nm light irradiation (6 
mW·cm–2). 1H NMR signal labelling: ⬣ and ⬣ Ru–(p-cymene) of 5, ⬣ and ⬣ Ru–(p-cymene) of the 
corresponding aqua complex, ● NADH, ● NAD+. 
a 
 
b 
 
Figure 38. Speciation of 5 and [(η6-p-cym)Ru(bpy)Cl][PF6] in (a) MES (20 mM, 10% D2O, 3.3% dmso-
d6) and (b) PB (pH 7, 100 mM, 10% D2O, 3.3% dmso-d6) with 2 mM NADH under different 
conditions. 1H NMR spectra show the chemical shift range corresponding to the isopropyl group of 
the p-cymene ligand (methyl resonances). 1H NMR signal labelling: ⬣ 5, ⬣ [(η6-p-cym)Ru(bpy)Cl]+, 
⬣ [(η6-p-cym)Ru(bpy)(dmso)]2+, ⬣ [(η6-p-cym)Ru(bpy)(H2O)]2+, ⬣ [(η6-p-cym)Ru(bpy)(H2O)]2+-
NADH adduct, * not assigned.[1-2]  
Figure S39. Net charge of miniSOG, NOX, GOX and GR at different pH. 
map were calculated with Bluues server.
 
 
Figure S40. Electrostatic surface potential of miniSOG. The figure was created using pymol 0.99 
(DeLano, USA) using a miniSOG molecular moldel based on the PDB ID: 4EET. The electrostatic 
potential was calculated using Bluues server.
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Figure S41. Electrostatic surface potential of NOX. The figure was created using pymol 0.99 
(DeLano, USA) using the PDB ID 1NOX. The electrostatic potential was calculated using Bluues 
server.[3] Color code: blue = positive and red = negative. 
 
 
Figure S42. Electrostatic surface potential of GOX. The figure was created using pymol 0.99 
(DeLano, USA) using the PDB ID 1CF3. The electrostatic potential was calculated using Bluues 
server.[3] Color code: blue = positive and red = negative. 
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Figure S43. Electrostatic surface potential of GR. The figure was created using pymol 0.99 (DeLano, 
USA) using the PDB ID 2HQM. The electrostatic potential was calculated using Bluues server.[3] 
Color code: blue = positive and red = negative. 
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Figure S44. Stability in the dark (
mM, 10% D2O) and in the presence of 10 µM GOX over time. 
OCOCH2CH2CO2–,  Pt–OCOCH2CH
a 
Figure S45. Stability in the dark (
100 mM, 10% D2O) in the presence of 2 mM NADH and 10 µM GOX over time. 
labelling:  Pt–OCOCH2CH2CO2–, 
a 
Figure S46. Stability in the dark (
100 mM, 10% D2O) in the presence of 20 mM glucose and 10 µM GOX over time. 
labelling:  Pt–OCOCH2CH2CO2–, 
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Figure S47. GOX-catalyzed photoreduction of 2 in MES buffer (pH 6, 20 mM) monitored by 1H 
NMR. Spectra were recorded for MES (10% D2O, 1% dmso-d6) solutions of 200 µM 2 and 10 µM 
GOX upon t = 0, 30 min and 1 h of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal labelling: 
 Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3, ● free –OCOCH2CH2CH2CH2CH3,  acetone impurity. 
 
Figure S48. GOX-catalyzed photoreduction of 2 in PB buffer (pH 7, 100 mM) in the presence of 
NADH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 10 µM GOX upon t = 0, 20 min, 40 min and 1 h of 460-nm light 
irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –
OCOCH2CH2CH2CH2CH3. 
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Figure S49. Dark stability of 1 in the presence of FMN in (a) MES buffer (pH 7, 20 mM, 10% D2O) 
and (b) PB buffer (pH 7, 100 mM, 10% D2O) over 2 h. NMR spectra were recorded for solutions of 
200 µM 1 and 10 µM FMN and 2 mM NADH in the case of PB (b). 1H NMR signal labelling:  Pt–
OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
a 
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Figure S50. FMN-catalyzed photoreduction of 1 in (a) MES buffer (20 mM) and (b) PB buffer (pH 7, 
100 mM) in the presence of NADH (2 mM). NMR spectra were recorded for solutions of 200 µM 1 
and 10 µM FMN upon 460-nm light irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–
OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–.The TOF of free FMN towards 1 
was determined to be 3.9 ± 0.5 and 35.6 ± 4.3 min-1 in MES and PB/NADH respectively. 
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Figure S51. Dark stability of 0.2 mM 1 in MES (pH 6, 20 mM, 10% D2O) in the presence of 10 µM 
miniSOG over 3 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
Figure S52. MiniSOG-catalyzed photoreduction of 1 in MES buffer (pH = 6, 20 mM). 1H NMR 
spectra were recorded for MES (10% D2O) solutions of 200 µM 1 and 10 µM miniSOG upon t = 0, 1, 
10, 15 and 20 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–
OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
 
Figure S53. PB buffer (pH 7, 100 mM) stability of 1 in the dark and in the presence of NADH (2 
mM). 1H NMR spectra were recorded for PB (10% D2O) solutions of 200 µM 1 and 10 µM miniSOG. 
1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
Signals above 2.65 correspond residual MES present in the protein stock solution. 
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Figure S54. MiniSOG-catalyzed photoreduction of 1 in PB buffer (pH 7, 100 mM) and in the 
presence of NADH (2 mM). 1H NMR spectra were recorded for PB (10% D2O) solutions of 200 µM 1 
and 10 µM miniSOG. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● 
free –O2CCH2CH2CO2–. Signals above 2.65 correspond residual MES present in the protein stock 
solution. 
 
Figure S55. Dark stability of 0.2 mM 2 in MES (pH 6, 20 mM, 10% D2O, 1% dmso-d6) in the 
presence of 10 µM FMN over 2 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
 
Figure S56. Dark stability of 2 in the dark and in PB buffer (pH 7, 100 mM) in the presence of NADH 
(2 mM) and FMN monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 10 µM FMN. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  
Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
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Figure S57. Dark stability of 0.2 mM 2 in MES (pH 6, 20 mM, 10% D2O, 1% dmso-d6) in the 
presence of 3 µM miniSOG over 3 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
 
Figure S58. Dark stability of 2 in the dark and in PB buffer (pH 7, 100 mM) in the presence of NADH 
(2 mM) and miniSOG monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 3 µM miniSOG. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3, 
 Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
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Figure S59. MiniSOG-catalyzed photoreduction of 2 in MES buffer (pH 6, 20 mM) monitored by 1H 
NMR. Spectra were recorded for MES (10% D2O, 1% dmso-d6) solutions of 200 µM 2 and 10 µM 
miniSOG upon t = 0, 1 min, 5 min and 10 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR 
signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –OCOCH2CH2CH2CH2CH3,  acetone 
impurity. 
 
Figure S60. MiniSOG-catalyzed photoreduction of 2 in PB buffer (pH 7, 100 mM) in the presence of 
NADH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 10 µM miniSOG upon t = 0, 1 min, 2 min and 3 min of 460-nm light 
irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –
OCOCH2CH2CH2CH2CH3. 
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Table S1. H2O2 production during the photoreduction of 1 by miniSOG in MES buffer. The H2O2 
content was spectrophotometrically determined by mixing a 50 µL of a solution containing 200 
µM 1 and 10 µM miniSOG with 50 µL of a solution of containing horseradish peroxidase (HRP, 60 
µg/mL) and 2 mM ABTS (20 mM MES, pH 6). The solution of 1 and miniSOG was irradiated for 5 
min at 460 nm before mixing with HRP and ABTS. 
 
 mini SOG + 1 mini SOG 
[H2O2] / µM 28  4 27  2 
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Figure S61. Dark stability of 0.2 mM 1 in MES (pH 6, 20 mM, 10% D2O) in the presence of 10 µM 
NOX over 3 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
Figure S62. NOX-catalyzed photoreduction of 1 in MES buffer (pH = 6, 20 mM). 1H NMR spectra 
were recorded for MES (10% D2O) solutions of 200 µM 1 and 10 µM NOX upon t = 0, 1, 5, 15 and 
30 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–, 
 Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
 
Figure S63. NOX-catalyzed reduction of 1 in PB buffer (pH 7, 100 mM) in the dark and in the 
presence of NADH (2 mM). 1H NMR spectra were recorded for PB (10% D2O) solutions of 200 µM 1 
and 10 µM NOX at t = 0, 2.5, 5 and 7.5 min. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–
OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
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Figure S64. NOX-catalyzed reduction of 1 in O2-free PB buffer (pH 7, 100 mM) in the dark and in 
the presence of NADH (0.2 mM). 1H NMR s pectra were recorded for PB (10% D2O) solutions of 
200 µM 1 and 10 µM NOX. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–
, ● free –O2CCH2CH2CO2–. 
 
Figure S65. Dark stability of 0.2 mM 2 in MES (pH 6, 20 mM, 10% D2O, 1% dmso-d6) in the 
presence of 3 µM NOX over 2 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
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Figure S66. NOX-catalyzed photoreduction of 2 in MES buffer (pH 6, 20 mM) monitored by 1H 
NMR. Spectra were recorded for MES (10% D2O, 1% dmso-d6) solutions of 200 µM 2 and 3 µM 
NOX upon t = 0, 1 min, 5 min and 10 min of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal 
labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –OCOCH2CH2CH2CH2CH3. 
 
Figure S67. NOX-catalyzed reduction of 2 in PB buffer (pH 7, 100 mM) in the dark and in the 
presence of NADH (2 mM). 1H NMR spectra were recorded for PB (10% D2O, 1% dmso-d6) 
solutions of 200 µM 2 and 1 µM NOX at t = 0, 7 min, 26 min and 1 h. 1H NMR signal labelling:  
Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–
OCOCH2CH2CH2CH2CH3, ● free –OCOCH2CH2CH2CH2CH3. 
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Figure S68. Dark stability of 0.2 mM 1 in MES (pH 6, 20 mM, 10% D2O) in the presence of 10 µM 
GR over 3 h. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
 
Figure S69. GR-catalyzed photoreduction of 1 in MES buffer (pH 6, 20 mM) monitored by 1H NMR. 
Spectra were recorded for MES (10% D2O) solutions of 200 µM 1 and 10 µM GR upon t = 0, 1 h and 
2 h of 460-nm light irradiation (6 mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  
Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
 
Figure S70. Photostability of 0.2 mM 2 in MES (pH 6, 20 mM, 10% D2O, 1% dmso-d6) in the 
presence of 10 µM GR over 2 h (460 nm, 6 mW·cm–2). 1H NMR signal labelling:  Pt–
OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–. 
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Figure S71. Dark stability of 1 in the dark and in PB buffer (pH 7, 100 mM) in the presence of 
NADPH (2 mM) and GR monitored by 1H NMR. Spectra were recorded for PB (10% D2O) solutions 
of 200 µM 1 and 10 µM GR. 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–
OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–. 
 
Figure S72. GR-catalyzed photoreduction of 1 in PB buffer (pH 7, 100 mM) in the presence of 
NADPH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O) solutions of 200 
µM 1 and 10 µM GR upon t = 0, 1 min, 2 min, 18 min and 30 min of 460-nm light irradiation (6 
mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –
O2CCH2CH2CO2–. 
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Figure S73. Dark stability of 2 in the dark and in PB buffer (pH 7, 100 mM, 1% dmso-d6) in the 
presence of NADPH (2 mM) and GR monitored by 1H NMR. Spectra were recorded for PB (10% 
D2O) solutions of 200 µM 2 and 10 µM GR. 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3, 
 Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3. 
 
Figure S74. GR-catalyzed photoreduction of 2 in PB buffer (pH 7, 100 mM, 1% dmso-d6) in the 
presence of NADPH (2 mM) monitored by 1H NMR. Spectra were recorded for PB (10% D2O) 
solutions of 200 µM 2 and 10 µM GR upon t = 0, 5 min and 10 min of 460-nm light irradiation (6 
mW·cm–2). 1H NMR signal labelling:  Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, 
 Pt–OCOCH2CH2CH2CH2CH3,  Pt–OCOCH2CH2CH2CH2CH3, ● free –OCOCH2CH2CH2CH2CH3. 
 
1.01.52.02.53.0
t = 1.5 h
t = 0
ppm
1.01.52.02.53.0
t = 10 min
t = 5 min
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a b 
Figure S75. (a) Dark stability and (b) photocatalytic activity of miniSOG in cell culture 
medium (pH 7, f12k integrated with FBS) in the presence of NADH over time. Spectra 
were recorded for solutions of 200 µM 1 and 10 µM miniSOG and 2 mM NADH. Light 
irradiation was performed with an LED light source (460 nm, 6 mW·cm–2). Signals 
above 2.75 correspond residual MES present in the protein stock solution. 1H NMR 
signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–
. 
a b 
Figure S76. (a) Dark stability and (b) photocatalytic activity of FAD in cell culture 
medium (pH 7, f12k integrated with FBS) in the presence of NADH over time. Spectra 
were recorded for solutions of 200 µM 1 and 10 µM FAD and 2 mM NADH. Light 
irradiation was performed with an LED light source (460 nm, 6 mW·cm–2). 1H NMR 
signal labelling:  Pt–OCOCH2CH2CO2–,  Pt–OCOCH2CH2CO2–, ● free –O2CCH2CH2CO2–
. 
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Table S2. Activity of GOX in presence of different concentrations of 1. The enzyme 
activity was spectrophotometrically determined by using 30 μM ABTS, 30 mM of 
glucose, 29 μg/mL of horseradish peroxidase (HRP) and 0.05 mg/mL of GOX in 25 mM 
sodium phosphate at pH 7.  
 
[1] / mM Oxidation Rate (U/mg) 
0 15.41  0.50 
2 15.98  3.20 
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